Continuous Cortisol Monitoring System with Microneedle Array

The cortisol monitoring system using a microneedle array with a biorecognition layer addresses the limitations of existing methods by providing accurate, continuous, and less invasive cortisol monitoring in skin interstitial fluid, enhancing sensitivity and selectivity.

JP2024544044APending Publication Date: 2024-11-27BIOLINQ INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024525340
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-27
Filing Date
2022-10-27
Publication Date
2024-11-27

AI Technical Summary

Technical Problem

Existing methods for real-time cortisol monitoring are invasive, painful, and lack accuracy due to poor correlation with blood measurements and high latency in non-circulating fluids like sweat, making them unsuitable for continuous, passive cortisol measurement.

Method used

A cortisol monitoring system using a microneedle array with insulated microneedles and a biorecognition layer that selectively binds cortisol, generating a sensor signal through a working electrode, allowing for continuous, non-invasive monitoring of cortisol levels in skin interstitial fluid.

Benefits of technology

The system provides accurate, continuous, and less painful cortisol monitoring by accessing skin interstitial fluid, correlating closely with blood measurements, and reducing invasiveness and discomfort, while improving sensitivity, selectivity, and stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544044000001_ABST
    Figure 2024544044000001_ABST
Patent Text Reader

Abstract

Variations of cortisol monitoring systems are described herein, including cortisol monitoring devices. For example, the cortisol monitoring device may include a skin-penetrating microneedle array for use in measuring cortisol, such as in a continuous manner. The microneedle array may include at least one microneedle including a working electrode that includes a cortisol-sensing aptamer that selectively and reversibly binds to cortisol, for example. The microneedle array may include at least one microneedle including, for example, a tapered distal portion having an insulated distal tip and an electrode on a surface of the tapered distal portion disposed proximal to the insulated distal tip. At least a portion of the microneedle may be electrically insulated such that one or more electrodes are individually addressable.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] (Government support) This invention was made with U.S. Government support pursuant to a grant awarded by the Air Force Research Laboratory under Contract No. FA8650-18-2-5402. The Government has certain rights in this invention.

[0002] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims priority to U.S. Provisional Patent Application No. 63 / 272,640, filed October 27, 2021, the contents of which are incorporated herein by reference in their entirety.

[0003] (See electronic sequence listing) The contents of the electronic sequence listing submitted electronically herewith (Filename: BLNQ_002_01WO_SeqList_ST26.xml; Size: 1,957 bytes; and Creation Date: October 24, 2022) are incorporated herein by reference in their entirety.

[0004] FIELD OF THEINVENTION The present invention relates generally to the field of cortisol monitoring. [Background technology]

[0005] Chronic stress is recognized as a premorbidity factor associated with many risk factors for a variety of chronic diseases. Acute stressors may trigger an individual's adaptive response to environmental demands, but when exposure is non-episodic, they may reduce the ability to complete cognitively demanding tasks. Excessive stress, whether chronic or non-episodic, causes cumulative negative effects on short-term performance and long-term health outcomes via a concept known as "allostatic load."

[0006] Being able to assess stress in real time in people engaged in high performance jobs is paramount to ensure the safety of all stakeholders and the faithful execution of the task at hand. To this end, active measures such as a series of questions and the completion of simple tasks are usually employed to assess the impact of stress. However, these approaches are highly disruptive in most relevant operating environments.

[0007] The need for real-time assessment of stress levels has driven recent efforts towards the identification of circulating biochemical markers of cognitive function as true molecular surrogates for assessing the systemic physiological impact of acute and chronic stressors. The glucocorticoid hormone cortisol is widely accepted by the scientific community as the primary biomarker of physiological stress. Release of cortisol from the zona fasciculata of the adrenal cortex of the adrenal gland triggers an acute catabolic response that is thought to promote gluconeogenesis, suppress immune responses, and contribute to allostatic load due to chronic elevation. Cortisol also exhibits systemic distribution and rapid uptake dynamics due to its ability to sequestrate glucose in anticipation of the “fight or flight” response. Summary of the Invention [Means for solving the problem]

[0008] Aspects of the present subject matter relate to a microneedle array configured to sense cortisol in skin interstitial fluid.

[0009] In some variations, a microneedle array for use in sensing cortisol in skin interstitial fluid may include a plurality of solid microneedles, at least one microneedle of the plurality of solid microneedles may include a tapered distal portion having an insulated distal apex. In some variations, the microneedle array may further include a semiconductor substrate, and the plurality of solid microneedles extend from the semiconductor substrate. In some variations, the at least one microneedle may include a cylindrical body portion. In some variations, the working electrode may be disposed on a surface of the tapered distal portion proximal to the insulated distal apex. In some variations, the working electrode may be an annular electrode. Optionally, a distal edge of the annular working electrode may be proximate to a proximal edge of the insulated distal apex. Optionally, the annular electrode may be on only a segment of a surface of the tapered distal portion of the microneedle. In some variations, the working electrode may be configured to generate a sensor signal indicative of a concentration of cortisol in the skin interstitial fluid when contacted with the skin interstitial fluid.

[0010] In some variations, the working electrode may include an electrode material and a biorecognition layer disposed at least partially on the electrode material, the biorecognition layer including an aptamer that selectively and reversibly binds to cortisol.

[0011] In some variations, the biorecognition layer may include a conductive polymer layer and an aptamer, and the electrode material may include platinum. In some variations, the aptamer may be attached to the conductive polymer layer via an amide linker. The amide linker may be formed by reduction of a carboxyl group in the conductive polymer layer with an amine group covalently attached to the 3' or 5' end of the aptamer, or conversely, may be formed by reduction of an amine group in the conductive polymer layer with a carboxyl group covalently attached to the 3' or 5' end of the aptamer.

[0012] In some variations, the electrode material may include gold and the aptamer may be bound to the electrode material via a thiol bond between the gold and a thiol group covalently attached to the 3' or 5' end of the aptamer. In some variations, the biorecognition layer may further include 6-mercapto-1-hexanol bound to the gold via a thiol bond.

[0013] In some variations, the aptamer may be covalently attached to the redox active molecule at the 3' or 5' end of the aptamer, such that selective binding of cortisol to the aptamer and the resulting conformational change of the aptamer brings the redox active molecule closer to or further from the surface of the electrode material, facilitating or attenuating electron transfer between the redox active molecule and the electrode material, thereby generating a sensor signal. In some variations, the redox active molecule may be methylene blue or anthraquinone.

[0014] In some variations, the working electrode may further include a biocompatible layer disposed at least partially over the electrode material and the biorecognition layer, hi some variations, the biocompatible layer may include or be a hydrophilic polymer, which may be poly(urethane), poly(ethylene glycol), poly(vinyl alcohol), poly(lactic acid), collagen, alginate, chitosan, Nafion, or cellulose acetate.

[0015] In some variations, the cortisol monitoring device may include the above-described embodiments of the microneedle array. In some variations, the cortisol monitoring device may be a wearable device including a wearable housing, and the microneedle array may extend outwardly from the wearable housing, with the working electrode configured to reach the user's skin interstitial fluid when the device is worn by the user. In some variations, the wearable housing may include a communication module operably connected to the microneedle array and configured to transmit a wireless signal in response to a sensor signal generated by at least one microneedle.

[0016] In some variations, a method for monitoring cortisol in a user includes providing a cortisol monitoring device having a plurality of solid microneedles, at least one microneedle of the plurality of solid microneedles including a tapered distal portion having an insulated distal tip, and may include accessing skin interstitial fluid of the user with the at least one microneedle, and generating a sensor signal responsive to a working electrode in contact with the skin interstitial fluid with the at least one solid microneedle. In some variations, the microneedle array may further include a semiconductor substrate, and the plurality of solid microneedles extend from the semiconductor substrate. In some variations, the at least one microneedle may include a cylindrical body portion. In some variations, the working electrode may be disposed on a surface of the tapered distal portion proximal to the insulated distal tip. In some variations, the working electrode may be an annular electrode. Optionally, a distal edge of the annular working electrode may be proximate to a proximal edge of the insulated distal tip. Optionally, the ring electrode may be on only a segment of the surface of the tapered distal portion of the microneedle.

[0017] In some variations, the working electrode may be configured to generate a sensor signal indicative of a concentration of cortisol in the skin interstitial fluid when the working electrode is in contact with the skin interstitial fluid. In some variations, the working electrode may include an electrode material and a biorecognition layer at least partially disposed on the electrode material, the biorecognition layer may include an aptamer that selectively and reversibly binds to cortisol. In some variations, the aptamer may be covalently attached to the redox active molecule at the 3' or 5' end of the aptamer such that selective binding of cortisol to the aptamer and the resulting conformational change of the aptamer brings the redox active molecule closer to the surface of the electrode material to facilitate electron transfer between the redox active molecule and the electrode material, thereby generating a sensor signal. In some variations, the redox active molecule may be methylene blue or anthraquinone. In some variations, the working electrode may further include a biocompatible layer at least partially disposed on the electrode material and the biorecognition layer.

[0018] In some variations, the method may further include transmitting a wireless signal in response to the sensor signal generated by the at least one microneedle.

[0019] In some variations, the cortisol monitoring device may include a wearable housing having a user interface, at least one microneedle extending outwardly from the wearable housing and configured to reach a user's skin interstitial fluid when the device is worn by a user, and a working electrode disposed on a surface of the at least one microneedle and configured to generate a sensor signal indicative of a concentration of cortisol in the skin interstitial fluid. In some variations, the user interface may include one or more indicator lights, each of the one or more indicator lights configured to be selectively illuminated in response to the sensor signal.

[0020] In some variations, the working electrode may include an electrode material and a biorecognition layer disposed at least partially on the electrode material, the biorecognition layer may include an aptamer that selectively and reversibly binds to cortisol, and the working electrode may be configured to generate a sensor signal responsive to cortisol binding to the aptamer.

[0021] In some variations, the cortisol monitoring device may include one or more processors and at least one memory storing instructions that, when executed by the one or more processors, result in operations including determining a user state based on the sensor signal and controlling illumination of one or more indicator lights based on the user state. In some variations, controlling the illumination may include selectively illuminating the one or more indicator lights in a spatial and / or temporal pattern based on the user state.

[0022] In some variations, the user state may be the user's current cortisol level. The current cortisol level may be the current cortisol concentration in skin interstitial fluid or the current cortisol concentration in the user's bloodstream. In some variations, the user state may be the user's psychological state, such as the user's degree of stress.

[0023] In some variations, the one or more indicator lights include a plurality of indicator lights and controlling the lighting includes illuminating the plurality of indicator lights in a progressive sequence in response to an upward or downward trend in the sensor signal. In some variations, controlling the lighting includes illuminating the plurality of indicator lights in a first direction to communicate an upward trend and illuminating the plurality of indicator lights in a second direction to communicate a downward trend.

[0024] In some variations, the cortisol monitoring device may be a skin adhesive patch.

[0025] In some variations, the cortisol monitoring device may include a plurality of solid microneedles, the plurality of solid microneedles including at least one microneedle configured to sense cortisol, hi some variations, the plurality of solid microneedles extend outwardly from the wearable housing in a direction opposite the user interface.

[0026] In some variations, the wearable housing may include a communications module operably connected to the at least one microneedle and configured to transmit a wireless signal in response to a sensor signal generated by the working electrode.

[0027] In some variations, a method of monitoring cortisol in a user may include accessing skin interstitial fluid of a user with at least one solid-state microneedle, generating a sensor signal indicative of a concentration of cortisol in the skin interstitial fluid in contact with the at least one microneedle, determining a user state based on the sensor signal, and selectively illuminating one or more indicator lights based on the user state. In some variations, the at least one solid-state microneedle may include a working electrode having a biorecognition layer at least partially disposed over an electrode material. In some variations, the biorecognition layer includes an aptamer that selectively binds cortisol, and the working electrode is configured to generate a sensor signal responsive to cortisol binding to the aptamer.

[0028] In some variations, the at least one solid microneedle is at least one of a plurality of solid microneedles extending outwardly from the wearable housing.

[0029] In some variations, the one or more indicator lights are illuminated in a spatial and / or temporal pattern based on a user state.

[0030] In some variations, the user state is the user's current cortisol level. In some variations, the current cortisol level may be a current cortisol concentration in skin interstitial fluid or the user's bloodstream. In some variations, the user state is the user's psychological state, such as the user's degree of stress.

[0031] In some variations, the one or more indicator lights include a plurality of indicator lights, and the method may further include illuminating the one or more indicator lights in a progressive sequence in response to an upward or downward trend in the user condition.

[0032] In some variations, the method further includes illuminating the plurality of indicator lights in a first direction to communicate an upward trend and illuminating the plurality of indicator lights in a second direction to communicate a downward trend.

[0033] In some variations, the method further includes transmitting a wireless signal based on the sensor signal or the user condition.

[0034] Both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive. Additional features and / or variations may be provided in addition to those described herein. For example, implementations described herein may be directed to various combinations and subcombinations of the disclosed features.

[0035] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate certain aspects of the subject matter disclosed herein and, together with the description, serve to explain some of the principles associated with the disclosed implementations. [Brief description of the drawings]

[0036] [Figure 1] FIG. 1 shows an exemplary schematic diagram of a cortisol monitoring system having a microneedle array.

[0037] [Figure 2A] FIG. 1 shows an exemplary schematic diagram of a cortisol monitoring device.

[0038] [Figure 2B] FIG. 1 shows an exemplary schematic of microneedle insertion depth in a cortisol monitoring device.

[0039] [Figure 3A] 1A and 1B show a top perspective view, a side view, and a bottom perspective view, respectively, of a cortisol monitoring device. [Figure 3B] 1A and 1B show a top perspective view, a side view, and a bottom perspective view, respectively, of a cortisol monitoring device. [Figure 3C] 1A and 1B show a top perspective view, a side view, and a bottom perspective view, respectively, of a cortisol monitoring device. [Figure 3D] FIG. 3B is a partial exploded view of the cortisol monitoring device shown in FIG. 3A, including the adhesive layer. [Figure 3E] 3B shows an exploded view of the cortisol monitoring device shown in FIG. 3A.

[0040] [Figure 3F] 1A-1C show top perspective, bottom perspective, side and exploded views of a sensor assembly in a cortisol monitoring device, respectively. [Figure 3G] 1A-1C show top perspective, bottom perspective, side and exploded views of a sensor assembly in a cortisol monitoring device, respectively. [Figure 3H] 1A-1C show top perspective, bottom perspective, side and exploded views of a sensor assembly in a cortisol monitoring device, respectively. [Figure 3I] 1A-1C show top perspective, bottom perspective, side and exploded views of a sensor assembly in a cortisol monitoring device, respectively.

[0041] [Figure 3J] FIG. 1 shows a perspective side view of a sensor assembly in a cortisol monitoring device.

[0042] [Figure 4A] 1 shows a perspective view, a side view, a bottom view, a side cross-sectional view, and a top perspective transparent view of a cortisol monitoring device, respectively. [Figure 4B] 1 shows a perspective view, a side view, a bottom view, a side cross-sectional view, and a top perspective transparent view of a cortisol monitoring device, respectively. [Figure 4C] 1 shows a perspective view, a side view, a bottom view, a side cross-sectional view, and a top perspective transparent view of a cortisol monitoring device, respectively. [Figure 4D] 1 shows a perspective view, a side view, a bottom view, a side cross-sectional view, and a top perspective transparent view of a cortisol monitoring device, respectively. [Figure 4E] 1 shows a perspective view, a side view, a bottom view, a side cross-sectional view, and a top perspective transparent view of a cortisol monitoring device, respectively.

[0043] [Figure 5A] 1 shows an exemplary schematic diagram of a microneedle array. [Figure 5B] 5B shows an exemplary schematic diagram of a microneedle of the microneedle array shown in FIG. 5A.

[0044] [Figure 6] FIG. 1 shows an exemplary schematic diagram of a microneedle array used for sensing multiple analytes, at least one of the analytes being cortisol.

[0045] [Figure 7A] FIG. 1 shows a side cross-sectional view of a cylindrical microneedle having a tapered distal end. [Figure 7B] 7B is an image showing a perspective view and a detailed view of the microneedle embodiment shown in FIG. 7A. [Figure 7C] 7B is an image showing a perspective view and a detailed view of the microneedle embodiment shown in FIG. 7A.

[0046] [Figure 8] FIG. 1 shows an exemplary schematic diagram of a cylindrical microneedle with a tapered distal end.

[0047] [Figure 9] FIG. 1 shows a side cross-sectional view of a cylindrical microneedle having a tapered distal end.

[0048] [Figure 10] FIG. 1 shows an exemplary schematic diagram of a cylindrical microneedle with a tapered distal end.

[0049] [Figure 11A] FIG. 1 shows a side cross-sectional view of a pyramidal microneedle with a tapered distal end. [Figure 11B] FIG. 11B is an image showing a perspective view of one embodiment of the microneedle shown in FIG. [Figure 11C] 11C is an image showing an exemplary variation of a microneedle array including microneedles similar to those shown in FIG. 11B.

[0050] [Figure 12] FIG. 1 shows an exemplary schematic diagram of a pyramidal microneedle with a tapered distal end.

[0051] [Figure 13A] FIG. 1 shows an exemplary schematic diagram of a pyramidal microneedle with a tapered distal end and an asymmetric cutting surface. [Figure 13B] 13B is an image showing an exemplary variation of the microneedle shown in FIG. 13A.

[0052] [Figure 13C-E] 13B illustrates a process for forming the pyramidal microneedle shown in FIG. 13A.

[0053] [Figure 14A] FIG. 1 shows an exemplary schematic diagram of a pillar-pyramidal microneedle with a tapered distal end. [Figure 14B] FIG. 14B shows a detailed view of the distal portion of the microneedle shown in FIG. 14A.

[0054] [Figure 15A] 1 shows an exemplary schematic diagram of the formation of conductive pathways in a microneedle array. [Figure 15B] 1 shows an exemplary schematic diagram of the formation of conductive pathways in a microneedle array. [Figure 15C] 1 shows an exemplary schematic diagram of the formation of conductive pathways in a microneedle array. [Figure 15D] 1 shows an exemplary schematic diagram of the formation of conductive pathways in a microneedle array.

[0055] [Figure 16A] 1 shows an exemplary schematic diagram of the layered structure of a working electrode, a counter electrode, and a reference electrode, respectively. [Figure 16B] 1 shows an exemplary schematic diagram of the layered structure of a working electrode, a counter electrode, and a reference electrode, respectively. [Figure 16C] 1 shows an exemplary schematic diagram of the layered structure of a working electrode, a counter electrode, and a reference electrode, respectively.

[0056] [Figure 16D] 1 shows an exemplary schematic diagram of the layered structure of a working electrode, a counter electrode, and a reference electrode, respectively. [Figure 16E] 1 shows an exemplary schematic diagram of the layered structure of a working electrode, a counter electrode, and a reference electrode, respectively. [Figure 16F] 1 shows an exemplary schematic diagram of the layered structure of a working electrode, a counter electrode, and a reference electrode, respectively.

[0057] [Figure 16G] 1 shows an exemplary schematic diagram of the layered structure of a working electrode, a counter electrode, and a reference electrode, respectively. [Figure 16H] 1 shows an exemplary schematic diagram of the layered structure of a working electrode, a counter electrode, and a reference electrode, respectively. [Figure 16I] 1 shows an exemplary schematic diagram of the layered structure of a working electrode, a counter electrode, and a reference electrode, respectively.

[0058] [Figure 16J]FIG. 1 shows an exemplary schematic diagram of the layered structure of a working electrode in which the biorecognition element is a cortisol-binding aptamer. [Figure 16K] FIG. 1 shows an exemplary schematic diagram of the layered structure of a working electrode in which the biorecognition element is a cortisol-binding aptamer. [Figure 16L] FIG. 1 shows an exemplary schematic diagram of the layered structure of a working electrode in which the biorecognition element is a cortisol-binding aptamer. [Figure 16M] FIG. 1 shows an exemplary schematic diagram of the layered structure of a working electrode in which the biorecognition element is a cortisol-binding aptamer. [Figure 16N] FIG. 1 shows an exemplary schematic diagram of the layered structure of a working electrode in which the biorecognition element is a cortisol-binding aptamer. [Figure 16O] FIG. 1 shows an exemplary schematic diagram of the layered structure of a working electrode in which the biorecognition element is a cortisol-binding aptamer. [Figure 16P] FIG. 1 shows an exemplary schematic diagram of the layered structure of a working electrode in which the biorecognition element is a cortisol-binding aptamer.

[0059] [Figure 17] 1 shows an exemplary schematic diagram of a microneedle array configuration.

[0060] [Figure 18A] 1A and 1B show perspective and orthogonal views, respectively, of an exemplary variation of a die containing a microneedle array. [Figure 18B] 1A and 1B show perspective and orthogonal views, respectively, of an exemplary variation of a die containing a microneedle array.

[0061] [Figure 19A] 1A-1D show exemplary schematic diagrams of different variations of microneedle array configurations. [Figure 19B] 1A-1D show exemplary schematic diagrams of different variations of microneedle array configurations. [Figure 19C] 1A-1D show exemplary schematic diagrams of different variations of microneedle array configurations. [Figure 19D] 1A-1D show exemplary schematic diagrams of different variations of microneedle array configurations. [Figure 19E] 1A-1D show exemplary schematic diagrams of different variations of microneedle array configurations. [Figure 19F] 1A-1D show exemplary schematic diagrams of different variations of microneedle array configurations. [Figure 19G] 1A-1D show exemplary schematic diagrams of different variations of microneedle array configurations. [Figure 19H] 1A-1D show exemplary schematic diagrams of different variations of microneedle array configurations. [Figure 19I] 1A-1D show exemplary schematic diagrams of different variations of microneedle array configurations. [Figure 19J] 1A-1D show exemplary schematic diagrams of different variations of microneedle array configurations.

[0062] [Figure 20] FIG. 1 illustrates an exemplary schematic diagram of pairing between a cortisol monitoring device and a mobile computing device running a mobile application.

[0063] [Figure 21A] 1A and 1B show exemplary schematic diagrams of a microneedle array and a microneedle, respectively. [Figure 21B] 1A and 1B show exemplary schematic diagrams of a microneedle array and a microneedle, respectively. [Figure 21C] 1A-1C show detailed partial views of exemplary variations of microneedles. [Figure 21D] 1A-1C show detailed partial views of exemplary variations of microneedles. [Figure 21E] 1A-1C show detailed partial views of exemplary variations of microneedles. [Figure 21F] 1A-1C show detailed partial views of exemplary variations of microneedles.

[0064] [Figure 22A] 1 illustrates an exemplary variation of a microneedle. [Figure 22B] 1 illustrates an exemplary variation of a microneedle.

[0065] [Figure 23A] 1 shows an exemplary schematic diagram of a microneedle array configuration. [Figure 23B] 1 shows an exemplary schematic diagram of a microneedle array configuration.

[0066] [Figure 24A] 1 shows an exemplary schematic diagram of a microneedle array configuration. [Figure 24B] 1 shows an exemplary schematic diagram of a microneedle array configuration.

[0067] [Figure 25A] 1 shows an exemplary schematic diagram of a housing for a cortisol monitoring device including a user interface having an indicator light element. [Figure 25B] 1 shows an exemplary schematic diagram of a housing for a cortisol monitoring device including a user interface having an indicator light element.

[0068] [Figure 26A] 1 shows an exemplary schematic diagram of an illumination mode in a cortisol monitoring device for showing cortisol measurement data. [Figure 26B] 1 shows an exemplary schematic diagram of an illumination mode in a cortisol monitoring device for showing cortisol measurement data. [Figure 26C] 1 shows an exemplary schematic diagram of an illumination mode in a cortisol monitoring device for showing cortisol measurement data.

[0069] [Figure 27A] 1 shows an exemplary schematic diagram of an illumination mode in a cortisol monitoring device for showing cortisol measurement data. [Figure 27B] 1 shows an exemplary schematic diagram of an illumination mode in a cortisol monitoring device for showing cortisol measurement data. [Figure 27C]1 shows an exemplary schematic diagram of an illumination mode in a cortisol monitoring device for showing cortisol measurement data. [Figure 27D] 1 shows an exemplary schematic diagram of an illumination mode in a cortisol monitoring device for showing cortisol measurement data.

[0070] [Figure 28A] 1 shows an exemplary schematic diagram of an illumination mode in a cortisol monitoring device for showing cortisol measurement data. [Figure 28B] 1 shows an exemplary schematic diagram of an illumination mode in a cortisol monitoring device for showing cortisol measurement data. [Figure 28C] 1 shows an exemplary schematic diagram of an illumination mode in a cortisol monitoring device for showing cortisol measurement data.

[0071] [Figure 29A] 1 shows an example schematic diagram of an illumination mode in a cortisol monitoring device for indicating device information (e.g., operating status and / or failure mode). [Figure 29B] 1 shows an example schematic diagram of an illumination mode in a cortisol monitoring device for indicating device information (e.g., operating status and / or failure mode). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0072] Non-limiting examples of various aspects and variations of the present invention are described herein and illustrated in the accompanying drawings.

[0073] Although single-shot immunoassays are widely used in clinical settings for cortisol determination in multiple physiological fluids, including those with minimal sample preparation (e.g., saliva), the development of wearable devices capable of continuous, passive quantification of cortisol remains an unmet need in multiple fields. To this end, contemporary research efforts have explored secreted sweat cortisol as a vehicle for circulating cortisol. However, many limitations associated with measuring analytes in secreted, non-circulating fluids have called into question the viability of this compartment for real-time quantitative cortisol determination. These limitations include poor correlation with clinical correlates in the circulatory system, hysteresis, large levels of latency / lag times, and complexities associated with sample refilling.

[0074] Variations of the present subject matter address the limitations of cortisol determination by providing an aptamer-based approach for measuring and monitoring cortisol in skin interstitial fluid using a microneedle array. Before providing further details regarding aspects of the aptamer-based approach for measuring and monitoring cortisol, the following provides a description of several examples of cortisol monitoring devices, including examples of microneedle arrays in which aspects of the present subject matter may be implemented. The following description is intended to be illustrative, and aspects related to the aptamer-based approach for measuring and monitoring cortisol consistent with the present subject matter are not limited to the exemplary cortisol monitoring devices and exemplary microneedle arrays described herein.

[0075] As generally described herein, a cortisol monitoring system may include a cortisol monitoring device worn by a user and including one or more sensors for monitoring the user's cortisol. The sensor may include, for example, one or more electrodes configured to perform electrochemical detection of cortisol. The cortisol monitoring device may communicate sensor data to an external computing device for storage, display, and / or analysis of the sensor data. For example, as shown in FIG. 1, a cortisol monitoring system 100 may include a cortisol monitoring device 110 worn by a user, which may be a continuous cortisol monitoring device. The cortisol monitoring device 110 may include, for example, a microneedle array including at least one electrochemical sensor for detecting and / or measuring cortisol in the user's bodily fluids. In some variations, the cortisol monitoring device may be applied to the user using a suitable applicator 160 or may be applied manually. The cortisol monitoring device 110 may include one or more processors for performing analysis of the sensor data and / or a communication module (e.g., a wireless communication module) configured to communicate the sensor data to the mobile computing device 102 (e.g., a smartphone) or other suitable computing device. In some variations, the mobile computing device 102 may include one or more processors for executing a mobile application to process the sensor data (e.g., display the data, analyze the data for trends, etc.) and / or provide appropriate alerts or other notifications related to the sensor data and / or its analysis. It should be understood that while in some variations the mobile computing device 102 may perform the sensor data analysis locally, other computing devices may alternatively or additionally analyze the sensor data and / or communicate information related to such analysis to the mobile computing device 102 (or other suitable user interface) for display to a user.Additionally, in some variations, the mobile computing device 102 may be configured to communicate the sensor data and / or analyses of the sensor data over the network 104 to one or more storage devices 106 (e.g., a server) for archiving data and / or other suitable information relevant to a user of the cortisol monitoring device.

[0076] The cortisol monitoring devices described herein have features that improve several properties that are advantageous to continuous cortisol monitoring devices. For example, the cortisol monitoring devices described herein have improved sensitivity (amount of sensor signal generated per given concentration of cortisol), improved selectivity (rejection of endogenous and exogenous circulating compounds that may interfere with the detection of cortisol), and improved stability to help minimize changes in sensor response over time due to storage and operation of the cortisol monitoring device. The cortisol monitoring devices described herein have a relatively short warm-up time that allows the sensor to quickly provide a stable sensor signal after implantation, as well as a fast response time that allows the sensor to quickly provide a stable sensor signal after changes in the user's cortisol concentration. Additionally, as described in more detail below, the cortisol monitoring devices described herein can be applied to and function within a variety of application sites, providing the user with a painless sensor insertion. Other properties, such as biocompatibility and mechanical integrity, are also optimized in the cortisol monitoring devices described herein.

[0077] Various aspects of exemplary variations of the cortisol monitoring system and methods of use are described in further detail below. Cortisol Monitoring Device

[0078] As shown in FIG. 2A, in some variations, the cortisol monitoring device 110 may generally include a housing 112 and a microneedle array 140 extending outwardly from the housing. The housing 112 may be, for example, a wearable housing configured to be worn on the skin of a user such that the microneedle array 140 extends at least partially into the user's skin. For example, the housing 112 may include an adhesive such that the cortisol monitoring device 110 is a simple and easy skin-adhesive patch for application to a user. The microneedle array 140 may include one or more electrochemical sensors (e.g., electrodes) configured to pierce the user's skin and measure cortisol accessible after the microneedle array 140 pierces the user's skin. In some variations, the cortisol monitoring device 110 may be integrated or self-contained as a single unit, and the unit may be disposable (e.g., used for a period of time and replaced with another instance of the cortisol monitoring device 110).

[0079] The electronics system 120 may include various electronic components, such as a sensor circuit 124 disposed at least partially within the housing 112 and configured to perform signal processing (e.g., biasing and readout of an electrochemical sensor, converting an analog signal from the electrochemical sensor to a digital signal, etc.). The electronics system 120 may also include at least one microcontroller 122 for controlling the cortisol monitoring device 110, at least one communication module 126, at least one power source 130, and / or various other suitable passive circuitry 127. The microcontroller 122 may be configured, for example, to interpret digital signals output from the sensor circuit 124 (e.g., by executing routines programmed in firmware), perform various suitable algorithms or mathematical transformations (e.g., calibration, etc.), and / or route processed data to and from the communication module 126. In some variations, the communication module 126 may include a suitable wireless transceiver (e.g., a Bluetooth transceiver, etc.) for communicating data with the external computing device 102 via one or more antennas 128. For example, the communication module 126 may be configured to provide unidirectional and / or bidirectional communication of data with an external computing device 102 that is paired with the cortisol monitoring device 110. The power source 130 may provide power to the cortisol monitoring device 110, for the electronics system, and the like. The power source 130 may include a battery or other suitable power source, and in some variations may be rechargeable and / or replaceable. The passive circuitry 127 may include various non-powered electrical circuits (e.g., resistors, capacitors, inductors, and the like) that provide interconnections between other electronic components, and the like. The passive circuitry 127 may be configured to perform, for example, noise reduction, biasing, and / or other purposes. In some variations, the electronic components in the electronics system 120 may be disposed on one or more printed circuit boards (PCBs), which may be, for example, rigid, semi-rigid, or flexible. Further details of the electronics system 120 are described further below.

[0080] In some variations, the cortisol monitoring device 110 may further include one or more additional sensors 150 to provide additional information that may be relevant to user monitoring. For example, the cortisol monitoring device 110 may further include at least one temperature sensor (e.g., a thermistor) configured to measure skin temperature, thereby allowing for temperature compensation of the sensor measurements obtained by the microneedle array electrochemical sensor.

[0081] In some variations, the microneedle array 140 of the cortisol monitoring device 110 may be configured to pierce the skin of a user. As shown in FIG. 2B, when the device 110 is worn by a user, the microneedle array 140 may extend into the user's skin such that the electrodes on the distal regions of the microneedles reside in the dermis. Specifically, in some variations, the microneedles may be designed to penetrate the skin and access the upper skin regions of the skin (e.g., the papillary dermis and upper reticular dermis layers) to allow the electrodes to access the interstitial fluid surrounding the cells of these layers. For example, in some variations, the microneedles may have a height generally ranging from at least 350 μm to about 515 μm. In some variations, one or more microneedles may extend from the housing such that the distal end of the electrode on the microneedle is positioned less than about 5 mm from the skin contacting surface of the housing, less than about 4 mm from the housing, less than about 3 mm from the housing, less than about 2 mm from the housing, or less than about 1 mm from the housing.

[0082] In contrast to traditional continuous monitoring devices that typically include sensors embedded about 8 mm to about 10 mm below the skin surface in the subcutaneous tissue or fat layer of the skin, the cortisol monitoring device 110 has a shallower microneedle insertion depth of about 0.25 mm (such that the electrodes are embedded in the upper dermal region of the skin), which provides many advantages, including access to the interstitial fluid of the skin, which contains cortisol, for detection, at least since cortisol measurements in the interstitial fluid of the skin have been found to closely correlate with measurements in blood.

[0083] Furthermore, when the microneedle array is in the upper skin region, the lower dermis below the microneedle array contains very high levels of vascularization and perfusion to support dermal metabolism, which allows for thermoregulation (via vasoconstriction and / or vasodilation) and provides a barrier function that helps stabilize the sensing environment around the microneedles. Yet another advantage of a shallower insertion depth is that the upper dermal layer lacks pain receptors, thus reducing the sensation of pain when the microneedle array pierces the user's skin, providing a more comfortable and less invasive user experience.

[0084] Thus, the cortisol monitoring devices and methods described herein allow for improved continuous monitoring of cortisol in a user. For example, as described above, the cortisol monitoring devices can be simple and easy to apply, thereby improving ease of use and user compliance. Furthermore, measuring cortisol in skin interstitial fluid can provide highly accurate cortisol detection. Furthermore, compared to conventional continuous cortisol monitoring devices, the insertion of the microneedle array and its sensors can be less invasive and less painful for the user. Additional advantages of other aspects of the cortisol monitoring devices and methods are further described below. housing

[0085] As discussed above, the cortisol monitoring device may include a housing. The housing may at least partially surround or enclose other components (e.g., electronics) of the cortisol monitoring device, such as for protection of such components. For example, the housing may be configured to help prevent dust and moisture from entering the cortisol monitoring device. In some variations, an adhesive layer may attach the housing to a surface (e.g., skin) of a user while allowing the microneedle array to extend outwardly from the housing into the user's skin. Additionally, in some variations, the housing may generally include rounded edges or corners and / or may be low-profile so as to be atraumatic and reduce interference with clothing worn by the user, etc.

[0086] For example, as shown in Figures 3A-3E, an exemplary variation of a cortisol monitoring device 300 may include a housing 310 configured to at least partially enclose various other internal components of the device 300, and a microneedle array 330 extending outwardly from a skin-facing surface (e.g., an underside) of the housing 310.

[0087] The housing 310 may include one or more rigid or semi-rigid protective shell components that may be coupled together, for example, via suitable fasteners (e.g., mechanical fasteners), mechanical interlocking or mating features, and / or engineered fit. For example, as shown in FIG. 3E, the housing may include a housing cover 310a and a housing base 310b, which may be secured together with one or more fasteners (e.g., fasteners that engage threaded holes in the upper and / or lower housing portions). The cover 310a and base 310b may include rounded edges and corners, and / or other atraumatic features. When coupled together, the cover 310a and base 310b may form an interior volume that houses other internal components, such as the device printed circuit board 350 (PCB), the sensor assembly 320, and / or other components, such as a gasket 312. For example, the internal components disposed within the interior volume may be arranged in a compact, low-profile stack, as shown in FIG. 3E. 3E shows that housing 310 includes multiple housing components, in some variations housing 310 may include a single component defining an interior volume for housing internal device components. In some embodiments, housing 310 may be filled with a suitable potting compound (e.g., epoxy) to reduce deleterious environmental effects such as temperature, humidity, pressure, and light.

[0088] Additionally, the cortisol monitoring device 300 may include an adhesive layer 340 configured to attach the housing 310 to a surface (e.g., skin) of a user. The adhesive layer 340 may be attached to the skin-facing side of the housing 310 via a double-sided adhesive liner 344, for example, as shown in the variation depicted in FIG. 3D. Alternatively, the adhesive layer 340 may be bonded directly to the skin-facing side of the housing 310 using one or more suitable fasteners (e.g., adhesive, mechanical fasteners, etc.). The adhesive layer 340 may be protected by a release liner that the user removes prior to skin application to expose the adhesive. In some variations, the cortisol monitoring device may include 3M® 1504XL™ double-sided adhesive and 3M® 4076™ skin-facing adhesive available from 3M®. These materials are selected for their breathability, wearability, mean water vapor transmission rate (MWVTR), biocompatibility, compatibility with sensor sterilization methods / strategies, appearance, durability, adhesion, and ability to maintain adhesion for the duration of sensor wear.

[0089] The adhesive layer 340 may, in some variations, have a perimeter that extends farther than the perimeter or perimeter of the housing 310 (e.g., to increase the surface area for attachment and increase the stability of retention or attachment to the user's skin). Additionally, in some variations, the adhesive layer 340 may include an opening 342 that allows for the passage of the outwardly extending microneedle array 330. The opening 342 may closely circumscribe the shape of the microneedle array 330 as shown in FIG. 3C (e.g., a square opening that closely corresponds in size and shape to a square microneedle array), or may have another suitable size and shape that is larger than the footprint area of ​​the microneedle array (e.g., a circular opening that is larger than a square microneedle array).

[0090] It should be understood that while the housing 310 shown in Figures 3A-3E is hexagonal and generally prism-shaped, in other variations, the housing 310 may have any suitable shape. For example, in other variations, the housing may be generally prism-shaped and may have a base having an elliptical (e.g., circular), triangular, rectangular, pentagonal, or other suitable shape. As another example, Figures 4A-4C show an exemplary variation of a cortisol monitoring device 400 that includes a dome-shaped housing 410. While the dome-shaped housing 410 shown in Figures 4A-4C is generally circular, in other variations, the dome-shaped housing may have a base having another suitable elliptical or polygonal shape.

[0091] Similar to the housing 310, the housing 410 may include an interior volume configured to at least partially surround other components of the cortisol monitoring device 400. For example, as shown in the cross-sectional view of FIG. 4D, the housing 410 may include a dome-shaped cover 410a coupled to a base 410b to form an interior volume in which a sensor assembly having a device PCB 450 and a microneedle array 430 may be placed. Additionally, the housing 410 may be configured to be coupled to a surface via an adhesive layer 440, and the microneedle array 430 may extend beyond the adhesive layer 440 outwardly from the housing. Additionally, as shown in FIGS. 4D and 4E, the adhesive layer 440 may extend beyond the perimeter of the housing 410. User Interface

[0092] In some variations, the cortisol monitoring system may provide user status, cortisol monitoring device status, and / or other suitable information directly via a user interface on the cortisol monitoring device (e.g., a display, indicator lights, etc., as described below). Thus, in contrast to cortisol monitoring systems that may solely communicate information to a separate peripheral device (e.g., a cell phone, etc.), which may then communicate that information to the user, in some variations, such information may be provided directly by the cortisol monitoring device. Advantageously, in some variations, such a user interface on the cortisol monitoring device may reduce the need for a user to constantly maintain a separate peripheral device to monitor user status and / or cortisol monitoring device status (which may be impractical due to cost, inconvenience, etc.). Additionally, the user interface of the cortisol monitoring device may mitigate risks associated with loss of communication between the cortisol monitoring device and a separate peripheral device, such as a user having an inaccurate understanding of their current cortisol level (e.g., leading a user to assume that their cortisol level is high when it is actually low, which could lead the user to self-administer an incorrect dose of medication or to withhold a therapeutic intervention when medically necessary).

[0093] Additionally, the ability to communicate information to the user via the cortisol monitoring device itself, independent of the separate peripheral device, can reduce or eliminate the need to maintain compatibility between the cortisol monitoring device and the separate peripheral device when the separate peripheral device is upgraded (e.g., replaced with a new device model or other hardware, running a new version of an operating system or other software, etc.).

[0094] Thus, in some variations, the housing may include a user interface, such as an interface that provides visual, auditory and / or tactile information to provide information regarding a user condition based on the cortisol measurements and / or the status of the cortisol monitoring device and / or other suitable information.

[0095] Examples of user states based on cortisol measurements that may be communicated via the user interface include information indicative of the cortisol measurements in the user, such as cortisol concentration in bodily fluids such as skin interstitial fluid or bloodstream, a cortisol measurement below a predetermined cortisol measurement threshold or range, within a predetermined cortisol measurement range, or above a predetermined cortisol measurement threshold or range, an increase or decrease in the cortisol measurement over time, a rate of change in the cortisol measurement, a cortisol variability indicating the standard deviation of the cortisol measurement over a period of time, information regarding trends in the cortisol measurement, and / or other appropriate alerts related to the cortisol measurement.

[0096] Examples of cortisol monitoring device states that may be communicated via the user interface include device operational modes (e.g., related to device warm-up state, cortisol monitoring state, battery power state such as low battery, etc.), device error states (e.g., operational error, pressure-induced sensing attenuation, failure, failure mode, etc.), device power state, device life state (e.g., expected end of sensor life), the state of the connection between the device and a mobile computing device, etc.

[0097] In some variations, the user interface may be enabled or in an "on" state by default to communicate such information at least whenever the cortisol monitoring device is performing a cortisol measurement) or whenever the cortisol monitoring device is powered on, thereby helping to ensure that the information is continually available to the user. For example, the user interface elements may communicate via displays or indicator lights (e.g., as described below) to flag for the user's attention or recommend corrective action, as well as when the user status and / or device status is normal. Thus, in some variations, the user does not need to perform an action to initiate a scan to know the current cortisol measurement level, and such information may always be readily available to the user. However, in some variations, the user may perform an action to temporarily disable the user interface (e.g., similar to a "snooze" button), such as for a predetermined amount of time (e.g., 30 minutes, 1 hour, 2 hours, etc.) at which the user interface is automatically re-enabled, or until a second action is performed to re-enable the user interface.

[0098] In some variations, the user interface of the housing can include a display configured to visually communicate information. The display can include, for example, a display screen (e.g., an LCD screen, an OLED display, an electrophoretic display, an electrochromic display, etc.) configured to display alphanumeric text (e.g., numbers, letters, etc.), symbols, and / or suitable graphics to convey information to a user. For example, the display screen can include numerical information, textual information, and / or graphics (e.g., slanted lines, arrows, etc.) of information such as a user status and / or condition of the cortisol monitoring device. For example, the display screen can include textual or graphical representations of cortisol measurement levels, trends, and / or recommendations. For example, the display screen may include textual and / or graphical representations related to recommendations for physical activity, meditation, rest, food, dietary supplements, and / or medical consultations.

[0099] As another example, the display on the housing can include one or more indicator lights (e.g., including LEDs, OLEDs, lasers, electroluminescent materials, or other suitable light sources, waveguides, etc.) that can be controlled in one or more predefined illumination modes to communicate different statuses and / or other suitable information. The indicator lights may be controlled to illuminate in multiple colors (e.g., red, orange, yellow, green, blue, and / or purple, etc.) or only one color. For example, the indicator lights can include multi-color LEDs. As another example, the indicator lights can include a transparent or translucent material (e.g., acrylic) disposed over one or more different color light sources (e.g., LEDs) such that the different color light sources can be selectively activated to illuminate the indicator lights in selected colors. Activation of the light sources can occur simultaneously or sequentially. The indicator lights can have any suitable form (e.g., raised from the housing body, flush, recessed, etc.) and / or shape (e.g., circular or other polygonal, ring, elongated strip, etc.). In some variations, the indicator light may have the size and / or shape of a pinhole that emits the same intensity of light as a larger light source, but requires significantly less power, helping to conserve on-board power of the cortisol monitoring device.

[0100] The indicator lights on the display may be illuminated in one or more of a variety of ways to communicate different types of information. For example, the indicator lights may be selectively illuminated or turned off to convey information (e.g., lighting "on" indicates one state and lighting "off" indicates another state). Additionally or alternatively, the indicator lights may be illuminated at a color or intensity selected to convey information (e.g., lighting of a first color or intensity indicates a first state and lighting of a second color or intensity indicates a second state). Additionally or alternatively, the indicator lights may be illuminated in a time pattern selected to convey information (e.g., lighting of a first time pattern indicates a first state and lighting of a second time pattern indicates a second state). For example, the indicator light may be selectively illuminated in one of a number of predetermined time patterns that vary in illumination frequency (e.g., repeating illumination at a fast or slow frequency), regularity (e.g., cyclically repeating illumination vs. intermittent illumination), duration of illumination "on" time, duration of illumination "off" time, rate of change of illumination intensity, duty cycle (e.g., ratio of illumination "on" time to illumination "off" time), etc., and each predetermined time pattern may indicate a respective state.

[0101] Additionally or alternatively, in some variations, the display may include multiple indicator lights that may be collectively illuminated in one or more predetermined lighting modes or sequences according to one or more predetermined spatial and / or temporal patterns. For example, in some variations, some or all of the indicator lights arranged on the display may be illuminated synchronously or sequentially to indicate a particular state. Thus, a selected subset of the indicator lights (e.g., the spatial arrangement of the illuminated indicator lights) and / or the manner in which they are illuminated (e.g., illumination sequence, illumination speed, etc.) may indicate a particular state. Additionally or alternatively, multiple indicator lights may be illuminated simultaneously or sequentially to increase the diversity of the color palette. For example, in some variations, red, green, and blue LEDs may be illuminated in rapid succession to create the impression of white light to the user.

[0102] It should further be appreciated that one or more of the above lighting modes can be combined in any suitable manner (e.g., combinations of various colors, intensities, brightness, luminosity, contrast, timing, location, etc.) to convey information. Additionally or alternatively, an ambient light sensor can be incorporated into the device body to allow for dynamically adjusted light levels of the indicator lights to compensate for environmental light conditions and conserve power. The ambient light sensor can, in some variations, be used in conjunction with a motion sensor (e.g., as described in more detail below) to further determine an appropriate period for the cortisol monitoring device to enter a power saving mode or reduced power state. For example, the detection of darkness and no motion by the cortisol monitoring device can indicate that the wearer of the cortisol monitoring device is asleep, which can cause the cortisol monitoring device to transition to a power saving mode or reduced power state.

[0103] FIG. 25A illustrates an example variation of a cortisol monitoring device 3100 including a user interface 3120 having a plurality of indicator lights (3122, 3124a-3124c). The indicator lights 3122 may be selectively illuminated to indicate, for example, a status of the device (e.g., an operating mode, an error state, a power state, an end of life state, etc.). The indicator lights 3122 are in the form of a symbol (e.g., a logo), although it should be understood that in other variations, the indicator lights 3122 may have any suitable shape (e.g., text, other geometric shapes, etc.). The indicator lights 3124a, 3124b, 3124c may be selectively illuminated to indicate a user status (e.g., information representative of a cortisol measurement). It should be understood that while the indicator lights 3124a, 3124b, 3124c are linear elements extending across the user interface (e.g., a cord across a circular display), in other variations the indicator lights 3124a, 3124b, 3124c have other suitable shapes (e.g., wavy lines, circles, etc.). In some variations, a one-dimensional array of indicator lights of any suitable shape can be arranged on the housing (e.g., arranged in rows, columns, arcs, etc.). Alternatively, the housing can include a multi-dimensional array of indicator lights of any suitable shape.

[0104] Further, in some variations, the indicator light may include icons (e.g., symbols) that may indicate cortisol information (e.g., an up arrow indicating an upward trend in measured cortisol levels, a down arrow indicating a downward trend in measured cortisol levels), a status of the cortisol monitoring device (e.g., an exclamation point indicating a device error state), and / or other suitable information. Additionally or alternatively, iconography within the indicator light may be used to communicate recommendations to the user, such as behavioral recommendations. Iconography may have the advantage, for example, of communicating recommendations to the user in a more universal or language-independent manner (e.g., not requiring language translation to tailor the device to different geographic regions or user preferences, etc.). In one example, an increase in cortisol levels may correlate with an increase in stress for the user. For example, as shown in FIG. 25B, in some variations, the user interface of the cortisol monitoring device 3100' may include a running person icon 3126 indicating a recommendation for the user to engage in physical activity, a tree icon 3218 indicating a recommendation for the user to go outside, and / or a thinking head icon 3132 indicating a recommendation for the user to meditate.

[0105] In the variation shown in Figures 25A and 25B, each of the indicator lights 3124a, 3124b, 3124c may be exclusively illuminated to indicate a different cortisol measurement (e.g., within target range, below target range, significantly below target range, above target range, significantly above target range, etc.). Additionally, the indicator lights 3124a, 3124b, 3124c may be positioned adjacent to one another such that they may be selectively illuminated in a progressive sequence to convey trend information of the cortisol measurement (e.g., a progressive sequence of illumination in a first direction corresponding to an increase in the measured amount of cortisol, a progressive sequence of illumination in a second direction corresponding to a decrease in the measured amount of cortisol, a pace of illumination progression in the first or second direction corresponding to a rate of increase or decrease in the measured amount of cortisol, etc.). An example of such a progressive sequence of illumination is further described below with reference to Figures 27A-D. 25A-B show one device status light 3122 and three user status lights 3124a, 3124b, 3124c, it should be understood that in other variations, the cortisol monitoring device may include any suitable number of lights, such as one, two, three, four, five or more device status lights and one, two, three, four, five or more user status lights. Further details regarding exemplary operation of the user interface 3120 to communicate device status and / or user status are provided below (see, e.g., FIGS. 26A-C, 27A-D, 28A-C, and 29A-B). Microneedle Array

[0106] As shown in the schematic diagram of FIG. 5A, in some variations, a microneedle array 510 for use in sensing cortisol may include one or more microneedles 510 protruding from a substrate surface 502. The substrate surface 502 may be, for example, a substantially planar semiconductor (e.g., silicon) substrate, and the one or more microneedles 510 may protrude orthogonally from the plane. In general, as shown in FIG. 5B, the microneedle 510 may include a body portion 512 (e.g., shaft) and a tapered distal portion 514 configured to pierce the skin of a user. In some variations, the tapered distal portion 514 may terminate in an insulated distal tip 516. The microneedle 510 may further include an electrode 520 on a surface of the tapered distal portion. In some variations, the electrode-based measurement may be performed at the interface between an electrode placed inside the body and interstitial fluid (e.g., on the outer surface of the entire microneedle). In some variations, the microneedle 510 may have a solid core (e.g., a solid body portion), while in some variations, the microneedle 510 may include one or more lumens that may be used, for example, for drug delivery or sampling of skin interstitial fluid. Other microneedle variations, as described below, may similarly include either a solid core or one or more lumens.

[0107] The microneedle array 500 may be at least partially formed from a semiconductor (e.g., silicon) substrate and includes various layers of materials applied and shaped using various suitable microelectromechanical systems (MEMS) fabrication techniques (e.g., deposition and etching techniques), as described further below. The microneedle array may be reflow soldered to the circuit board, similar to a typical integrated circuit. Furthermore, in some variations, the microneedle array 500 may include a three-electrode configuration including a working (sensing) electrode having an electrochemical sensing coating (including a biorecognition element such as an enzyme) that allows for the detection of cortisol, a reference electrode, and a counter electrode. In other words, the microneedle array 500 may include at least one microneedle 510 including a working electrode, at least one microneedle 510 including a reference electrode, and at least one microneedle 510 including a counter electrode. Further details of these types of electrodes are described in more detail below.

[0108] In some variations, the microneedle array 500 may include multiple microneedles that are insulated such that the electrodes on each microneedle in the multiple microneedles are individually addressable and electrically isolated from all other electrodes on the microneedle array. The resulting individual addressability of the microneedle array 500 may allow greater control over the function of each electrode since each electrode may be probed separately. For example, the microneedle array 500 may be used to provide multiple independent measurements of cortisol, which improves the sensing reliability and accuracy of the device. Furthermore, in some variations, the electrodes of the multiple microneedles may be electrically connected to generate enhanced signal levels. As another example, the same microneedle array 500 may additionally or alternatively be interrogated to measure multiple analytes simultaneously to provide a more comprehensive assessment of a physiological condition. For example, as shown in the schematic diagram of FIG. 6, the microneedle array may include a portion of microneedles for detecting cortisol, a second portion of microneedles for detecting a second analyte B, and a third portion of microneedles for detecting a third analyte C. It should be understood that the microneedle array may be configured to detect any suitable number of analytes (e.g., 1, 2, 3, 4, 5 or more, etc.), provided that at least one of the analytes is cortisol.

[0109] In some variations of the microneedle (e.g., a microneedle having a working electrode), the electrode 520 may be positioned proximal to the insulated distal apex 516 of the microneedle. In other words, in some variations, the electrode 520 does not cover the apex of the microneedle. Rather, the electrode 520 may be offset from the apex or tip of the microneedle. The electrode 520 is proximal to or offset from the insulated distal apex 516 of the microneedle, advantageously providing more accurate sensor measurements. For example, this arrangement prevents concentration of the electric field at the microneedle apex 516 during manufacturing, thereby avoiding uneven deposition of the sensing chemistry on the electrode surface 520 that would result in erroneous sensing. The electrode 520 may be configured to have an annular shape and may include a distal edge 521a and a proximal edge 521b.

[0110] As another example, placing the electrode 520 offset from the microneedle apex further improves sensing accuracy by reducing undesirable signal artifacts and / or erroneous sensor readings caused by stresses during microneedle insertion. The distal apex of the microneedle is the first area to penetrate the skin and therefore experiences the greatest stresses caused by mechanical shear phenomena associated with tearing or cutting the skin. If the electrode 520 were placed at the apex or tip of the microneedle, this mechanical stress could peel off the electrochemical sensing coating on the electrode surface when the microneedle is inserted and / or cause a small but interfering amount of tissue to be transported onto the active sensing portion of the electrode. Thus, placing the electrode 520 sufficiently offset from the microneedle apex can improve sensing accuracy. For example, in some variations, the distal edge 520 of the electrode 521a can be placed at least about 10 μm (e.g., about 20 μm to about 30 μm) from the distal apex or tip of the microneedle as measured along the longitudinal axis of the microneedle.

[0111] The body portion 512 of the microneedle 510 may further include a conductive path extending between the electrode 520 and a back electrode or other electrical contact (e.g., disposed on the back side of the substrate of the microneedle array). The back electrode may be soldered to a circuit board and may be in electrical communication with the electrode 520 via the conductive path. For example, during use, the in vivo sensed current measured at the working electrode (inside the dermis) is interrogated by the back electrical contact, and the electrical connection between the back electrical contact and the working electrode is facilitated by the conductive path. In some variations, this conductive path may be facilitated by a metal via running through the interior of the microneedle body portion (e.g., shaft) between the proximal and distal ends of the microneedle. Alternatively, in some variations, the conductive path may be provided by the entire body portion formed from a conductive material (e.g., doped silicon). In some of these variations, the complete substrate on which the microneedle array 500 is constructed may be conductive, and each microneedle 510 of the microneedle array 500 may be electrically isolated from adjacent microneedles 510 as described below. For example, in some variations, each microneedle 510 in the microneedle array 500 may be electrically isolated from adjacent microneedles 510 using an insulating barrier including an electrically insulating material (e.g., a dielectric material such as silicon dioxide) that surrounds the conductive pathway extending between the electrode 520 and the backside electrical contact. For example, the body portion 512 may include an insulating material that forms a sheath around the conductive pathway, thereby preventing electrical communication between the conductive pathway and the substrate. Other exemplary variations in structures that provide electrical isolation between microneedles are described in more detail below.

[0112] Such electrical isolation between the microneedles in the microneedle array allows the sensors to be individually addressable. This individual addressability advantageously allows for independent, parallelized measurements between sensors, as well as dynamic reconfiguration of sensor assignments (e.g., for different analytes). In some variations, the electrodes of the microneedle array can be configured to provide redundant cortisol measurements, which is an advantage over conventional cortisol monitoring devices. For example, redundancy can improve performance by improving accuracy (e.g., averaging multiple cortisol measurements from different microneedles to reduce the impact of extreme high or low sensor signals on the determination of cortisol levels) and / or can improve device reliability by reducing the likelihood of overall failure.

[0113] In some variations, as described in further detail below with each different variation of microneedles, the microneedle array may be at least partially formed by suitable semiconductor and / or MEMS manufacturing techniques and / or mechanical cutting or dicing. Such processes may be advantageous, for example, to enable large-scale, cost-effective manufacture of microneedle arrays. Microneedle structure

[0114] Described herein are several exemplary variations of microneedle structures incorporating one or more of the microneedle features described above for microneedle arrays in cortisol monitoring devices.

[0115] In some variations, the microneedle may have a generally cylindrical body portion and a tapered distal portion having an electrode. For example, Figures 7A-7C show an exemplary variation of a microneedle 700 extending from a substrate 702. Figure 7A is a schematic side cross-sectional view of the microneedle 700, Figure 7B is a perspective view of the microneedle 700, and Figure 7C is a detailed perspective view of the distal portion of the microneedle 700. As shown in Figures 7B and 7C, the microneedle 700 may include a cylindrical body portion 712, a tapered distal portion 714 terminating in an insulated distal apex 716, and a ring electrode 720. The ring electrode 720 includes a conductive material (e.g., Pt, Ir, Au, Ti, Cr, Ni, combinations thereof, etc.) disposed on the tapered distal portion 714, e.g., on a segment thereof, and includes a distal edge 721a and a proximal edge 721b. 7A, the ring electrode 720 may be proximal to (or offset or spaced from) the distal apex 716. The ring electrode 720 may be electrically insulated from the distal apex 716 by a distal insulating surface 715a that includes an insulating material, such as SiO2. For example, the distal edge 721a of the ring electrode 720 may be proximate to the proximal edge of the distal insulating surface 715a of the insulated distal apex 716. In some variations, the distal edge 721a of the ring electrode 720 may be proximal (e.g., immediately proximal, adjacent, abutting) the proximal edge of the distal apices 716 (proximal edge of the distal insulating surface 715a), while in other variations, the distal edge 721a of the ring electrode 720 may be distal (e.g., immediately distal, adjacent) to the proximal edge of the insulated distal apices 716 (proximal edge of the distal insulating surface 715a), but remain proximal to the apices themselves. Thus, in some variations, the ring electrode 720 may overlie a portion of the distal insulating surface 715a, but remain proximal to (and may be offset from) the insulated distal apices themselves (see, e.g., FIG. 21C).

[0116] 7A, the proximal edge 721b of the ring electrode 720 may be distal to the cylindrical body portion 712, or in some variations may be offset or spaced therefrom. In some variations, the proximal edge 721b of the ring electrode 720 may also be electrically insulated from the cylindrical body portion 712 by a second distal insulating surface 715b comprising an insulating material (e.g., SiO2) at the proximal end or region of the tapered distal portion 714. For example, the proximal edge 721b of the ring electrode 720 may be proximate to the distal edge of the second distal insulating surface 715b. In some variations, the proximal edge 721b of the ring electrode 720 may be proximal (e.g., immediately proximal, adjacent, abutting) to the distal edge of the second distal insulating surface 715b, while in other variations, the proximal edge 721b of the ring electrode 720 may be distal (e.g., immediately distal, adjacent) to the distal edge of the second distal insulating surface 715b but remain proximal to the cylindrical body portion 712. Thus, in some variations, the ring electrode 720 may overlie a portion of the second distal insulating surface 715b but remain proximal to (and offset from) the cylindrical body portion 712(a). See, e.g., FIG. 21C). As shown in FIG. 7A and some other variations, the ring electrode 720 may be on only a portion of the surface of the tapered distal portion 714 and may or may not extend to the cylindrical body portion 712.

[0117] The electrode 720 may be in electrical communication with a conductive core 740 (e.g., a conductive path) that passes along the body portion 712 to a backside electrical contact 730 (e.g., made from a Ni / Au alloy) or other electrical pad in or on the substrate 702. For example, the body portion 712 may include a conductive core material (e.g., heavily doped silicon). As shown in FIG. 7A, in some variations, an insulating moat 713 comprising an insulating material (e.g., SiO2) may be disposed around (e.g., around the periphery) of the body portion 712 and extend at least partially through the substrate 702. The insulating moat 713 may thus serve to prevent electrical contact between, for example, the conductive core 740 and the surrounding substrate 702. The insulating moat 713 may further extend onto the surface of the body portion 712. The top and / or bottom surfaces of the substrate 702 may also include a substrate insulating layer 704 (e.g., SiO2). Thus, the insulation provided by the insulating moat 713 and / or substrate insulator 704 may at least partially contribute to the electrical insulation of the microneedles 700 enabling addressability of the microneedles 700 within a microneedle array. Additionally, in some variations, the insulating moat 713 extending onto the surface of the body portion 712 may function to increase the mechanical strength of the microneedle 700 structure.

[0118] The microneedle 700 may be formed at least in part by a suitable MEMS fabrication technique, such as plasma etching, also referred to as dry etching. For example, in some variations, the insulating moat 713 around the body portion 712 of the microneedle may be fabricated by first forming a trench in a silicon substrate by deep reactive ion etching (DRIE) from the backside of the substrate, and then filling the trench with a SiO2 / polycrystalline silicon (poly-Si) / SiO2 sandwich by low pressure chemical vapor deposition (LPCVD) or other suitable process. In other words, the insulating moat 713 passivates the surface of the body portion 712 of the microneedle and may continue as a recessed feature in the substrate 702 near the proximal portion of the microneedle. By including a compound that is primarily silicon, the insulating moat 713 may provide good filling and adhesion to adjacent silicon walls (e.g., conductive core 740, substrate 702, etc.). The sandwich structure of the insulating moat 713 can further help provide an excellent coefficient of thermal expansion (CTE) match with the adjacent silicon, thereby advantageously reducing failure, cracking, and / or other thermally induced weaknesses of the insulating structure 713.

[0119] The tapered distal portion may be formed by isotropic dry etching from the front side of the substrate, and the body portion 712 of the microneedle 700 may be formed by DRIE. A front metal electrode 720 may be deposited and patterned on the distal portion by special lithography (e.g., electron beam evaporation) that allows metal deposition on the desired annular region of the electrode 720 without coating the distal tip 716. Additionally, a Ni / Au backside electrical contact 730 may be deposited by an appropriate MEMS fabrication technique (e.g., sputtering).

[0120] The microneedle 700 may have any suitable dimensions. By way of example, the microneedle 700 may have a height of about 300 μm to about 500 μm in some variations. In some variations, the tapered distal portion 714 may have a tip angle of about 60 degrees to about 80 degrees and a top diameter of about 1 μm to about 15 μm. In some variations, the surface area of ​​the ring electrode 720 may be about 9000 μm. 2 ~about 11000μm 2 , or about 10,000 μm 2 FIG. 8 illustrates various dimensions of an exemplary variation of a cylindrical microneedle having a tapered distal portion and an annular electrode, similar to the microneedle 700 described above. The cylindrical microneedle of FIG. 8, similar to the microneedle 700 described above, comprises a cylindrical body portion, a tapered distal portion terminating in an insulated distal apex, a contact trench formed in the tapered distal portion, and an annular electrode (labeled "Pt" in FIG. 8) disposed on the tapered distal portion and covering the contact trench. The annular electrode may comprise a conductive material (e.g., Pt, Ir, Au, Ti, Cr, Ni, combinations thereof, etc.). In some variations, the contact trench may have a width of about 1 μm, about 2 μm, about 3 μm, about 4 μm, about 5 μm, about 10 μm, about 15 μm, about 20 μm, about 25 μm, about 30 μm, about 35 μm, about 40 μm, about 45 μm, about 50 μm, or about 20 μm as shown in Figure 8. The ring electrode may include a distal edge and a proximal edge, and in some variations, the distance between the distal and proximal edges of the ring electrode may be about 20 μm, about 30 μm, about 40 μm about 50 μm, about 60 μm, about 70 μm, about 80 μm, about 90 μm, about 100 μm, or about 60 μm as shown in Figure 8. In some variations, as shown in FIG. 8 by the dimension callouts 60 μm and 20 μm, the annular electrode may overlap a portion of the insulating surface of the contact trench, the tapered distal portion (labeled "Oxide" in FIG. 8).

[0121] 9 illustrates another exemplary variation of a microneedle 900 having a generally cylindrical body portion. The microneedle 900 may be similar to the microneedle 700 described above, except as described below. For example, similar to the microneedle 700, the microneedle 900 may include a cylindrical body portion 912 and a tapered distal portion 914 terminating in an insulated distal apex 916. The microneedle 900 may further include an annular electrode 920 comprising a conductive material and disposed on the tapered distal portion 914 at a location proximal to (or offset or spaced from) the distal apex 916. Other elements of the microneedle 900 are numbered similarly to the corresponding elements of the microneedle 700.

[0122] However, compared to microneedle 700, microneedle 900 may have a sharper tip at distal apex 916 and modified insulating moat 913. For example, distal apex 916 may have a sharper tip angle, such as about 25 degrees to about 45 degrees, and an apex radius of less than about 100 nm, which provides a sharper microneedle profile that may penetrate skin more easily, at a slower speed, with less energy, and / or with less trauma. Furthermore, in contrast to insulating moat 713 (which extends through substrate 702 and along the height of microneedle body portion 712, as shown in FIG. 7A), modified insulating moat 913 may extend only through substrate 902 such that the sandwich structure filling the trench (e.g., created by DRIE as described above) forms only a buried feature in the substrate. Although the sidewalls of the microneedle 900 are shown in FIG. 9 as extending approximately perpendicular to the substrate surface, it should be understood that because the modified insulating moat 913 does not need to extend the entire height of the microneedle body portion 712, in some variations the sidewalls of the microneedle 900 may be sloped at a non-orthogonal angle to the substrate (e.g., the sidewalls may have a slight positive taper of between about 1 degree and about 10 degrees, or between about 5 degrees and about 10 degrees).

[0123] In some variations, the remainder of the microneedle surface 900 (other than the annular electrode 920) may include insulating material extending from the substrate insulator 904. For example, a layer of insulating material (e.g., SiO2) may extend from the front surface of the substrate 902 to provide body portion insulation 918 and may further extend over the proximal edge 921b of the electrode 920 as shown in FIG. 9. Another region of insulating material may similarly cover the distal edge 921a of the electrode 920 and insulate the distal tip 916. Such regions of insulating material and / or modified insulating moat 913 may help prevent electrical contact between the conductive core 940 and the surrounding substrate 902. Thus, similar to the microneedle 700, the microneedle 900 may maintain electrical isolation for addressability within a microneedle array. In some variations, the process of forming the microneedle 900 may result in higher yields and / or offer lower manufacturing costs compared to the process of forming the microneedle 700.

[0124] The microneedle 900 may have any suitable dimensions. By way of example, the microneedle 900 may include a height of about 400 μm to about 600 μm, or about 500 μm in some variations. In some variations, the tapered distal portion 914 may have a tip angle of about 25 degrees to about 45 degrees, with a tip radius of less than about 100 nm. Additionally, the microneedle may have a shaft diameter of about 160 μm to about 200 μm. FIG. 10 illustrates further various dimensions of an exemplary variation of a cylindrical microneedle having a tapered distal portion and a ring electrode, similar to the microneedle 900 described above.

[0125] 21A-21F show another exemplary variation of a microneedle 2700 having a generally cylindrical body portion. The microneedle 2700 may be similar to the microneedle 700 described above. For example, as shown in FIG. 21B, similar to the microneedle 700, the microneedle 2700 may include a cylindrical body portion 2712 and a tapered distal portion 2714 disposed on a cylinder 2713 and terminating in an insulated distal apex 2716. The cylinder 2613 may be insulated and may have a smaller diameter than the cylindrical body portion 2712. The microneedle 2700 may further include a ring electrode 2720 comprising a conductive material and disposed on the tapered distal portion proximal to (or offset or spaced from) the distal apex 2916. The electrode 2720 may be electrically insulated from the distal tip 2716 by a distal insulating surface 2715a comprising an insulating material (e.g., SiO2). In some variations, the proximal edge of the electrode 2720 may be electrically insulated from the post-shaped body portion 2712 by a second distal insulating surface 2715b comprising an insulating material (e.g., SiO2). Other elements of the microneedle 2700 shown in Figures 21A-21F are numbered similarly to the corresponding elements of the microneedle 700.

[0126] 21B, 21C, and 21F, the tapered distal portion 2714, and more specifically, the electrode 2720 on the tapered distal portion 2714 of the microneedle 2700, can include a tip contact trench 2722. This contact trench can be configured to establish an ohmic contact between the electrode 2720 and the underlying conductive core 2740 of the microneedle. In some variations, the shape of the tip contact trench 2722 can include an annular recess formed in a surface of the tapered distal portion 2714. In some variations, the shape of the tip contact trench 2722 can include an annular recess formed in a surface of the conductive core 2740 (e.g., in contact with a conductive path within or otherwise within the body portion of the microneedle). In some variations, the tip contact trench 2722 may be formed in the insulating material on the tapered distal portion 2714 and may have a depth approximately equal to the thickness of the insulating material (e.g., distal insulating surface 2715a and / or second distal insulating surface 2715b). In some examples, the depth of the contact trench may be greater than the thickness of the insulating material such that the contact trench extends beyond the surface of the conductive core 2740 (e.g., into the conductive core 2740). The electrode 2720 may overlie the tip contact trench 2722 such that an ohmic contact is established between the electrode 2720 and the conductive core 2740. In some variations, the electrode 2720 may extend beyond the tip contact trench 2722 such that when the material of the electrode 2720 is deposited on the conductive core 2740, the electrode 2720 with the tip contact trench 2722 may have a stepped profile in side view. Thus, the tip contact trench 2722 may advantageously help to ensure contact between the electrode 2720 and the underlying conductive core 2740. Any of the other microneedle variations described herein may have similar tip contact trenches to help ensure contact between the electrode (which may be, for example, a working electrode, a reference electrode, a counter electrode, etc.) and the conductive pathway within the microneedle.

[0127] 22A and 22B show further various dimensions of an exemplary variation of a cylindrical microneedle having a tapered distal portion and a ring electrode, similar to the microneedle 2700 described above. For example, the microneedle variation shown in FIG. 22A and 22B may have a tapered distal portion having a taper angle of generally about 80 degrees (or about 78 degrees to about 82 degrees, or about 75 degrees to about 85 degrees) and a cone diameter of about 140 μm (or about 133 μm to about 147 μm, or about 130 μm to about 150 μm). The cone of the tapered distal portion may be disposed on the cylinder such that the combined height of the cone and cylinder is about 110 μm (or about 99 μm to about 116 μm, or about 95 μm to about 120 μm). The ring electrode on the tapered distal portion can have an outer or base diameter of about 106 μm (or about 95 μm to about 117 μm, or about 90 μm to about 120 μm) and an inner diameter of about 33.2 μm (or about 30 μm to about 36 μm, or about 25 μm to about 40 μm). The length of the ring electrode measured along the slope of the tapered distal portion can be about 57 μm (or between about 55 μm to about 65 μm), and the total surface area of ​​the electrode can be about 12,700 μm. 2 (or about 12500μm 2 ~Approx. 12900μm 2 Between 12000μm and approx. 2 ~about 13000μm 2 As shown in FIG. 22B, the electrode may further have a tip contact trench extending around the conical central region of the tapered distal portion, the contact having a width of about 11 μm (or about 5 μm to about 50 μm, about 10 μm to about 12 μm, or about 8 μm to about 14 μm) as measured along the slope of the tapered distal portion, and a trench depth of about 1.5 μm (or about 0.1 μm to about 5 μm, or about 0.5 μm to about 1.5 μm, or about 1.4 μm to about 1.6 μm, or about 1 μm to about 2 μm). The microneedle has an insulated distal tip having a diameter of about 5.5 μm (or about 5.3 μm to about 5.8 μm, or about 5 μm to about 6 μm).

[0128] In some variations, the microneedle may have a generally pyramidal body portion and a tapered distal portion having an electrode. For example, FIG. 11A shows an exemplary variation of a microneedle 1100 having a generally pyramidal body portion 1112 and a tapered distal portion 1114 extending from the body portion 1112. The microneedle 1100 may also include an annular electrode 1120 disposed on the tapered distal portion 1114 and proximal to an insulated distal tip 1116. The electrode 1120 may be conductively coupled to a backside electrical contact 1130 via a conductive path through a conductive core 1140 of the microneedle. Similar to the microneedle 900 described above with respect to Figure 9, the microneedle 1100 may include an insulating moat 1113 disposed about the base of the body portion 1112 and extending through the substrate 1102 to provide electrical insulation about the microneedle 1100 (e.g., for individual addressability) and to help prevent electrical contact between the conductive core 1140 and the surrounding substrate 1102. However, in contrast to the insulating moat 913 shown in Figure 9, the insulating moat 1113 may be offset from the base of the microneedle 1100. The moat may be offset, for example, by about 10 μm to about 400 μm, about 10 μm to about 300 μm, about 10 μm to about 200 μm, or about 10 μm to about 100 μm from where the base of the microneedle 1100 meets the substrate 1102 to which it is attached. In some variations, the insulating moat may include a filler material including parylene, Si3N4, and SiO2, which may provide low thermal stress and chemically and water resistant insulating material. An additional body portion insulator 1118 may extend from the front surface of the substrate 1102 to the proximal edge of the electrode 1120. Another region of insulating material may extend from the distal edge of the electrode 1120 and insulate the distal tip 1116.

[0129] As shown in FIG. 11B, in some variations, a microneedle 1100 having a pyramidal body portion 1112 may include a polygonal base, although the base may have any suitable shape (e.g., circular). The pyramidal body portion 1112 may include multiple planar facets each extending from each of the polygonal bases of the microneedle. In some variations, the planar facets are anisotropically etched to increase the mechanical strength (e.g., compressive strength and shear strength) of the microneedle 1110 and / or to increase the electrode surface area compared to a cone having a non-planar faceted surface. <311> For example, the microneedle 1110 may include anisotropically etched surfaces that enhance mechanical strength and enhance the metallization surface of the microneedle 110 relative to the electrode surface. <311> It may have an octagonal base with planar facets.

[0130] The microneedle 1100 may be formed at least in part by suitable MEMS fabrication techniques. For example, the microneedle pyramidal structure may be formed by timed anisotropic wet etching of a silicon wafer substrate. Metal deposition on the tapered distal portion of the microneedle may be performed, such as by using specialized lithography techniques as described above with respect to the electrode 720, without coating the distal apex 1116, to form an annular electrode surface. However, in comparison to the above processes for forming the microneedle 700, many of the processes for forming the microneedle 1100 do not require expensive RIE techniques, thereby substantially reducing manufacturing costs. Furthermore, in some variations, instead of utilizing a dry etching process as described above with respect to the microneedle 700, the process for forming the microneedle 1100 may include mechanical dicing, bulk micromachining, or other cutting techniques to shape the microneedle 1100 to have a pyramidal body. Furthermore, such techniques may be performed on a large scale, for example to form a plurality of microneedles 1110 arranged in an array as shown in FIG. 11C.

[0131] The microneedle 1100 may have any suitable dimensions. By way of example, the microneedle 1100 may have a height of about 400 μm to about 600 μm, or about 500 μm, in some variations. In some variations, the tapered distal portion 714 may have a tip angle of about 30 degrees to about 50 degrees, or about 40 degrees, which may provide a good balance between sharpness of skin penetration and lithographic processability on the beveled surface on which the electrode 1120 is disposed.

[0132] 12 shows various dimensions of example variations of pyramidal microneedles having a tapered distal portion with planar facets and an electrode disposed on at least some of the planar facets. It should be understood that in some variations, the electrode may be annular or annular in that all of the planar facets on the pyramidal microneedle may include a metallized surface of the electrode, but alternatively, in some variations, only a portion of the planar facets on the pyramidal microneedle may include a metallized surface (e.g., 1, 2, 3, 4, 5, 6, or 7 planar facets of a pyramidal microneedle having an octagonal base and eight planar facets extending distally from the octagonal base).

[0133] In some variations, the pyramidal microneedles may be similar to those described above with respect to Figure 11A, except that the microneedles may have an asymmetric shape as shown in Figures 13A and 13B. For example, in some variations as shown in Figure 13A, the microneedle 1300 may have a non-circular or polygonal (e.g., square, octagonal) base, but may taper asymmetrically in the radial direction. For example, the microneedle 1300 may include at least one cutting surface 1350 (e.g., a plane) that is offset from the distal apex 1316 of the microneedle (i.e., does not extend through a central z-axis that is defined as passing from the base of the microneedle 1300 to the distal apex 1316. The insulated distal apex 1316 may be kept intact so as not to compromise the surface area for electrode metallization. In some variations, the cutting surface 1350 may be inclined at a non-orthogonal angle to the base of the microneedle (and / or the surface of the substrate 1302), as shown in FIG. 13A. For example, in some variations, the cutting surface may be configured to generate a sharp, asymmetric distal tip at the distal apex 1316 that is less than about 50 degrees, less than 40 degrees, less than about 30 degrees, or less than about 20 degrees. Alternatively, in some variations, the cutting surface 1350 may be inclined to be perpendicular or orthogonal to the base of the microneedle (and / or the surface of the substrate 1302).

[0134] Additionally or alternatively, as shown in FIG. 13A, an exemplary variation of an asymmetric microneedle 1300 can have a polygonal (e.g., octagonal) base, but includes various beveled surfaces that taper at different angles. As shown in FIG. 13A, the body portion 1316 of the microneedle 1300 can have a first taper angle (A) and a second taper angle (B) measured relative to the base of the body portion (and / or the surface of the substrate 1302). The second taper angle (B) can be greater than the first taper angle (A) such that the microneedle has a sharper piercing tip extending from a stable and mechanically strong base. For example, in some variations, the first taper angle (A) can be about 10 degrees to about 30 degrees, about 15 degrees to about 25 degrees, or about 20 degrees. Additionally, in some variations, the second taper angle (B) may be between about 60 degrees and about 80 degrees, between about 65 degrees and about 75 degrees, or about 70 degrees.

[0135] 13C-13E show a sequence of steps of an exemplary variation for forming a pyramidal microneedle with an asymmetric cut surface. As shown in FIG. 13C, an anisotropic wet etching process can form a symmetric pyramidal microneedle with two taper angles. The two taper angles of the microneedle can include, for example, a first taper angle of about 20 degrees located near the base of the microneedle and a second taper angle of about 70 degrees located distal to the first taper angle, thereby forming a gradually sloping surface (e.g., along the planar facet of the pyramidal microneedle). As shown in FIG. 13D, a dicing blade can be applied at an angle offset from the distal apex of the microneedle to form a cut surface similar to cut surface 1350 described above. The cut surface can leave a reduced microneedle base diameter (e.g., about 150 μm to about 190 μm, or about 170 μm) to result in low tissue trauma. As shown in FIG. 13E, the resulting microneedle (with its offset cut surface) is asymmetric but has an intact, sharp distal tip.

[0136] Similar to the pyramidal microneedle 1100 described above with respect to FIG. 11A, the microneedle 1300 is anisotropically etched. <311> The asymmetric pyramidal microneedle derives its mechanical strength at least in part from its planar and pyramidal shape. However, asymmetric pyramidal microneedles with asymmetric cut surfaces may be advantageous in that they can reduce longitudinal shear forces compared to symmetric microneedles of similar dimensions but lacking an asymmetric cut. Furthermore, sharper (e.g., more acute) distal microneedle tips can be achieved with such asymmetric cut surfaces. Although the cut surface 1350 is shown in FIG. 13A as being disposed at a non-orthogonal angle to the base of the microneedle, or as described above, in some variations, the cut surface 1350 may be approximately orthogonal or perpendicular to the base of the microneedle (and / or the surface of the substrate 1302), which can further reduce the longitudinal shear forces of the microneedle.

[0137] In some variations, the microneedle may be similar to those described above, except that the microneedle may include a columnar body portion and a pyramidal distal portion. For example, as shown in Figures 14A-14B, a columnar pyramidal microneedle 1400 may include a columnar body portion 1412 that may extend from a polygonal (e.g., octagonal) base from a non-conductive substrate 1402, such as intrinsic (undoped) silicon. Additionally, the columnar pyramidal microneedle 1400 may include a tapered distal portion 1414 having a pyramidal shape with multiple planar facets. For example, the columnar pyramidal microneedle 1400 may have a pyramidal tapered distal portion 1414 with octagonal facets extending from an octagonal columnar body portion 1412. However, the pyramidal shape may have any suitable number of planar facets (e.g., 1, 2, 3, 4, 5, 6, 7, 9, or more). The annular electrode 1420 may be formed on all planar facets of the pyramidal distal portion 1414, or only a portion of the planar facets (e.g., on one, two, three, four, five, six, seven facets) may include a metallized surface of the electrode. Similar to that described above, the cylindrical body portion 1412 may include a conductive core including a conductive material that serves as a conductive path for signals to and from the electrode 142. The cylindrical body portion 1412 may further include an insulating material 1418 that may extend along the body portion 1412 to (or slightly overlap) the proximal edge of the electrode 1420. The distal apex 1416 may or may not be covered by a similar insulating material.

[0138] In some variations, the tapered distal portion 1414 may be similar to those described above with respect to Figures 11A-11C, 12, and / or 13A-13E. For example, the tapered distal portion 1414 may be formed using anisotropic wet etching techniques. The electrode 1420 may be formed on the tapered distal portion 1414 by lithography, electrodeposition, or other suitable techniques. The tapered distal portion 1414 may then be protected by an etch resistant material while the body portion 1412 is formed from the substrate by dry etching (e.g., DRIE) or other suitable process.

[0139] The combination of the pillar-shaped and pyramidal aspects of the microneedle 1400 has several advantages. The tapered distal portion 1414 and apex 1416 are similar to those described above. <311> It has high mechanical strength due to the wet-etched surface and pyramidal shape. Furthermore, because the substrate is formed from a non-conductive material, insulating "moats" as described above may not be required to electrically isolate the microneedles, thereby simplifying manufacturing and reducing costs. The lack of insulating moats also allows for continuity of material within the substrate, which may result in better mechanical integrity of the overall microneedle array structure.

[0140] While the pillared pyramidal microneedle 1400 has been described above as including a non-conductive substrate, it should be understood that in some variations the pillared pyramidal microneedle may alternatively include a conductive core extending from a conductive substrate (e.g., doped silicon). For example, in some variations the pillared body portion 1412 may be similar to that described above with respect to Figures 7A-7C and 8-10 (e.g., may include an insulating moat for electrically isolating the microneedle, etc.).

[0141] In some variations of a microneedle array including one or more microneedles 1400, a conductive path may be formed in a non-conductive substrate to facilitate communication with the electrode 1420. For example, as described above, the body portion 1412 of each microneedle may have a conductive core including a conductive material. Such conductive material may extend between the electrode 1420 and the substrate 1402. As shown in FIG. 15D, the microneedle array may include one or more connectors 1510 made of a conductive material (e.g., gold, aluminum), each of which is coupled to a backside electrical contact 1530 for further sensor communication. In some variations, as shown in FIGS. 15A-15D, the one or more connectors 1510 may extend laterally along the surface of the substrate and then connect to the backside electrical contact 1530 using a conductive via 1520 in the substrate.

[0142] Further details of exemplary variations in microneedle array configurations are described in more detail below. electrode

[0143] As mentioned above, each microneedle in the microneedle array may include an electrode. In some variations, multiple different types of electrodes may be included among the microneedles of the microneedle array. For example, in some variations, the microneedle array may function as an electrochemical cell capable of electrolytic operation using three types of electrodes. In other words, the microneedle array may include at least one working electrode, at least one counter electrode, and at least one reference electrode. Thus, the microneedle array may include three different electrode types, but one or more of each electrode type may form a complete system (e.g., the system may include multiple separate working electrodes). Furthermore, multiple separate microneedles may be electrically joined to form an effective electrode type (e.g., a single working electrode may be formed from two or more connected microneedles having working electrode sites). Each of these electrode types may include a metallization layer and one or more coatings or layers on the metallization layer that help facilitate the function of that electrode.

[0144] In general, the working electrode is the electrode at which the oxidation and / or reduction reaction of interest occurs for detection of the analyte of interest. The counter electrode functions to source (supply) or sink (store) the electrons necessary to sustain the electrochemical reaction at the working electrode via current. The reference electrode functions to provide a reference potential for the system; that is, the potential at which the working electrode is biased is referenced to the reference electrode. A fixed, time-varying, or at least controlled potential relationship is established between the working and reference electrodes, and within practical limits, no current is sourced from or sunk to the reference electrode. Furthermore, to implement such a three-electrode system, the cortisol monitoring device can include a suitable potentiostat or electrochemical analog front end to maintain a fixed potential relationship between the working and reference electrode contingencies in the electrochemical system (via an electronic feedback mechanism), while dynamically varying the counter electrode to the potential required to sustain the redox reaction of interest.

[0145] Turning to an aptamer-based approach for measuring and monitoring cortisol in skin interstitial fluid consistent with implementation aspects of the present subject matter, aspects of a working electrode, a counter electrode, and a reference electrode are provided. working electrode

[0146] As mentioned above, the working electrode is the electrode at which detection of an analyte, such as cortisol, takes place. In some variations, sensing may be performed at the interface of the working electrode placed in the body and the interstitial fluid (e.g., on the outer surface of the entire microneedle). In some variations, the working electrode may include an electrode material and a biorecognition layer in which biorecognition elements (e.g., aptamers) are immobilized on the working electrode to facilitate selective analyte quantification. In some variations, the biorecognition layer may also function as an interference blocking layer, helping to prevent endogenous and / or exogenous species from being oxidized (or reduced) directly at the electrode.

[0147] In some variations, the redox current detected at the working electrode can be correlated to the concentration of the analyte of interest because, assuming a steady-state diffusion-limited system, the redox current detected at the working electrode follows the Cotterell relationship, Equation (1):

number

[0148] In some variations, for example, when the system is biased to a time-varying potential, the redox current detected at the working electrode can be correlated to the concentration of the analyte of interest based on the relationship in equation (2).

number

[0149] In some variations, the surface of the electrode is functionalized with redox active molecules via aptamer immobilization, and the binding of cortisol to these surface sites follows the Michaelis-Menten model. Upon binding to cortisol, the cortisol-binding aptamer undergoes a conformational change that moves the redox active molecule closer to the electrode, or further away from it. The redox active molecule is held in its oxidized state, and a sweep to more negative potentials reduces the redox active molecule within the range of electron transfer. The final relationship is nonlinear, and quasi-linear over a limited range when comparing the signal gain to the logarithm of the cortisol concentration. The relationship of the redox current detected at the working electrode is expressed as follows:

number

[0150] Furthermore, because the detection current is a direct function of the electrode surface area A, the surface area of ​​the electrode can be increased to increase the sensitivity of the sensor (e.g., amperes per mole of analyte). For example, multiple single working electrodes can be grouped into an array of two or more components to increase the total effective sensing surface area. Additionally or alternatively, for redundancy, multiple working electrodes can be operated as a parallelized sensor to obtain multiple independent measurements of the concentration of the analyte of interest. A working electrode can operate as an anode (so that the analyte is oxidized at its surface) or as a cathode (so that the analyte is reduced at its surface).

[0151] In some variations, the biorecognition element in the biorecognition layer can be an aptamer that selectively and reversibly binds to the glucocorticoid hormone cortisol ("cortisol-binding aptamer"). Aptamers are single-stranded oligonucleotides that fold into a predefined structure that selectively binds to a particular target, which can be, for example, a protein, peptide, hormone, or small molecule. The recognition and binding of an aptamer to its target involves three-dimensional shape-dependent interactions as well as hydrophobic interactions, base stacking, and intercalation, and is typically reversible by dissociation. Aptamers with affinity for a desired target, such as cortisol, are conventionally selected from large oligonucleotide libraries by a process called SELEX (Sequential Evolution of Ligands by Exponential Enrichment). Through an iterative process, non-binding aptamers are discarded and aptamers that bind to the proposed target are amplified by polymerase chain reaction (PCR). An initial positive selection round can be followed by a negative selection, which improves the selectivity of the resulting aptamer candidates. Multiple rounds of SELEX can be performed with increasing stringency to further enrich the oligonucleotide pool until one or more oligonucleotides having the desired degree of affinity and selectivity for the desired target are selected for use.

[0152] In some variations, the oligonucleotides contained in the aptamer can be DNA or RNA. The oligonucleotides can be functionalized at the 3' or 5' end. One end can provide a chemical moiety for surface immobilization ("immobilization moiety"), such as an amine, aldehyde, carboxylic acid, thiol, disulfide, azide, n-hydroxysuccinimide (NHS), maleimide, vinyl, silane, chlorosilane, methoxysilane, ethoxysilane, or acetylene group. The immobilization moiety can be separated from the oligonucleotide sequence by a linker selected for its ability to create distance between the oligonucleotide sequence and the surface to which it is immobilized. The linker can also be selected for compatibility with other chemical layers on the electrode surface, for example, a hydrocarbon linker having a length equal to or similar to the hydrocarbon chain used in the self-assembled monolayer coating the remaining part of the electrode surface. The opposite end of the oligonucleotide may be functionalized with one or more redox-active molecules that function as probes, such as methylene blue, ferrocene, pentamethylferrocene, C5-ferrocene, Nile blue, thionine, anthraquinone, C5-anthraquinone, gallocyanine, indophenol, neutral red, dabsyl, or carboxy-X-rhodamine. These redox-active molecules may also be attached to the oligonucleotide via a custom linker. The backbone of the oligonucleotide may be modified to increase stability in physiological conditions. For example, RNA arrays incorporating L-ribose or DNA arrays incorporating L-deoxyribose, as opposed to the respective natural dextrorotatory sugars, may be used to protect the oligonucleotide from degradation by enzymes in the body. In some variations, the backbone modification may include replacing the ribose in RNA or deoxyribose in DNA with 2'-O-methylribose, which also has the effect of protecting against enzymatic cleavage in physiological conditions.In some variations, the cortisol binding aptamer is defined by the following DNA array: 5'-GGACGACGCCAGAAGTTTACGAGGATATGGTAACATAGTCGT-3', where G, A, C, and T represent typical DNA nucleotides including guanine, adenine, cytosine, and thymine, respectively.

[0153] In some variations, the cortisol-binding aptamers may be selected not for maximum affinity to cortisol, but for an intermediate affinity such that a portion of the population of selected aptamers having cortisol molecules bound thereto are sensitive to the physiological concentration range of cortisol in skin interstitial fluid, which may be from about 0.001 μmol / L to about 1 μmol / L. In some variations, the selection criteria for cortisol-binding aptamers may include cortisol-binding aptamers having about 10% to about 75% "on" increment from minimum to maximum cortisol concentration, and / or about 10% to about 40% "off" increment from minimum to maximum cortisol concentration. An "on gain" signal may refer to a set of square wave voltammetry parameters (frequency, peak value, step height) selected to maximize the current signal obtained in the presence of the target analyte. A signal "off gain" may refer to a set of square wave voltammetry parameters selected to minimize the current signal obtained in the presence of the target analyte. The sensitivity of the aptamer to cortisol in skin interstitial fluid advantageously makes it possible to avoid interference or signal degradation over time from biofouling or irreversible changes to the aptamer structure due to folding or damage.

[0154] The cortisol-sensing aptamer may be functionalized at the 3' or 5' end with a redox-active molecule, for example methylene blue, ferrocene, pentamethylferrocene, C5-ferrocene, Nile blue, thionine, anthraquinone, C5-anthraquinone, gallocyanine, indophenol, neutral red, dabsyl, or carboxy-X-rhodamine, such that the specific and reversible binding of cortisol to the cortisol-binding aptamer and the resulting conformational change of the cortisol-binding aptamer results in a change in the proximity between the redox-active molecule and the working electrode corresponding to the cortisol concentration, and thus a change in the electron transfer properties. This change in the electron transfer properties of the electrode caused by cortisol binding can be investigated by various electrochemical techniques, such as voltammetry, potentiometry, chronoamperometry, and / or electrochemical impedance spectroscopy. Voltammetric techniques vary the potential as a function of time and plot the resulting current as a function of potential. For example, cyclic voltammetry (CV) sweeps the potential of a cell linearly over a range of voltages, while fast-scan CV (FSCV) techniques do this at a faster rate. Square-wave voltammetry (SWV) provides a sweep measurement using a square wave superimposed on a step function to provide two sampling instances per potential. As a result of this sampling technique, contributions to the total current resulting from non-faradaic currents are minimized in SWV. In potentiometric measurements, the open circuit potential between the reference and working electrodes is measured. In chronoamperometry, the potential is stepped at the beginning of the measurement and then remains constant throughout the duration of the measurement, and the current resulting from this stimulus can be plotted as a function of time. In electrochemical impedance spectroscopy, the complex impedance of the electrode is determined at one or more frequencies. Contributions to impedance (or admittance) from resistive and reactive circuit elements depend on the position of the redox probe attached to the surface-bound aptamer and can be correlated to cortisol concentration.

[0155] FIG. 16A shows a schematic diagram of an exemplary set of layers for a cortisol-sensing working electrode 1610. For example, as described above, in some variations, the working electrode 1610 may include an electrode material 1612 and a biorecognition layer 1614 including a cortisol-binding aptamer functionalized with a redox-active molecule. The electrode material 1612 is used to electrically detect changes in electron transfer properties between the redox-active molecule bound to the cortisol-binding aptamer included in the biorecognition layer 1614 and the electrode material 1612 caused by cortisol binding to the cortisol-binding aptamer. The electrode material 1612 also provides an ohmic contact and routes the electrical signal from the electrocatalytic reaction to a processing circuit. In some variations, the electrode material 1612 may be platinum as shown in FIG. 16A or may be gold. In other variations, the electrode material 1612 can include, for example, palladium, iridium, rhodium, ruthenium, titanium, nickel, alloys of the above-mentioned metals, cobalt chromium alloys, cobalt chromium molybdenum alloys, stainless steel 316L, iridium oxide, titanium nitride, carbon, doped diamond, silicon, doped silicon, or other suitable materials. The carbon can be pyrolytic carbon, pyrolytic graphite, or glassy carbon.

[0156] In some variations, the electrode material 1612 may be coated with a highly porous electrocatalytic layer, such as a platinum black layer 1613, which may increase the electrode surface area for increased sensitivity (e.g., as shown in FIG. 16D). In some variations, the platinum black layer 1613 may be omitted (e.g., as shown in FIGS. 16A and 16G).

[0157] In some variations, the biorecognition layer 1614 may include a conductive polymer. The conductive polymer may be selectively permeable to contribute to the robustness of the biorecognition layer to circulating endogenous electroactive species (e.g., ascorbic acid, vitamin C, etc.), the fluctuations of which may adversely affect the sensitivity of the sensor. Such a selectively permeable conductive polymer in the biorecognition layer may be more robust to pharmacological interferences (e.g., acetaminophen) in interstitial fluids that may affect the sensor accuracy. The conductive polymer may be made selectively permeable, for example, by removing excess charge carriers through an oxidative electropolymerization process, or by intentionally overoxidizing the conductive polymer at high potentials after polymerization, breaking its conjugated backbone and making it non-conductive. These oxidatively polymerized conductive polymers exhibit selective permeability and thus may exclude ions of similar charge polarity (net positive or negative) as the dopant ions, or by size exclusion due to the dense, compact morphology of the conductive polymer. In some variations, the conductive polymer may include one or more of aniline, pyrrole, pyrrole-3-carboxylic acid, pyrrole-1-propionic acid, acetylene, phenylene, phenylenevinylene, phenylenediamine, thiophene, 3-methylthiophene, 3-hexylthiophene, 3-thiophenecarboxylic acid, 3,4-ethylenedioxythiophene (EDOT), EDOT carboxylic acid, and aminophenylboronic acid. An example of a working electrode 1610 in which the biorecognition layer 1614 includes a film 1623 of a conductive polymer is shown in Figures 16J-16K.

[0158] In some variations, the conductive polymer may exhibit self-sealing and / or self-healing properties. For example, the conductive polymer may undergo oxidative electropolymerization, in which the conductive polymer may lose its conductivity as the thickness of the conductive polymer deposited on the electrode increases until the lack of sufficient conductivity reduces the deposition of additional conductive polymer. If the conductive polymer sustains minor physical damage (e.g., during use), the polymer backbone may reassemble to neutralize free charges, thereby lowering the overall surface energy of the molecular structure, which may manifest as self-sealing and / or self-healing properties.

[0159] Examples of working electrodes 1610 including an electrode material 1612 and an aptamer-based cortisol-sensing biorecognition layer 1614 are shown in Figures 16K, 16L, 16N, and 16P. In a first exemplary variation shown in Figure 16K, the electrode material 1612 may be platinum, gold, palladium, iridium, rhodium, ruthenium, titanium, nickel, alloys of the above-mentioned metals, cobalt chromium alloys, cobalt chromium molybdenum alloys, stainless steel 316L, iridium oxide, titanium nitride, carbon, doped diamond, silicon, doped silicon, or other suitable materials. The carbon may be pyrolytic carbon, pyrolytic graphite, or glassy carbon.

[0160] The biorecognition layer 1614 may optionally include a conductive polymer layer 1623 having a cortisol-binding aptamer 1625 attached to the conductive polymer layer 1623 via a linker. The linker may be an amide linker formed from a carboxyl group and a primary amine group. In some variations, the carboxyl group may be substituted with an NHS-ester, an isocyanate, an isothiocyanate, or a benzoyl fluoride. The present disclosure also provides aptamers attached via other linkers, such as a triazole linker or a thioether linker. The thioether linker may be based on a combination of a maleimide moiety on the conductive polymer and a thiol moiety on the terminus of the aptamer, a combination of a vinyl surface attached to the conductive polymer layer and a thiol moiety on the terminus of the aptamer, or a combination of an epoxide moiety on the conductive polymer and a thiol moiety on the terminus of the aptamer.

[0161] The cortisol binding aptamer 1625 may be functionalized with a redox active molecule 1626, such as methylene blue (MB), ferrocene, pentamethylferrocene, C5-ferrocene, Nile blue, thionine, anthraquinone, C5-anthraquinone, gallocyanine, indophenol, neutral red, dabsyl, or carboxy-X-rhodamine.

[0162] The conductive polymer layer 1623 may have a thickness of about 10 nm to about 100 nm and includes a conductive polymer and, optionally, a counterion. The conductive polymer may include one or more of aniline, pyrrole, pyrrole-3-carboxylic acid, pyrrole-1-propionic acid, acetylene, phenylene, phenylenevinylene, phenylenediamine, thiophene, 3-methylthiophene, 3-hexylthiophene, 3-thiophenecarboxylic acid, EDOT, EDOT carboxylic acid, and aminophenylboronic acid. The conductive polymer may also be a copolymer of two or more of the listed monomers. Examples of counter ions include sulfate, bisulfate, nitrate, bromide, perchlorate, hexafluorophosphate, tetrafluoroborate, paratoluenesulfonate, benzenesulfonate, camphor-10-sulfonate, trifluoromethanesulfonate, bis(trifluoromethylsulfonyl)imide, dodecylbenzenesulfonate, poly(styrenesulfonate), poly(styrenesulfonate-co-acrylic acid), poly(acrylic acid), poly(methacrylic acid), poly(acrylic acid-co-acrylamide), sulfone, Examples of suitable branched polymers include branched polytetrafluoroethylene (i.e., Nafion), poly(maleic acid), poly(maleic acid-co-acrylic acid), poly(maleic acid-co-acrylamide), poly(2-acrylamido-2-methylpropanesulfonic acid), poly(styrenesulfonate-block-butylene-lan-ethylene-block-styrenesulfonate), alginates, glycosaminoglycans, hyaluronic acid, collagen, and any combination of the above polymers as copolymers or block copolymers not expressly mentioned.

[0163] In a second exemplary variation shown in FIG. 16L, the electrode material 1612 may be gold and the biorecognition layer 1614 may include a cortisol-sensing aptamer 1625 functionalized with a redox reporter molecule 1626, such as methylene blue (MB), ferrocene, pentamethylferrocene, C5-ferrocene, Nile blue, thionine, anthraquinone, C5-anthraquinone, gallocyanine, indophenol, neutral red, dabsyl, or carboxy-X-rhodamine. The cortisol-sensing aptamer may be coupled to the electrode material 1612 via a thiol linker 1628. Optionally, the biorecognition layer 1614 further includes other thiol-group-containing small molecules 1629 (which may be referred to herein as "small molecule thiols") coupled to the electrode material 1612. The small molecule thiol may act as a chemically neutral spacer that provides a desired surface density of the cortisol-sensing aptamer 1625 on the surface of the electrode material 1612. The small molecule thiol may also act to passivate the exposed gold surface from undesired chemical reactions, such as the reduction of oxygen. In some variations, the small molecule thiol has the following structure: HS-C X -Z (formula 1) where X has a value between 2 and 16 and constitutes a linear, unbranched hydrocarbon chain, and Z is a terminal functional group selected from the group consisting of hydrogen, hydroxyl, carboxyl, amine, trimethylammonium, phosphatidylcholine, sulfonate, sulfate ester, phosphonate, phosphate ester, and oligomers of polyethylene glycol (PEG) of 1 to 50 units in length (also known as PEG / polyethylene oxide / PEO). Small molecule thiols can also act to provide biocompatibility and non-fouling properties, for example, by including a hydrophilic moiety at the end opposite the thiol group attached to the electrode material 1612. Small molecule thiols 1629 including a hydrophilic moiety can be zwitterionic, for example, phosphatidylcholine. In some variations, small molecule thiols can include 6-mercapto-1-hexanol, 1-hexanethiol, 6-mercaptohexanoic acid, 6-mercapto-1-hexanamine, 6-mercapto-1-phosphatidylcholine hexane, and the entire homologous series of the foregoing thiols with different carbon chain lengths.

[0164] In a third exemplary variation shown in Figure 16N, the electrode material 1612 may be optionally doped silicon. The biorecognition layer 1614 may include a monolayer of silane 1641 bound to the silicon surface and a cortisol-sensing aptamer 1625 functionalized with a redox reporter molecule 1626 (e.g., methylene blue, ferrocene, pentamethylferrocene, C5-ferrocene, Nile blue, thionine, anthraquinone, C5-anthraquinone, gallocyanine, indophenol, neutral red, dabsyl, or carboxy-X-rhodamine) optionally bound to the silicon electrode material via an amide linker.

[0165] In a fourth exemplary variation shown in Figure 16P, the electrode material 1612 may be carbon, optionally pyrolytic carbon, pyrolytic graphite, or glassy carbon. The biorecognition layer 1614 may include a cortisol-sensing aptamer 1625 functionalized with a redox reporter molecule 1626 (e.g., methylene blue (MB), ferrocene, pentamethylferrocene, C5-ferrocene, Nile blue, thionine, anthraquinone, C5-anthraquinone, gallocyanine, indophenol, neutral red, dabsyl, or carboxy-X-rhodamine) optionally coupled to the carbon electrode material via an amide linker.

[0166] The working electrode 1610, in some variations as shown in FIG. 16A, may further include a biocompatible layer 1616 that provides a biocompatible interface to reduce a foreign body response while allowing, for example, the passage of cortisol to reach the cortisol-binding aptamer 1625. The biocompatible layer may include one or more hydrophilic polymers, such as poly(urethane), poly(N-vinylpyrrolidone), poly(acrylamide), poly(acrylic acid), poly(methacrylic acid), poly(2-hydroxyethyl methacrylate), poly(acrylic acid-co-acrylamide), poly(N-isopropylacrylamide), poly(2-acrylamido-2-methylpropanesulfonic acid), poly(ethylene glycol), poly(vinyl alcohol), poly(lactic acid), poly(glycolic acid), poly(glycolic acid-co-lactic acid), collagen, alginate, hyaluronic acid, heparin, glycosaminoglycan, chitosan, Nafion, carboxymethylcellulose, or cellulose acetate. The biocompatible layer 1616 may be applied over the biorecognition layer 1614 and / or the diffusion-limiting layer 1615 (if present) by at least one of spray coating, dip coating, drop casting, plasma deposition, and electrodeposition. In some variations, for example, where the biorecognition layer 1614 includes hydrophilic moieties that function to reduce a foreign body response while allowing cortisol to reach the cortisol-binding aptamer 1625, the biocompatible layer 1616 may be omitted. Polar opposite

[0167] As mentioned above, the counter electrode is an electrode that supplies or sinks the electrons (via current) necessary to sustain the electrochemical reaction at the working electrode. The number of counter electrode components can be increased in the form of a counter electrode array to increase the surface area so that the current carrying capacity of the counter electrode does not limit the change in the electron transfer properties between the redox active molecules of the working electrode and the electrode material 1612. Therefore, it may be desirable to have an excess of counter electrode area relative to the working electrode area to avoid current carrying capacity limitations. When the working electrode operates as an anode, the counter electrode functions as a cathode, and vice versa. Similarly, when an oxidation reaction occurs at the working electrode, a reduction reaction occurs at the counter electrode, and vice versa. Unlike the working or reference electrodes, the counter electrode can dynamically swing to the potential required to sustain the change in the electron transfer properties of the working electrode.

[0168] 16B, the counter electrode 1620 can include an electrode material 1622, similar to the electrode material 1612. For example, similar to the electrode material 1612, the electrode material 1622 of the counter electrode 1620 can include gold, platinum, palladium, iridium, rhodium, ruthenium, titanium, nickel, alloys of the above-mentioned metals, cobalt chromium alloys, cobalt chromium molybdenum alloys, stainless steel 316L, iridium oxide, titanium nitride, carbon, doped diamond, silicon, doped silicon, or other suitable materials.

[0169] In some variations, the counter electrode 1620 may have little or no additional layer on top of the electrode material 1622 (as shown in FIG. 16B). However, in some variations, the counter electrode 1620 may benefit from an increased surface area to increase the amount of current it can support. For example, the counter electrode material 1622 may be textured or otherwise roughened to increase the surface area of ​​the electrode material 1622 to enhance current source or sink capability. Additionally or alternatively, the counter electrode 1620 may include a layer of platinum black 1624 as shown in FIG. 16E, which may enhance the electrode surface as described above with respect to some variations of the working electrode. However, in some variations of the counter electrode, the layer of platinum black may be omitted (as shown, for example, in FIGS. 16B and 16H).

[0170] Additionally or alternatively, in some variations shown in Figure 16H, the counter electrode 1620 may include a biocompatible layer 1626 disposed over the electrode, e.g., to reduce foreign body response. The biocompatible layer 1626 may be similar in structure and composition to the biocompatible layer 1616 described above with respect to Figure 16A, for example. reference electrode

[0171] As mentioned above, the reference electrode functions to provide a reference potential for the system, i.e., the potential to which the working electrode is biased is referenced to the reference electrode. A fixed or at least controlled potential relationship may be established between the working and reference electrodes, and, within practical limits, no current is sourced from or sunk to the reference electrode.

[0172] As shown in FIG. 16C, the reference electrode 1630 can include an electrode material 1632, similar to the electrode material 1612. In some variations, the electrode material 1632 of the reference electrode 1630, similar to the electrode material 1612, can include a metal salt or a metal oxide that functions as a stable redox coupled with a known electrode potential. For example, the metal salt can include, for example, silver-silver chloride (Ag / AgCl) and the metal oxide can include iridium oxide (IrOx / Ir2O3 / IrO2). In other variations, noble and inert metal surfaces, as well as those coated with conductive polymers such as poly(3,4-ethylenedioxythiophene), can function as quasi-reference electrodes and can include gold, platinum, palladium, iridium, carbon, doped diamond, and / or other suitable catalytic and inert materials. Additionally, in some variations, the reference electrode 1630 can be textured or otherwise roughened to enhance adhesion with any subsequent layers. Such subsequent layers on the electrode material 1632 may include a platinum-black layer 1634 (as shown in FIG. 16F) and / or a biocompatible layer 1637 (as shown in FIG. 161). The biocompatible layer 1637 may be similar to the biocompatible layer 1616 described above with respect to FIG. 16A, for example. In some variations, the platinum-black layer may be omitted (e.g., as shown in FIGS. 16C and 161).

[0173] The reference electrode 1630 may further include a redox couple layer 1636 that may include a surface-immobilized solid-state redox couple with a stable thermodynamic potential. For example, the reference electrode may operate at a stable standard thermodynamic potential versus the standard hydrogen electrode (SHE). High stability of the electrode potential may be achieved by using a redox system with constant (e.g., buffered or saturated) concentrations of each participant in the redox reaction. For example, the reference electrode may include a metal with an Ag / AgCl salt film (E=+0.197 V vs. SHE) or IrOx (E=+0.177 vs. SHE, pH=7.00) in the redox couple layer 1636. In some variations, the reference electrode may be used as a half-cell to build a complete electrochemical cell. Example of electrode layer formation process

[0174] The various layers of working, counter, and reference electrodes may be applied and / or functionalized, etc. to the microneedle array using appropriate processes as described below.

[0175] In a pretreatment step for the microneedle array, the microneedle array can be plasma cleaned in an inert gas (e.g., an RF-generated inert gas such as argon) plasma environment to render the surfaces of the materials, including the electrode materials (e.g., electrode materials 1612, 1622, and 1632 as described above), more hydrophilic and chemically reactive. This pretreatment serves not only to physically remove organic debris and contaminants, but also to clean and prepare the electrode surfaces to enhance adhesion of subsequently deposited films thereon. working electrode

[0176] Anodization: To configure the working electrode after the pretreatment step, the electrode material 1612 may undergo an anodization process using an amperometric approach in which the electrode components assigned to the working electrode function are exposed to a fixed high anodic potential (e.g., +1.0 V to +1.3 V vs. Ag / AgCl reference electrode) in a moderate strength acidic solution (e.g., 0.1 M to 3 M H2SO4) for an appropriate time (e.g., about 30 seconds to about 10 minutes). In this process, a thin but stable native oxide layer can be generated on the electrode surface. Due to the low pH that occurs at the electrode surface, trace amounts of contaminants can be removed as well.

[0177] In an alternative embodiment using coulometric techniques, anodization may continue until a specified amount of charge (measured in coulombs) has passed. An anodic potential may be applied as described above. However, the duration of this may vary until the specified amount of charge has elapsed.

[0178] Activation: Following the anodization process, the working electrode component may be subjected to a periodically scanned potential waveform in an activation process using cyclic voltammetry. In the activation process, which may take place in a moderate strength acidic solution (e.g., 0.1-3 M H2SO4), the applied potential may vary in time with a suitable function (e.g., sawtooth or trigonometric). For example, the voltage may be linearly scanned between cathodic values ​​(e.g., between -0.3 V and -0.2 V versus an Ag / AgCl reference electrode) and anodic values ​​(e.g., between +1.0 V and +1.3 V versus an Ag / AgCl reference electrode) in an alternating function (e.g., between 15 and 50 linear sweep segments). The scan rate of this waveform may take values ​​between 1 mV / s and 1000 mV / s. It should be noted that the current peak occurring during the anodic sweep (sweep towards the positive electrode) corresponds to the oxidation of a chemical species, and the current peak occurring during the subsequent cathodic sweep (sweep towards the negative electrode) corresponds to the reduction of a chemical species.

[0179] Electrodeposition of Gold: Following the activation and cleaning process, the working electrode component may be subjected to a cyclically scanned potential waveform or a constant potential to electrodeposit gold metal onto the surface. In the deposition process, which may occur with dilute concentrations of gold complexes (e.g., 0.5 wt.% to 3 wt.% AuCl3 or Au(CN)2), the applied potential may vary with time with an appropriate function. For example, the voltage may be linearly scanned between anodic values ​​(e.g., between +0.2 V and +1.2 V versus an Ag / AgCl reference electrode) in an alternating function (e.g., 10 to 30 linear sweep segments). The scan rate of this waveform may take values ​​between 100 mV / s and 1000 mV / s. Note that the rise in current during the cathodic sweep (the sweep to the negative electrode) corresponds to the reduction in gold species in the solution and plating onto the working electrode surface. Note also that the sudden increase in current during the first scan is due to the formation of nucleation sites.

[0180] Activation of the gold surface: Whether the gold electrodes are plated on a native electrode material such as platinum applied at the foundry during microfabrication or the gold is deposited by the foundry itself, both types of gold electrodes require electrochemical activation. Activation can be initiated with a basic solution (e.g., 0.1 M to 3 M NaOH) and the applied potential can be varied in time with an appropriate function (e.g., trigonometric function) such as cyclic voltammetry. For example, the voltage may be linearly scanned between cathodic values ​​(e.g., between -2.0 V and -1.2 V vs. Ag / AgCl reference electrode) and anodic values ​​(e.g., between -1.1 V and -0.5 V vs. Ag / AgCl) in an alternating function (e.g., 50 to 1000 sweep segments). The scan rate of this waveform can take values ​​between 10 mV / s and 2000 mV / s. After potential cycling in alkaline medium, the gold electrode must be cycled in an acidic solution (e.g., 0.1M to 3M H2SO4). The potential may vary with time with an appropriate function (e.g., trigonometric). For example, the voltage me is scanned linearly between cathodic values ​​(e.g., between -0.2V and +0.2V vs. Ag / AgCl reference electrode) and anodic values ​​(e.g., between +1.2V and +1.8V vs. Ag / AgCl reference electrode) in an alternating function (e.g., 50 to 1000 sweep segments). The scan rate of this waveform can take values ​​between 10mV / s and 2000mV / s. It should be noted that in both basic and acidic media, the current peaks occurring during the anodic sweep (sweep to the positive electrode) correspond to the oxidation of the chemical species, while the current peaks occurring during the subsequent cathodic sweep (sweep to the negative electrode) correspond to the reduction of the chemical species.

[0181] Following the activation process for functionalizing the biorecognition layer, the working electrode component may be functionalized with a biorecognition layer 1614 as described above. Assuming that the working electrode associated with the microneedle array has undergone the above steps such as deposition and activation, the biorecognition layer may be applied in a variety of ways. The process for applying the biorecognition layer may depend on a variety of factors including what material is used for the working electrode material 1612. Various exemplary processes are described herein below.

[0182] In some variations, the electrode material 1612 is electrochemically coated with a conductive polymer film by oxidation of reactive monomers at the electrode surface, either potentiostatically (e.g., chronoamperometry), potentiodynamically (e.g., cyclic voltammetry), or galvanostatically (e.g., chronopotentiometry). The conditions required for polymerization of the monomer depend on the chemical properties of the conductive polymer used. By adjusting the current, potential, sweep rate, and / or duration of the electrolysis process, the final properties of the conductive polymer film can be controlled (e.g., thickness, conductivity, permselectivity). If necessary, the conductive polymer film may be overoxidized in a secondary oxidation step by potentiostatic, potentiodynamic, or galvanostatic electrochemical processes. This secondary oxidation step can be used to modify the conductivity and barrier properties of the conductive polymer film. The conductive polymer and / or counterions incorporated within the conductive polymer can provide pendant chemical moieties for covalent attachment to aptamers functionalized with compatible moieties. By way of example, the pendant chemical moiety in the conducting polymer film may comprise a carboxyl group and the aptamer may be functionalized at the 3' or 5' end with a primary amine. Alternatively, the pendant chemical moiety in the conducting polymer film may be a primary amine and the aptamer may be functionalized at the 3' or 5' end with a carboxyl group.

[0183] In some variations, for example where the electrode material 1612 is gold, the aptamers may be functionalized at one end with reactive organosulfur compounds (e.g., thiols / mercaptans, disulfides) that spontaneously react and attach to the surface of the gold working electrode material. The remaining gold surface of the working electrode may optionally be passivated with a small molecule that contains a terminal thiol group to form a self-assembled monolayer.

[0184] In an exemplary variation shown in Figure 16J, the working electrode 1610 may be functionalized with an aqueous solution containing a monomer precursor of a conductive polymer and, optionally, a counterion. The functionalization may be performed by constant current electrodeposition (e.g., chronopotentiometry), where the anodic current density through the working electrode is less than 0.05 mA / cm. 2 ~5mA / cm 2 and the duration may be from about 1 minute to about 100 minutes. In another variation, the functionalization may be performed through chronocoulometric deposition, and the deposition charge may be about 1 mC / cm 2 ~10C / cm 2 The duration may be from about 1 minute to about 100 minutes. The conductive polymer, the counterion, or both may include carboxyl groups 1621. In this process, as shown in FIG. 16J, a thin film (e.g., about 10 nm to about 100 nm) of biorecognition layer 1614 including conductive polymer layer 1623 may be generated (e.g., electrodeposited or electropolymerized) on the surface of electrode material 1612, which may include platinum. After conductive polymer layer 1623 is formed, cortisol-sensing aptamer 1625 is introduced that is functionalized with primary amine group 1267 on one end and redox active molecule 1626 on the other end. The aptamer 1625 is covalently attached to the carboxyl groups 1621 contained in the conductive polymer layer 1623 using a carbodiimide crosslinking method, for example, EDC / NHS coupling using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS). Another method for coupling primary amines and carboxylic acids to amide bonds is by DMTMM crosslinking with 4-(4,6-dimethoxy-1,3,5 triazin-2-yl)-4-methyl-morpholinium chloride. The remaining pendant activated carboxylic acid groups on the silane layer that are not bound to the aptamer can be optionally crosslinked to another amine-containing molecule (e.g., ethanolamine, glycine, lysine, PEG-amine) to alter the working electrode surface properties and biocompatibility. The resulting functionalized working electrode 1610 is shown in FIG. 16K.

[0185] In some variations, the arrangement of the carboxyl and primary amine groups for carbodiimide crosslinking may be reversed so that the conductive polymer, the counterion, or both may contain primary amine groups and the aptamer may be functionalized with the carboxyl groups. The two moieties may then be linked by EDC / NHS coupling or DMTMM crosslinking, as described above with respect to Figure 16J. An example of a conductive polymer that contains primary amine groups is a p-phenylenediamine (PPD) based polymer.

[0186] Although Figures 16J-16K show aptamers attached via an amide linker formed between a carboxyl group and a primary amine group, the present disclosure provides for the use of other moieties. By way of example, the carboxyl group may be substituted with an NHS-ester, an isocyanate, an isothiocyanate, or a benzoyl fluoride. The present disclosure also provides for aptamers attached via other linkers, such as a triazole linker or a thioether linker. The thioether linker may be based on a combination of a maleimide moiety on the conductive polymer and a thiol moiety on the terminus of the aptamer, a combination of a vinyl surface attached to the conductive polymer layer and a thiol moiety on the terminus of the aptamer, or a combination of an epoxide moiety on the conductive polymer and a thiol moiety on the terminus of the aptamer.

[0187] In an exemplary variation shown in FIG. 16L, the gold working electrode material 1612 may be functionalized with an aqueous solution containing an aptamer 1625 having a terminal thiol group 1628 at one end and a redox active molecule 1626 at the other end. The functionalization may proceed for about 30 minutes to about 10 hours, and the concentration of the aptamer may be about 0.1 to about 2 uM. The functionalization process may include an optional secondary step ("backfilling") of functionalizing the remaining portion of the surface of the gold working electrode with a small molecule thiol 1629 to passivate the surface and / or add biocompatible functionality. Backfilling of the surface of the electrode material 1612 with the small molecule thiol 1629 may be performed in an aqueous or organic solution (e.g., methanol, ethanol, isopropanol) at a concentration of about 0.1 to about 5 mM for about 3 to 30 hours. After this process, as shown in FIG. 16L, a monolayer of aptamer 1625 is immobilized on the surface along with an optionally backfilled small molecule thiol 1629 that serves to passivate the remaining portion of the surface of the working electrode material 1612.

[0188] Thiol-based functionalization of gold as shown in FIG. 16L can be accomplished via an alternative functionalization process in which a gold working electrode 1612 is functionalized using an organic solution (e.g., methanol, ethanol, isopropanol) containing both aptamer 1625 (functionalized at one end with a terminal thiol group 1628 and at the other end with a redox-active molecule 1626) and a small molecule thiol 1629 that is added to passivate the surface and / or add biocompatible functionality. Functionalization may proceed for about 3 hours to about 30 hours. The concentration of aptamer 1625 may be about 0.1 uM to about 2 uM and the concentration of small molecule thiol 1629 may be about 0.1 mM to about 5 mM. The resulting working electrode 1610 as shown in FIG. 16L shows that a monolayer of biorecognition elements is immobilized on the surface and the optional addition of small molecule thiol 1629 passivates the remainder of the surface.

[0189] In another exemplary variation shown in FIG. 16M, a working electrode 1610 comprising silicon electrode material 1612 may be functionalized with aptamer 1625 via silane chemistry. The silicon electrode material may comprise doped silicon. First, the surface of the silicon electrode material 1612 is activated by exposure to oxygen plasma for about 0.5 minutes to about 10 minutes at a pressure of about 200 mTorr to about 700 mTorr with an operating power of about 50 W to about 500 W. The activated electrode material surface is then transferred to a vacuum chamber for 10 to 90 minutes at a pressure of about 1 Torr to about 100 Torr containing a small amount of a suitable reactive silane 1641 comprising a terminal primary amine (for example, 4-aminobutyltrimethoxysilane shown in FIG. 16M). The working electrode is then removed and rinsed with an organic solvent (e.g., methanol, ethanol, or isopropanol) and then baked at about 80° C. to about 140° C. for a time period of about 10 minutes to about 60 minutes to cure the attached silane 1641. FIG. 16M shows a schematic of a silicon electrode material 1612 having a monolayer of attached silane 1641. Also shown in FIG. 16M is treating the electrode material with a solution containing an aptamer 1625 terminated at one end with a carboxyl group 1643 and at the other end with a redox active molecule 1626. The solution can be an aqueous solution, such as a phosphate buffer solution, having a concentration of the aptamer at about 0.1 uM to 2 uM. The carboxyl group 1643 forms an amide linker with the pendant amine group of the attached silane 1641, resulting in binding of the aptamer 1625 to the electrode material 1612. The resulting biorecognition layer 1614 including bound aptamer 1625 and silane 1641 formed on silicon electrode material 1612 is shown in Figure 16N. The amide linker can be formed by EDC / NHS crosslinking chemistry or DMTMM crosslinking chemistry. The remaining portion of the pendant amine groups on the silane layer that are not bound to the aptamer (not shown) can be optionally crosslinked to another carboxyl group-containing molecule (e.g., glycolic acid, oxalic acid, glycine, PEG-carboxylic acid) to alter the working electrode surface properties and biocompatibility.

[0190] In a variation shown in FIG. 16O, a working electrode 1610 comprising a glassy carbon electrode material 1612 may be functionalized with an aptamer via activation of the carbon surface and formation of an amide bond that binds the aptamer to the carbon surface. In a first step, the surface of the glassy carbon electrode material 1612 is electrochemically activated by holding a constant potential at 1.2 V to 2.0 V in an acidic solution (e.g., 0.1 M to 3 M H2SO4 solution) for 1 to 60 minutes. The activation step forms terminal carboxyl groups 1645 on the surface of the carbon electrode material 1612. The activated surface of the electrode material 1612 is then functionalized with an aptamer 1625 having a primary amine group 1627 at its 3' or 5' end and a redox active molecule 1626 at the other end. The carboxyl group 1645 forms an amide linker with the amine group 1627, resulting in the aptamer 1625 being bound to the electrode material 1612. The resulting biorecognition layer 1614 including bound aptamers 1625 formed on the carbon electrode material 1612 is shown in Figure 16P. The amide linkers can be formed by EDC / NHS crosslinking chemistry or DMTMM crosslinking chemistry.

[0191] Although Figures 16M-16P show aptamers attached via an amide linker formed between a carboxyl group and a primary amine group, the present disclosure provides for the use of other moieties. By way of example, the carboxyl group may be substituted with an NHS-ester, an isocyanate, an isothiocyanate, or a benzoyl fluoride. The present disclosure also provides for aptamers attached via other linkers, such as a triazole linker or a thioether linker. The thioether linker may be based on a combination of a maleimide moiety on the conductive polymer and a thiol moiety on the terminus of the aptamer, a combination of a vinyl surface attached to the conductive polymer layer and a thiol moiety on the terminus of the aptamer, or a combination of an epoxide moiety on the conductive polymer and a thiol moiety on the terminus of the aptamer.

[0192] In some variations, the working electrode surface can be electrochemically roughened to enhance adhesion of the biorecognition layer to the electrode material 1612 surface (and / or Pt black layer). The roughening process can include cathodic treatment (e.g., cathodic deposition, a subset of amperometry) in which the electrode is subjected to a fixed cathodic potential (e.g., between −0.4V and +0.2V vs. Ag / AgCl reference electrode) in an acidic solution (e.g., 0.01 mM to 100 mM H2 PtCl6) containing the desired metal cations dissolved therein for a specific time (e.g., 5 seconds to 10 minutes). Alternatively, the electrode is subjected to a fixed cathodic potential (e.g., about −0.4V to about +0.2V vs. Ag / AgCl reference electrode) in an acidic solution (e.g., 0.01 mM to 100 mM H2 PtCl6) containing the desired metal cations dissolved therein until a certain amount of charge (e.g., 0.1 mC to 100 mC) has passed. In this process, a thin but highly porous layer of metal is produced on the electrode surface, which can dramatically increase the electrode surface area. Additionally or alternatively, in some variations described above, elemental platinum metal can be deposited on the electrode to form or deposit a platinum black layer 1613. Polar opposite

[0193] Anodization: In some variations, the counter electrode material can be anodized using an amperometric approach in which the electrode component assigned to the counter electrode function is exposed to a certain high anodic potential or a moderate strength acidic solution for a suitable time. Exemplary parameters and other details of the anodization process of the counter electrode can be similar to those described above for the working electrode. Similarly, the anodization of the counter electrode may instead use a coulometric technique as described above.

[0194] Activation: In some variations, following the anodization process, the counter electrode component may be subjected to a periodically scanned potential waveform in an activation process using cyclic voltammetry. In some variations, the activation process may be similar to the process described above for the working electrode.

[0195] Roughening: Additionally, in some variations, the surface of the counter electrode may be electrochemically roughened to enhance the current sinking or current supplying capabilities of this electrode condition. The electrochemical roughening process may be similar to that described above for the working electrode. Additionally or alternatively, in some variations described above, elemental platinum metal may be deposited on the electrode to form or deposit a platinum black layer 1624. reference electrode

[0196] Anodization: Similar to the working and counter electrodes described above, the reference electrode can be anodized using an amperometric approach in which the electrode component assigned to the counter electrode function is exposed to a constant high anodic potential or in a medium strength acid solution for an appropriate time. Exemplary parameters and other details of the anodization process for the counter electrode can be similar to those described above for the working electrode. Similarly, the anodization of the counter electrode can be performed ...

[0197] Activation: Following the anodization process, the reference electrode component may be subjected to a periodically scanned potential waveform in an activation process using cyclic voltammetry. In some variations, the activation process may be similar to that described above for the working electrode.

[0198] Functionalization: Following the activation process, the reference electrode component can be functionalized. Assuming that the reference electrode conditioned on the microneedle array has undergone the steps described above, a fixed anodic potential (e.g., between +0.4 and +1.0 V versus an Ag / AgCl reference electrode) can be applied in an aqueous solution for a certain suitable period of time (e.g., about 10 seconds to about 10 minutes). Alternatively, the reference electrode is subjected to a fixed anodic potential (e.g., between about +0.4 V and about +1.0 V versus an Ag / AgCl reference electrode) until a certain amount of charge passes in the aqueous solution (e.g., 0.01 mC to 10 mC). In some variations, the aqueous solution may include a monomer precursor of the conductive polymer and a dopant counterion or material having an opposite charge (e.g., poly(styrenesulfonate)). In this process, a thin film (e.g., about 10 nm to about 10,000 nm) of the conductive polymer with the counterion or material dispersed therein can be produced on the reference electrode surface. This results in a surface-immobilized solid-state redox coupled with a stable thermodynamic potential. In some variations, the conductive polymer may include one or more of aniline, pyrrole, acetylene, phenylene, phenylenevinylene, phenylenediamine, thiophene, 3,4-ethylenedioxythiophene, and aminophenylboronic acid.

[0199] In some alternative embodiments, a native iridium oxide film (e.g., IrO2 or Ir2O3 or IrO4) can be electrochemically grown on the iridium electrode surface in an oxidation process, which also generates a stable redox couple as described above.

[0200] Furthermore, in some variations, the reference electrode surface can be electrochemically roughened to enhance adhesion of the surface-immobilized redox couple. The electrochemical roughening process can be similar to that described above for the working electrode. Additionally or alternatively, in some variations described above, elemental platinum metal can be deposited on the electrode to form or deposit a platinum black layer 1633. Microneedle array configuration

[0201] A plurality of microneedles (e.g., any of the microneedle variations described herein, each of which may have a working electrode, counter electrode, or reference electrode as described above) may be arranged in a microneedle array. Considerations for how to configure the microneedles include factors such as the desired insertion force for penetrating the skin with the microneedle array, optimization of electrode signal levels and other performance aspects, and manufacturing cost and complexity.

[0202] For example, a microneedle array may include multiple microneedles spaced apart at a predetermined pitch (the distance between the center of one microneedle and the center of its nearest neighboring microneedle). In some variations, the microneedles may be spaced apart at a pitch sufficient to distribute the force applied to the user's skin to penetrate the microneedle array into the skin (e.g., avoiding a "needle-rat" effect). As the pitch increases, the force required to insert the microneedle array tends to decrease and the depth of penetration tends to increase. However, it has been found that the pitch only begins to affect the insertion force at low values ​​(e.g., less than about 150 μm). Thus, in some variations, the microneedles of the microneedle array may have a pitch of at least 200 μm, at least 300 μm, at least 400 μm, at least 500 μm, at least 600 μm, at least 700 μm, or at least 750 μm. For example, the pitch may be from about 200 μm to about 800 μm, from about 300 μm to about 700 μm, or from about 400 μm to about 600 μm. In some variations, the microneedles may be arranged in a periodic grid and the pitch may be uniform across all directions and areas of the microneedle array. Alternatively, the pitch may be different when measured along different axes (e.g., X, Y directions) and / or some areas of the microneedle array may include a smaller pitch and other areas may include a larger pitch.

[0203] Additionally, for more consistent penetration, the microneedles may be spaced equidistant from one another (e.g., the same pitch in all directions). To that end, in some variations, the microneedles in a microneedle array may be arranged in a hexagonal configuration, as shown in Figure 17. Alternatively, the microneedles of the microneedle array may be arranged in a rectangular array (e.g., a square array) or another suitably symmetrical manner.

[0204] Another consideration for determining the configuration of a microneedle array is the overall signal level provided by the microneedles. In general, the signal level at each microneedle is invariant to the total number of microneedle elements in the array. However, the signal level can be enhanced by electrically interconnecting multiple microneedles in the array. For example, an array with a large number of electrically connected microneedles is expected to generate a greater signal strength (and therefore improve accuracy) than an array with fewer microneedles. However, a larger number of microneedles on a die increases the die cost (given a constant pitch) and also requires a greater force and / or speed to insert into the skin. In contrast, a smaller number of microneedles on a die reduces the die cost and allows insertion into the skin with a reduced applied force and / or speed. Furthermore, in some variations, a smaller number of microneedles on a die may reduce the overall footprint area of ​​the die, which may result in less undesirable local edema and / or erythema. Thus, in some variations, a balance of these factors can be achieved with a microneedle array including 37 microneedles as shown in Figure 17, or a microneedle array including 7 microneedles as shown in Figures 23A and 23B. However, in other variations, the number of microneedles in the array may be low (e.g., about 5 to about 35, about 5 to about 30, about 5 to about 25, about 5 to about 20, about 5 to about 15, about 5 to about 100, about 10 to about 30, about 15 to about 25, etc.) or the number of microneedles in the array may be high (e.g., greater than 37, greater than 40, greater than 45, etc.).

[0205] Additionally, as described in more detail below, in some variations, only a subset of the microneedles in the microneedle array may be active during operation of the cortisol monitoring device. For example, some of the microneedles in the microneedle array may be inactive (e.g., no signal is read from the electrodes of the inactive microneedles). In some variations, some of the microneedles in the microneedle array may be activated at a particular time during operation and remain active for the remainder of the operational life of the device. Additionally, in some variations, some of the microneedles in the microneedle array may additionally or alternatively be deactivated at a particular time during operation and remain inactive for the remainder of the operational life of the device.

[0206] Considering the characteristics of the die for microneedle array, the die size is a function of the number of microneedles in the microneedle array and the pitch of the microneedles.Manufacturing cost should also be considered, since a smaller die size contributes to lower costs, since the number of dies that can be formed from a single wafer of a given area increases.In addition, a smaller die size is also less susceptible to brittle fracture due to the relative fragility of the substrate.

[0207] Additionally, in some variations, microneedles on the periphery of the microneedle array (e.g., near the edge or border of the die, near the edge or border of the housing, near the edge or border of an adhesive layer on the housing, along the outer edge of the microneedle array, etc.) may be found to have better performance (e.g., sensitivity) due to better penetration compared to microneedles in the center of the microneedle array or die. Thus, in some variations, the working electrode may be located mostly or completely on microneedles located on the periphery of the microneedle array to obtain more accurate and / or precise cortisol measurements.

[0208] FIG. 17 shows an exemplary schematic diagram of 37 microneedles arranged in an exemplary variation of a microneedle array. The 37 microneedles may be arranged in a hexagonal array, for example, with a needle-to-needle center-to-center pitch of about 750 μm (or about 700 μm to about 800 μm, or about 725 μm to about 775 μm) between the center of each microneedle and the center of its immediate neighbor in any direction. FIG. 18A shows an exemplary schematic diagram of an exemplary variation of a die including the microneedle arrangement shown in FIG. 17. Exemplary dimensions of the die (e.g., about 4.4 mm by about 5.0 mm) and the microneedle array are shown in FIG. 18B.

[0209] 23A and 23B show perspective views of an exemplary schematic of seven microneedles 2910 arranged in an exemplary variation of a microneedle array 2900. The seven microneedles 2910 are arranged in a hexagonal array on a substrate 2902. As shown in FIG. 23A, electrodes 2920 are disposed on distal portions of the microneedles 2910 extending from a first side of the substrate 2902. As shown in FIG. 23B, proximal portions of the microneedles 2910 are conductively connected to respective backside electrical contacts 2930 on a second side of the substrate 2902 opposite the first side of the substrate 2902. FIGS. 24A and 30B show plan and side views of an exemplary schematic of a microneedle array similar to the microneedle array 2900. As shown in Figures 24A and 24B, the seven microneedles are arranged in a hexagonal array with a needle-to-needle center-to-center pitch of about 750 μm between the center of each microneedle and the center of its immediate neighbor in any direction. In other variations, the needle-to-needle center-to-center pitch may be, for example, about 700 μm to about 800 μm, or about 725 μm to about 775 μm. The microneedles may have an approximate outer axial diameter of about 170 μm (or about 150 μm to about 190 μm, or about 125 μm to about 200 μm) and a height of about 500 μm (or about 475 μm to about 525 μm, or about 450 μm to about 550 μm).

[0210] Additionally, the microneedle arrays described herein can have a high degree of configurability with respect to where the working, counter, and reference electrodes are located within the microneedle array, and this configurability can be facilitated by the electronics system.

[0211] In some variations, the microneedle array may include electrodes distributed symmetrically or asymmetrically in two or more groups within the microneedle array, with each group featuring the same or different number of electrode components depending on the requirements for signal sensitivity and / or redundancy. For example, electrodes of the same type (e.g., working electrodes) may be distributed bilaterally or radially symmetrically within the microneedle array. For example, FIG. 19A shows a variation of a microneedle array 1900A including two symmetric groups of seven working electrodes (WE), with two working electrode groups labeled "1" and "2". In this variation, the two working electrode groups are distributed bilaterally symmetrically within the microneedle array. The working electrodes are generally positioned between a central region of three reference electrodes (RE) and a peripheral region of twenty counter electrodes (CE). In some variations, each of the two working electrode groups may include seven working electrodes electrically connected between them (e.g., to enhance the sensor signal). Alternatively, only a portion of one or both of the working electrode groups may include multiple electrodes electrically connected between them. As yet another alternative, the working electrodes may include working electrodes that are stand-alone and not electrically connected to other working electrodes.Furthermore, in some variations, the working electrodes may be distributed across the microneedle array in an asymmetric or random configuration.

[0212] As another example, FIG. 19B shows a variation of a microneedle array 1900B that includes four symmetric groups of three working electrodes (WE) with the four working electrode groups labeled "1," "2," "3," and "4." In this variation, the four working electrode groups are radially symmetrically distributed in the microneedle array. Each working electrode group is adjacent to and symmetrically positioned with one of the two reference electrode (RE) components in the microneedle array. The microneedle array also includes counter electrodes (CE) positioned around the periphery of the microneedle array, except for two electrodes on the vertices of a hexagon that may be inactive or used for other features or modes of operation.

[0213] In some variations, only a portion of the microneedle array may include active electrodes. For example, FIG. 19C shows a variation of a microneedle array 1900C having 37 microneedles and a reduced number of active electrodes, including four working electrodes (labeled "1", "2", "3", and "4") in a bilateral symmetrical arrangement, 22 counter electrodes, and three reference electrodes. The remaining eight electrodes of the microneedle array are inactive. In the microneedle array shown in FIG. 19C, each working electrode is surrounded by a group of counter electrodes. The two groups of such clusters of working and counter electrodes are separated by a row of three reference electrodes.

[0214] As another example, FIG. 19D shows a variation of a microneedle array 1900D having 37 microneedles and a reduced number of active electrodes, including four working electrodes (labeled "1," "2," "3," and "4") arranged symmetrically on both sides, 20 counter electrodes, and three reference electrodes; the remaining 10 electrodes of the microneedle array are inactive.

[0215] As another example, FIG. 19E shows a variation of a microneedle array 1900E having 37 microneedles and a reduced number of active electrodes, including four working electrodes (labeled "1", "2", "3", and "4"), 18 counter electrodes, and two reference electrodes. The remaining 13 electrodes of the microneedle array are inactive. The inactive electrodes are along a partial perimeter of the overall microneedle array, thereby reducing the effective size and shape of the active microneedle arrangement to a smaller hexagonal array. Within the active microneedle arrangement, the four working electrodes are in a generally radially symmetric arrangement, with each working electrode surrounded by a group of counter electrodes.

[0216] FIG. 19F shows another exemplary variation of a microneedle array 1900F having 37 microneedles and a reduced number of active electrodes including four working electrodes (labeled "1", "2", "3", and "4"), two counter electrodes, and one reference electrode. The remaining 30 electrodes of the microneedle array are inactive. The inactive electrodes are arranged in two layers around the periphery of the overall microneedle array, thereby reducing the effective size and shape of the active microneedle arrangement to a smaller hexagonal array centered on the reference electrode. Within the active microneedle arrangement, the four working electrodes are in a bilateral symmetrical arrangement and the counter electrodes are equidistant from the central reference electrode.

[0217] Figure 19G shows another exemplary variation of a microneedle array 1900G having 37 microneedles and a reduced number of active electrodes. The active electrodes of the microneedle array 1900G are arranged similarly to the microneedle array 1900F shown in Figure 19F, except that the microneedle array 1900G includes one counter electrode and two reference electrodes, with a smaller hexagonal array of active microneedles centered around the counter electrode. In the active microneedle arrangement, the four working electrodes are in a bilateral symmetrical arrangement, and the reference electrodes are equidistant from the central counter electrode.

[0218] FIG. 19H shows another exemplary variation of a microneedle array 1900H having seven microneedles. The microneedle arrangement includes two microneedles assigned as independent working electrodes (1 and 2), a counter electrode condition consisting of four microneedles, and a single reference electrode. There is a symmetry in the arrangement of the working and counter electrodes that are equidistant from the central reference electrode. Furthermore, the working electrodes are placed as far away from the center of the microneedle array (e.g., the periphery of the die or array) as possible to take advantage of the location where the working electrodes are expected to have higher sensitivity and overall performance.

[0219] FIG. 19I shows another exemplary variation of a microneedle array 1900I having seven microneedles. The microneedle arrangement includes four microneedles assigned as two independent groups (1 and 2) of two working electrodes each, a counter electrode consisting of two microneedles, and a single reference electrode. There is a symmetry in the arrangement of the working and counter electrodes, which are equidistant from the central reference electrode. Furthermore, the working electrodes are placed as far away as possible from the center of the microneedle array (e.g., the periphery of the die or array) to take advantage of the location where the working electrodes are expected to have higher sensitivity and overall performance.

[0220] FIG. 19J shows another exemplary variation of a microneedle array 1900J having seven microneedles. The microneedle arrangement includes four microneedles assigned as independent working electrodes (1, 2, 3, and 4), a counter electrode condition consisting of two microneedles, and a single reference electrode. There is a symmetry in the arrangement of the working and counter electrodes that are equidistant from the central reference electrode. Furthermore, the working electrodes are placed as far away from the center of the microneedle array (e.g., the periphery of the die or array) as possible to take advantage of the location where the working electrodes are expected to have higher sensitivity and overall performance.

[0221] While Figures 19A-19J show exemplary variations of microneedle array configurations, it should be understood that these figures are not limiting and other microneedle configurations (including different numbers and / or distributions of working, counter, and reference electrodes, as well as different numbers and / or distributions of active and inactive electrodes, etc.) may be suitable for other variations of microneedle arrays.

[0222] Warm-up: Many implanted electrochemical sensors require a "warm-up" time, or time for the sensor to achieve a stable signal value after implantation. This process stems from both physiology and sensor kinetics. However, various embodiments of the cortisol monitoring devices described herein are configured to mitigate factors that contribute to warm-up time. For example, the cortisol monitoring devices described herein may have a warm-up time of about 30 minutes or less (e.g., about 10 minutes to about 30 minutes, about 15 minutes to about 30 minutes, about 20 minutes to about 30 minutes, about 25 minutes to about 30 minutes), about 45 minutes or less, about 60 minutes or less, about 90 minutes or less, or about 120 minutes or less. In some variations, following the warm-up period, the cortisol monitoring device may be calibrated during a calibration period.

[0223] Wound response: For example, sensor implantation generates a wound response due to localized tissue disruption, displacement, and destruction. The larger the sensor or the deeper the implantation, the more vigorous the wound response. Thus, there is a compelling rationale for miniaturizing the sensor to induce a dampened wound response that results in a more rapid warm-up.

[0224] Protein Adsorption: Furthermore, following implantation of the sensor, a foreign body response is immediately triggered. The foreign body response involves a complex biochemical cascade aimed at encapsulating the foreign body with cellular material. Hydrophobic surfaces tend to undergo endogenous protein adsorption very quickly after implantation. This is called biofouling. Hydrophilic surfaces, on the other hand, resist biofouling due to their high water content. Human serum albumin (HSA) is the major protein in skin interstitial fluid, constituting approximately 60% of the total protein and maintaining a negative charge at physiological pH. When the sensor is polarized at a positive potential (as in some variations of cortisol monitoring devices), endogenous HSA undergoes electrical drift and charge attraction to the positive (working) electrode of the sensor. This can result in an increased propensity of the sensor surface for biofouling. This is the rationale behind the implementation of either a hydrophilic diffusion-limiting layer or an outer biocompatible layer to effectively mask the sensor from being recognized as a foreign body, as explained in more detail above.

[0225] As described herein, the cortisol monitoring device reduces the impact of the above-mentioned physiological factors on warm-up time due to, for example, the shallow nature of the implant, the minimal volume of tissue replaced, the minimal amount of trauma to the tissue during implantation, and the lack of permeability of the deeper vasculature in the reticular dermis which, when disturbed, can elicit a more proliferative wound response that would result in accelerated efforts to encapsulate the implant.

[0226] Achieving Equilibrium: One example of the effect of sensor dynamics on warm-up time concerns the achievement of equilibrium. Electrochemical sensors require a finite time to achieve equilibrium when used in a new environment. This is typically associated with the establishment of thermodynamic equilibrium due to an adsorbed surface layer of ions at the electrode. Since the reference electrode in most implantable electrochemical sensors does not use an internal fill solution with a redox couple sealed from the rest of the electrochemical cell, this reference electrode must achieve equilibrium with its surroundings to establish a stable reference potential.

[0227] Hydration of the sensor layer: The electrode sensor layer must be immersed in an aqueous environment to function properly. The resulting hydration process activates the polymer layer and biorecognition elements of the electrode, allowing them to rearrange and return to their native active tertiary structure that is primarily responsible for their activity or intrinsic properties. This process is often known as sensor "wetting" and allows the medium in which the sensing action occurs to intercalate the sensor layer to a sufficient degree.

[0228] Decay of Non-Faradic Reactions: Biasing an electrochemical sensor (applying a voltage) results in the formation of a double layer of ions at the electrode surface. This process requires a finite time for charging of the adsorbed species on the electrode surface. This results in a double layer capacitance. The non-faradaic time constant is equal to the product of the double layer capacitance and the solution resistance. In many cases, the non-faradaic reactions (current) decay to negligible levels more rapidly than other physical phenomena, and in many cases this is not the rate-limiting step in the warm-up process. Once the non-faradaic reactions have decayed to negligible levels, the faradaic reactions follow, which reflect the electrochemical / redox reactions of interest.

[0229] As described herein, the cortisol monitoring device may reduce the effect of sensor kinetics on warm-up time, for example, due to the thin layer mounting (on the order of 10 nm to 5000 nm) that allows the layer to hydrate quickly. Furthermore, due to the small dimensions of the electrodes (e.g., the geometric surface area of ​​the working electrode) described herein, non-faradaic reactions are shorter in duration (due to reduced double layer capacitance and thus charging of the double layer). In some variations, a high potential (e.g., >0.75 V) bias for a limited period of time after application of the device to the skin may further facilitate burn-in or warm-up of the sensor to achieve equilibrium and stable signal levels. Electronic Equipment Systems

[0230] 2A schematic of a cortisol monitoring device 110, the electronics system 120 may be integrated within the housing 112 such that the electronics system 120 may be combined with a sensing element (e.g., a microneedle array) as part of a single unit. Further details of exemplary variations of the electronics system 120 are described below. PCB

[0231] In some variations, the cortisol monitoring device may include one or more PCBs. For example, the cortisol monitoring device may include at least one PCB in the sensor assembly 320 that includes the microneedle array and at least one device PCB 350, as shown in FIG. 3E.

[0232] For example, as shown in Figures 3F-3I, the sensor assembly 320 may include a sensor standoff PCB 322 coupled to a connection PCB 324. The microneedle array 330 may be attached to the sensor standoff PCB 322 (e.g., FR-4, PTFE, Rogers 4350B) by a soldering process or the like combined with an epoxy underfill for mechanical strength. In some variations, an epoxy skirt may be deposited along the edge of the silicon microneedle array 330 to relieve sharp edges from the silicon dicing process described above. The epoxy may also provide a transition from the edge of the silicon substrate of the microneedle array silicon to the edge of the PCB 322. Alternatively, the epoxy may be replaced or supplemented with a rubber gasket or the like.

[0233] As shown in FIG. 3J, the sensor standoff PCB 322 can function as a standoff that at least partially determines the desired distance that the microneedle array 330 protrudes from the housing 310. Thus, the standoff height of the sensor standoff PCB 322 can be selected to help ensure that the microneedle array 330 is properly inserted into the user's skin. During needle insertion, the bottom surface of the housing 310 acts as a stopper for needle insertion. If the sensor standoff PCB 322 has a low height and its bottom surface is flush or nearly flush with the bottom surface of the housing, the housing 310 can prevent the microneedle array 330 from being fully inserted into the skin. However, increasing the standoff height can result in higher pressure of the microneedle array on the skin during microneedle insertion, which can lead to dermatological irritation and / or erythema (redness of the skin).

[0234] The sensor standoff PCB 322 may be secured to the housing 310 and / or secured within a stack within the housing using suitable fasteners or the like. For example, as shown in FIGS. 3H-3J, the sensor standoff PCB 322 (having the microneedle array 330) may be coupled to a first side of the connection PCB 324, and a second, opposing side of the connection PCB 324 may be coupled to the interposer PCB connector 326. As shown in FIG. 3J, the interposer PCB connector 326 may be communicatively coupled to the device PCB 350 for signal processing, etc., as described below. Thus, signals from the microneedle array 330 may be communicated via the sensor standoff PCB 322, through the sensor standoff PCB 322, the connection PCB 324, and the interposer PCB connector 326 to the device PCB. However, in some variations, the cortisol monitoring device may include fewer PCBs. For example, in some variations, the sensor assembly 320 may omit the sensor standoff PCB 322, thereby allowing the microneedle array 330 to electrically communicate directly to the connection PCB 324 (or directly to the device PCB 350).

[0235] Additionally or alternatively, in some variations, at least one of the PCBs in the sensor assembly 320 may include or be coupled to one or more additional sensors in combination with the microneedle array 330. For example, the sensor assembly 320 may include a temperature sensor (e.g., a thermistor, a resistance temperature detector, a thermocouple, a bandgap reference, a non-contact temperature sensor, etc.). In some variations, the temperature measurement may additionally or alternatively be performed by one or more analyte-insensitive electrodes in the microneedle array.

[0236] In some variations, the sensor standoff PCB 322 may have a thickness of about 0.05 inches to about 0.15 inches, or about 0.093 inches to about 0.127 inches. The sensor standoff PCB 322, in some variations, may include one or more conductive through-substrate vias configured to route electrical signals from a front side of the PCB to a rear side of the PCB. In some variations, the sensor standoff PCB 322 may include a semiconductor (e.g., silicon) with conductive through-substrate vias configured to route electrical signals from a front side of the semiconductor to a rear side of the semiconductor. In yet other variations, the microneedle array 330 may be attached directly to the PCB 324 without the sensor standoff PCB 322. Analog Front End

[0237] In some variations, the cortisol monitoring device electronics system may include an analog front end. The analog front end may include a sensor circuit (e.g., sensor circuit 124 as shown in FIG. 2A) that converts analog current measurements into digital values ​​that can be processed by a microcontroller. The analog front end may include, for example, a programmable analog front end suitable for use with an electrochemical sensor. For example, the analog front end may include MAX30131, MAX30132, or MAX30134 components (having 1, 2, and 4 channels, respectively) available from Maxim Integrated (San Jose, Calif.), which are ultra-low power programmable analog front ends for use with electrochemical sensors. The analog front end may also include AD5940 or AD5941 components available from Analog Devices (Norwood, Mass.), which are high-precision, impedance, and electrochemical front ends. Similarly, the analog front end may also include the LMP91000 available from Texas Instruments (Dallas, TX), which is a configurable analog front end potentiostat for low power chemical sensing applications. The analog front end may provide bias and a complete measurement path including an analog to digital converter (ADC). The ultra-low power may allow continuous biasing of the sensor to maintain accuracy and fast response when measurements are required for extended periods (e.g., 7 days) using a body-worn battery-operated device.

[0238] In some variations, the analog front-end device may be compatible with both two and three terminal electrochemical sensors, such as to enable both DC current measurement, AC current measurement, and electrochemical impedance spectroscopy (EIS) measurement capabilities. Additionally, the analog front-end may include an internal temperature sensor and programmable voltage reference, support external temperature monitoring and external reference sources, and integrate voltage monitoring of bias and supply voltages for safety and compliance.

[0239] In some variations, the analog front end may include a multi-channel potentiostat for multiplexing the sensor inputs and processing multiple signal channels.

[0240] In some variations, the analog front end and peripheral electronics may be integrated into an application specific integrated circuit (ASIC), which may help to reduce costs, for example. This integrated solution may include a microcontroller, as described below. Microcontroller

[0241] In some variations, the cortisol monitoring device's electronics system may include at least one microcontroller (e.g., controller 122 shown in FIG. 2A). The microcontroller may include, for example, a processor with integrated flash memory. In some variations, the microcontroller in the cortisol monitoring device may be configured to perform analytics that correlate the sensor signals to cortisol measurements. For example, the microcontroller may execute programmed routines in firmware to interpret the digital signals (e.g., from the analog front end), perform any associated algorithms and / or other analytics, and route the processed data to and from the communications module. By keeping the analytics on-board the cortisol monitoring device, for example, the cortisol monitoring device may broadcast cortisol measurements in parallel to multiple devices (e.g., mobile computing devices such as smartphones or smartwatches, therapy delivery systems such as insulin pens or pumps, etc.) while ensuring that each connected device has the same information.

[0242] In some variations, the microcontroller may be configured to activate and / or deactivate the cortisol monitoring device upon one or more detected conditions. For example, the device may be configured to power up the cortisol monitoring device upon insertion of the microneedle array into the skin. This may enable, for example, a power saving feature where the battery is disconnected until the microneedle array is placed on the skin, at which point the device may begin broadcasting sensor data. Such a feature may help, for example, to improve the shelf life of the cortisol monitoring device and / or simplify the cortisol monitoring device-external device pairing process for a user.

[0243] Additionally or alternatively, the microcontroller may be configured to actively verify insertion of the microneedle array into the skin based on sensor measurements performed with the microneedle array. For example, a fixed or time-varying potential or current may be applied to two or more microneedles in the microneedle array after they are presumed to be inserted into the skin. Successful insertion of the microneedle array into the skin is verified by measuring a signal (e.g., potential or current value) generated between the electrodes of the inserted microneedle and comparing it to a known reference value. The reference value may include, for example, voltage, current, resistance, conductance, capacitance, inductance, and / or impedance.

[0244] In some variations, the microcontroller may utilize 8-bit, 16-bit, 32-bit, or 64-bit data structures. Suitable microcontroller architectures include ARM® and RISC® architectures, and flash memory may be embedded in the microcontroller or external to the microcontroller as suitable data storage. In some variations, the microcontroller may be a single-core microcontroller, and in some variations, the microcontroller may be a multi-core (e.g., dual-core) microcontroller that may enable flexible architectures to optimize power and / or performance within a system. For example, the cores within a microcontroller may include similar or different architectures. For example, in one exemplary variation, the microcontroller may be a dual-core microcontroller that includes a first core having a high performance and high power architecture and a second core having a low performance and low power architecture. The first core may function as a "workhorse" in that it may be used to process higher performance functions (e.g., sensor measurements, algorithmic calculations, etc.), and the second core may be used to perform lower performance functions (e.g., background routines, data transmission, etc.). Thus, different cores of the microcontroller can operate at different duty cycles optimized for their respective functions (e.g., a second core for a lower performance function can operate at a higher duty cycle), thereby improving overall power efficiency. Additionally or alternatively, in some variations, the microcontroller may include embedded analog circuitry, such as for interfacing with additional sensors and / or microneedle arrays. In some variations, the microcontroller may be configured to operate using a 0.8V to 5V power supply, such as a 1.2V to 3V power supply. Communication Module

[0245] In some variations, the electronics system of the cortisol monitoring device may include at least one communication module, such as a wireless communication module (e.g., communication module 126 as shown in FIG. 2A), for communicating with one or more devices via wireless signals. For example, the communication module may include a wireless transceiver integrated into the microcontroller device and configured to receive and transmit wireless signals. However, the electronics system may additionally or alternatively include a communication module separate from the microcontroller device. In some variations, the communication module may communicate via a wireless network (e.g., via Bluetooth, NFC, WiFi, RFID, or any type of data transmission not connected by a cable). For example, the devices may communicate with each other directly in a pair-wise connection (1:1 relationship, unicast), or a hub-spoke or broadcast connection ("one-to-many" or 1:m relationship, multicast). As another example, the devices may communicate with each other through a mesh networking connection (e.g., "many-to-many", m:m relationship, or ad-hoc), such as Bluetooth mesh networking.Wireless communications include, but are not limited to, Global System for Mobile Communications (GSM), Enhanced Data GSM Environment (EDGE), high speed downlink packet access (HSDPA), high speed uplink packet access (HSUPA), Evolution, Data-Only (EV-DO), HSPA, HSPA+, Dual-Cell HSPA (DC-HSPADA), long term evolution (LTE), near field communication (NFC), wideband code division multiple access (W-CDMA), code division multiple access (CDMA), time division multiple access (TDMA), Bluetooth, Wireless Any of a number of communication standards, protocols, and technologies may be used, including Wireless Fidelity (WiFi) (e.g., IEEE 802.11a, IEEE 802.11b, IEEE 802.11g, IEEE 802.11n, etc.), or any other suitable communication protocol. Some wireless network deployments may combine networks from multiple mobile radio networks or use a mix of mobile radio, Wi-Fi, and satellite communications. In an exemplary variation, the communication module may include a wireless transceiver integrated into the microcontroller and including a Bluetooth® Low Energy compatible radio that complies with the Bluetooth® Special Interest Group 5.0 specification.

[0246] The communications module may further include or be coupled to one or more antennas (e.g., antenna 128 shown in FIG. 2A). For example, the electronics system may include a chip antenna mounted on the PCB, or an antenna mounted directly on the PCB, which may provide better range while reducing cost and complexity. In some variations, the user wearing the cortisol monitoring device 110 may act as the antenna (e.g., antenna 128). For example, the antenna input / output 128 of the communications module 126 may be electrically connected to a single microneedle or multiple microneedles that are inserted into the wearer's skin (e.g., similar to the microneedle array 140 shown in FIG. 2B). This may help to increase the effective cross-sectional area of ​​the antenna, provide a proper impedance match between the antenna input / output of the communications module and the free space, and / or improve operational metrics such as antenna gain, antenna diversity, omnidirectionality, and receiver sensitivity / transmitter efficiency of the communications module.

[0247] Devices can connect and reconnect in and out of range of the communications module, allowing users to seamlessly connect and transfer information between devices. In some variations, the microcontroller on each cortisol monitoring device may have a unique serial number that allows tracking of the particular cortisol monitoring device during manufacture and / or field use. Additional Sensors

[0248] As mentioned above, in some variations, the cortisol monitoring device may include one or more sensors in addition to the microneedle array. For example, the cortisol monitoring device may include one or more temperature sensors configured to measure the temperature of the skin, thereby enabling temperature compensation of the analyte sensor. For example, in some variations, the temperature sensor (e.g., thermistor, RTD, semiconductor junction, bimetallic sensor, thermopile sensor) may be coupled to the device PCB in the housing such that the temperature sensor is located near the skin-facing portion or bottom of the housing 112. The housing may be thinned to reduce thermal resistance and improve heat transfer and therefore measurement accuracy. Additionally or alternatively, a thermally conductive material may thermally couple the surface-mounted temperature sensor to the user's skin. In variations in which the temperature sensor is coupled to the device PCB near the microneedle array die substrate, the thermally conductive material may be molded as a skirt, for example, to cushion the sharp edges of the die and wrap along the edges of the die and along the surface of the main PCB.

[0249] In some variations, the cortisol monitoring device may include at least one microneedle with an electrode configured to function as a cortisol insensitive channel with known temperature sensitivity, which may be used to compensate for temperature. For example, one advantage of using a cortisol insensitive channel includes proximity to the cortisol sensor (e.g., less error from temperature gradients) and cost (e.g., by reducing external components and specialized processes to thermally couple the sensor to the skin). In some variations, the cortisol monitoring device may include both a thermistor and a cortisol insensitive channel, along with an algorithm that utilizes information from both. Additionally or alternatively, the cortisol monitoring device may include an additional sensor(s) that measures ambient temperature, which may also be useful in the temperature compensation algorithm. In other variations, the cortisol insensitive channel may be used to eliminate or subtract the effects of background currents or interferences that may perturb the cortisol measurement. In yet another variation, a cortisol-insensitive channel can be used in combination with a cortisol-selective channel to obtain a differential measurement that is more reflective of cortisol concentration and eliminates extraneous noise sources that erode the signal-to-noise ratio (SNR or S / N) of the sensor.

[0250] In some variations, the cortisol insensitive channel can be used to perform differential measurements and / or subtract background noise levels from the cortisol sensitive channel to improve signal fidelity and / or signal to noise ratio. The cortisol insensitive channel can be sensitive to common mode signals that also arise in the cortisol sensitive channel (e.g., endogenous and pharmacological interferences, pressure attenuation, etc.).

[0251] Additionally or alternatively, in some variations, the cortisol monitoring device may include at least one motion sensor. The motion sensor may comprise, for example, an accelerometer, gyroscope, and / or inertial measurement unit to capture values ​​of position, displacement, trajectory, velocity, acceleration, and / or orientation of the device. For example, such measurements may be used to infer the wearer's physical activity (e.g., steps, strenuous exercise) over a finite period of time. Additionally or alternatively, in some variations, the motion sensor may be used to enable detection of wearer interactions with the cortisol monitoring device, such as touches or taps. For example, touch or tap detection may be used to silence or snooze notifications, alerts, and alarms, control a wirelessly connected mobile computing device, or activate / deactivate a user interface on the cortisol monitoring device (e.g., an embedded display or indicator light). Touches or taps may be performed in a defined sequence and / or for a predetermined period of time (e.g., at least 3 seconds, at least 5 seconds) to trigger a particular action (e.g., deactivating / activating a display or indicator light). Additionally or alternatively, in some variations, the cortisol monitoring device may enter a power saving mode upon detection of limited movement or activity (e.g., no significant acceleration) as measured by the motion sensor for at least a predetermined period of time (e.g., 15 minutes, 30 minutes, 45 minutes, 1 hour, or other suitable time).

[0252] Additionally or alternatively, in some variations, the cortisol monitoring device may include at least one real-time clock (RTC). The real-time clock may be used to track absolute time (e.g., Coordinated Universal Time, UTC, or local time) when the cortisol monitoring device is stored or in use. In some variations, synchronization to absolute time may be performed after manufacture of the cortisol monitoring device. The real-time clock may be used to timestamp cortisol measurements during operation of the cortisol monitoring device for later review by a user (e.g., wearer of the cortisol monitoring device), the user's support network, the user's health care provider, etc., to create a time series data set that is communicated to a connected peripheral device (e.g., a mobile computing device), cloud storage, or other suitable data storage device. power supply

[0253] As shown in FIG. 2A, the cortisol monitoring device may include one or more power sources 130 (e.g., batteries) within a housing 112 configured to power the other components. For example, the cortisol monitoring device may include an AgO battery, which has a high energy density and is more environmentally friendly than lithium batteries. In some variations, a primary (e.g., non-rechargeable) battery may be used. Additionally, in some variations, a secondary (e.g., rechargeable) battery may be used. However, any suitable power source may be used, including lithium-based batteries.

[0254] In some variations, the power source can be coupled to the device PCB using a low profile holder or mount that reduces the overall height of the electronics, thereby minimizing the height or profile of the cortisol monitoring device. For example, conventional battery holders use conductive metal with a spring force to apply force to the top side of the battery, while in some variations, a laterally mounted battery holder can contact the side of the battery to complete the electrical circuit. In some variations, the housing can be sized and / or shaped with appropriate tolerances to apply a normal or downward force to the battery towards the device PCB to keep the battery in contact with the PCB. Applicator

[0255] In some variations, the cortisol monitoring device may be applied manually. For example, a user may remove a protective film on the adhesive layer and manually press the device onto their skin at a desired application site. Additionally or alternatively, as shown in FIG. 1, in some variations, the cortisol monitoring device may be applied to the skin using a suitable applicator 160. The applicator 160 may be configured to, for example, urge the cortisol monitoring device 110 toward the user's skin such that the microneedle array 140 of the cortisol monitoring device 110 may be inserted into the skin (e.g., to a desired target depth). kit

[0256] In some variations, some or all of the components of the cortisol monitoring system may be provided in a kit (e.g., to a user, a clinician, etc.). For example, the kit may include at least one cortisol monitoring device 110 and / or at least one applicator 160. In some variations, the kit may include multiple cortisol monitoring devices 110, which may form a supply of cortisol monitoring devices sufficient for a given period of time (e.g., 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months, 1 year, etc.). The kit may include any suitable ratio of applicators to cortisol monitoring devices (e.g., 1:1, less than 1:1, greater than 1:1). For example, the kit may include the same number of applicators as cortisol monitoring devices, such as where each applicator is disposable and configured to be disposed of after its use in applying the respective cortisol monitoring device to a user. As another example, the kit may include a number of applicators that is fewer than the number of cortisol monitoring devices in the kit (e.g., one applicator for every two or three cortisol monitoring devices), such as when an applicator is intended to be reused to apply multiple cortisol monitoring devices or when multiple cortisol monitoring devices are loaded onto a single applicator for repeated applications. As another example, the kit may include a number of applicators that is greater than the number of cortisol monitoring devices in the kit (e.g., two applicators per cortisol monitoring device), such as to provide extra or redundant applicators in case of loss or breakage of an applicator.

[0257] In some variations, the kit may further include user instructions for operating the cortisol monitoring device and / or applicator (e.g., instructions for applying the cortisol monitoring device manually or with an applicator, instructions for pairing the cortisol monitoring device with one or more peripheral devices (e.g., a computing device such as a mobile phone), etc.). Using a Cortisol Monitoring System

[0258] Below is an overview of various aspects of the method of use and operation of the cortisol monitoring system, including the cortisol monitoring device and peripherals. Application of Cortisol Monitoring Devices

[0259] As described above, the cortisol monitoring device is applied to the skin of a user such that the microneedle array in the device penetrates the skin and the electrodes of the microneedle array are positioned on the dermis for access to dermal interstitial fluid. For example, in some variations, the microneedle array may be geometrically configured to penetrate the outer layer of the skin, the stratum corneum, penetrate the epidermis, and rest within the papillary or upper reticular dermis. The sensing area limited to the electrodes at the distal extent of each microneedle component of the array (as described above) may be configured to remain resting and seated in the papillary or upper reticular dermis after application to ensure adequate exposure to circulating dermal interstitial fluid (ISF) without risk of bleeding or undue influence by nerve endings.

[0260] In some variations, the cortisol monitoring device may include a wearable housing or patch having an adhesive layer configured to adhere to the skin and secure the microneedle array in place. While the cortisol monitoring device may be applied manually (e.g., by removing a protective film over the adhesive layer and manually pressing the patch onto the skin at the desired wear site), in some variations, the cortisol monitoring device may be applied to the skin using a suitable applicator.

[0261] The cortisol monitoring device may be applied at any suitable location, although in some variations it may be desirable to avoid anatomical areas of thick or raw skin (e.g., palmar and plantar regions), or areas that undergo significant flexion (e.g., olecranon or patella). Suitable application sites may include, for example, arms (e.g., upper arms, lower arms), shoulders (e.g., over the deltoids), backs of hands, neck, face, scalp, torso (e.g., on the back, such as the pectoral region, lumbar region, sacral region, or on the chest or abdomen), buttocks, legs (e.g., upper legs, lower legs, etc.), and / or tops of feet, etc.

[0262] As mentioned above, in some variations, the cortisol monitoring device may be configured to automatically activate upon insertion and / or to confirm correct insertion into the skin, the details of these features are described in more detail above. Pairing with peripherals

[0263] In some variations, the cortisol monitoring device may be paired with at least one peripheral device such that the peripheral device receives broadcast or otherwise transmitted data from the cortisol monitoring device, including measurement data. Suitable peripheral devices include, for example, mobile computing devices (e.g., smartphones, smart watches) that may be running mobile applications. Additionally alternatively, the cortisol monitoring device may be paired (or otherwise combined) with a therapy delivery device.

[0264] As previously mentioned, pairing may be accomplished by a suitable wireless communication module (e.g., implementing Bluetooth®). In some variations, pairing may occur after the cortisol monitoring device is applied and inserted into the user's skin (e.g., after the cortisol monitoring device is activated). Additionally or alternatively, pairing may occur before the cortisol monitoring device is applied and inserted into the user's skin.

[0265] Thus, a paired mobile or other device may receive data broadcast or transmitted from the cortisol monitoring device. The peripheral device may display, store, and / or transmit the measurement data to the user and / or health care provider and / or support network. Additionally, in some variations, the paired mobile or wearable device may perform algorithmic processing on the data to improve signal fidelity, accuracy, and / or calibration, etc. In some variations, the measurement data and / or other user information may additionally or alternatively be communicated and / or stored over a network (e.g., a cloud network).

[0266] By way of example, in some variations, a mobile computing device or other computing device (e.g., a smartphone, smartwatch, tablet, etc.) may be configured to run a mobile application that provides an interface for displaying estimated cortisol-based values, trend information, historical data, etc.

[0267] In some variations, the mobile application may use the Bluetooth framework of the mobile computing device to scan for cortisol monitoring devices. As shown in FIG. 20, the cortisol monitoring device may power on or initialize as soon as it is applied to the skin, and the cortisol monitoring device may begin the notification process. The mobile application may then connect to the cortisol monitoring device and begin priming the sensor for measurement. If the mobile application detects multiple cortisol monitoring devices, the mobile application may detect the cortisol monitoring device that is closest to itself and / or may request the user (e.g., via a user interface on the mobile device) to confirm disambiguation. In some variations, the mobile application may also be able to connect to multiple cortisol monitoring devices simultaneously. This may be useful, for example, to replace sensors that are reaching the end of their life.

[0268] In some variations, the Bluetooth® Low Energy™ (BLE) protocol may be used for the connection. For example, the sensor implements a custom BLE peripheral profile for the cortisol monitoring system. Data may be exchanged after establishing a standard secure BLE connection between the cortisol monitoring device and a smartphone, smartwatch, or tablet running the mobile application. The BLE connection may be maintained permanently for the life of the sensor. If the connection is lost for any reason (e.g., weak signal), the cortisol monitoring device may begin advertising itself again and the mobile application may re-establish the connection at the earliest opportunity, for example, when in range based on physical proximity.

[0269] In some variations, one or more additional layers of security may be implemented on top of the BLE connection to ensure authorized access consisting of a combination of one or more techniques such as passcode protection, shared secrets, encryption, and multi-factor authentication.

[0270] The mobile application can guide the user through starting a new cortisol monitoring device. Once this process is complete, the mobile application is not required for the cortisol monitoring device to operate and record measurements. A secondary display device, such as a smartwatch, can be authorized by the mobile application to receive cortisol readings directly from the sensor.

[0271] Further, in some variations, the mobile application may additionally or alternatively assist in calibrating the cortisol monitoring device, for example, the cortisol monitoring device may indicate a calibration request to the mobile application, and the mobile application may request calibration input from the user to calibrate the sensor. Sensor Measurement

[0272] Once the cortisol monitoring device is inserted and warm-up and any calibration is completed, the cortisol monitoring device may be ready to provide a sensor measurement of cortisol from the biological environment, through the biocompatible and diffusion-limiting layer on the working electrode, to the biorecognition layer that includes a biorecognition element.

[0273] A bias potential can be applied between the working and reference electrodes of the cortisol monitoring device, and a current can be passed from the counter electrode to maintain a fixed potential relationship between the working and reference electrodes. This causes the electroactive product to be oxidized or reduced, resulting in a current flow between the working and counter electrodes. The current value is proportional to the proximity of the redox reporter molecule functionalized to the cortisol-binding aptamer to the electrode material of the working electrode, as described in more detail above, and specifically, is proportional to the concentration of cortisol in the skin interstitial fluid or some derivative thereof according to Cotterell's relationship.

[0274] The current may be converted to a voltage signal by a transimpedance amplifier and quantized to a digital bit stream by an analog-to-digital converter (ADC). Alternatively, the current may be directly quantized to a digital bit stream by a current-mode ADC. The digital representation of the current may be processed within an embedded microcontroller within the cortisol monitoring device and relayed to a wireless communication module for broadcast or transmission (e.g., to one or more peripheral devices). In some variations, the microcontroller may perform additional algorithmic processing on the data to improve signal fidelity, accuracy, and / or calibration, etc.

[0275] In some variations, the digital representation of the current or sensor signal may be correlated with the cortisol measurement by the cortisol monitoring device. For example, a microcontroller may execute programmed routines in firmware to interpret the digital signal and perform any associated algorithms and / or other analyses. Interpreting the digital signal may include translating the digital signal into a user state based on the cortisol measurement associated with the user or caregiver. Examples of the user state include cortisol concentration in bodily fluids, e.g., skin interstitial fluid or blood, a % change in cortisol concentration, whether the cortisol concentration is above, within, or below a threshold, and the user's state of mind, e.g., degree of stress and / or whether the stress is acute or chronic, or tracking diurnal variations in cortisol levels. Keeping the analytics on-board the cortisol monitoring device may, for example, allow the cortisol monitoring device to broadcast cortisol measurements to multiple devices in parallel while ensuring that each connected device has the same information. Thus, in general, a user's value based on cortisol may be estimated and stored in the cortisol monitoring device and communicated to one or more peripheral devices.

[0276] Data exchange can be initiated by either the mobile application or the cortisol monitoring device. For example, the cortisol monitoring device can notify the mobile application of new cortisol data as new cortisol data becomes available. The frequency of updates can vary, for example, between about 5 seconds to about 5 minutes and can depend on the type of data. Additionally or alternatively, the mobile application can request data from the cortisol monitoring device (e.g., if the mobile application identifies a gap in collected data due to a disconnection, etc.).

[0277] When the mobile application is not connected to the cortisol monitoring device, the mobile application may not receive data from the sensor electronics. However, the electronics in the cortisol monitoring device may store each actual and / or estimated cortisol data point. When the mobile application is reconnected to the cortisol monitoring device, the mobile application can request the data that was missed during the disconnection period, and the electronics on the cortisol monitoring device can transmit (e.g., backfill) that data set as well.

[0278] In general, the mobile application may be configured to provide a display of real-time or near real-time cortisol measurement data, such as on a display of a mobile computing device executing the mobile application. In some variations, the mobile application may communicate via a user interface regarding analysis of the cortisol measurements, such as alerts, alarms, insights regarding trends, such as to notify the user of cortisol measurements that require attention or follow-up action (e.g., high cortisol readings, low cortisol readings, high rates of change, cortisol readings outside of pre-set ranges, etc.). In some variations, the mobile application may additionally or alternatively facilitate communication of the measurement data to a cloud for storage and / or archiving for later retrieval. Interpreting the Cortisol Monitoring Device User Interface

[0279] In some variations, the cortisol measurement data and / or information about the cortisol monitoring device may be communicated via a user interface of the cortisol monitoring device. In some variations, the user interface of the cortisol monitoring device may be used to communicate information to the user in addition to, or instead of, communicating such information via a peripheral device, such as via a mobile application on a computing device. Thus, the user and / or those around the user can easily and intuitively look at the cortisol monitoring device itself for evaluation of the cortisol measurement data (e.g., cortisol measurement status, such as current and / or trending cortisol measurement levels) and / or the status of the device, without having to look at a separate device (e.g., a peripheral device or other device that is remote from the cortisol monitoring device and in communication with the cortisol monitoring device). Having such information available directly on the cortisol monitoring device itself can also allow the user and / or those around the user to be more quickly alerted of any concerns (e.g., cortisol measurements above or below the target range, and / or cortisol measurements that are increasing or decreasing at an alarming rate), thereby allowing the user to take appropriate corrective action more quickly.

[0280] For example, FIGS. 26A-C illustrate an example variation of a cortisol measuring device 3200 that includes a user interface 3220 having multiple indicator lights, including indicator lights 3224a, 3224b, 3224c, that can be selectively illuminated to communicate a user status (e.g., information regarding a cortisol measurement in a user). The user interface 3220 may be similar to the user interface 3120 described above with respect to FIGS. 25A and / or 25B, for example. Although the user interface 3220 includes three indicator lights 3224a, 3224b, 3224c, it should be understood that in some variations, the user interface 3220 can include any suitable number of lights, including less than three (e.g., 1, 2) or more than three (e.g., 4, 5, 6, or more).

[0281] The indicator lights 3224a, 3224b, 3224c may be arranged sequentially such that their relative positions help a user intuitively understand the information collectively communicated by the user interface. For example, the three indicator lights 3224a, 3224b, 3224c may be illuminated to generally indicate three progressive levels (or ranges) of cortisol readings, with the lowest indicator light 3224a being illuminated to generally indicate the lowest cortisol reading of the three levels, the middle indicator light 3224b being illuminated to generally indicate a cortisol reading that is in the middle of the three levels, and the highest indicator light 3224c being illuminated to generally indicate the highest cortisol reading of the three levels. In one exemplary variation, the lowest indicator light 3224a may be illuminated to indicate a cortisol measurement that is within the target range (FIG. 26A), the middle indicator light 3224b may be illuminated to indicate a cortisol measurement that is above the target range (FIG. 26B), and the highest indicator light 3224c may be illuminated to indicate a cortisol measurement that is significantly above the target range (FIG. 26C). In another exemplary variation, the lowest indicator light 3224a may be illuminated to indicate a cortisol measurement that is below the target range, the middle indicator light 3224b may be illuminated to indicate a cortisol measurement that is within the target range, and the highest indicator light 3224c may be illuminated to indicate a cortisol measurement that is above the target range.

[0282] The target range thresholds may be any suitable values. For example, in some variations where cortisol monitoring is performed, cortisol measurements may be considered to be within the target range if they are between about 100 nM and 500 nM, and below the target range if they are less than about 100 nM. The different thresholds for "above" the target range and "significantly above" the target range may have any suitable values. For example, in some variations, a cortisol measurement may be considered to be "above" the target range if it is above a first predetermined threshold (e.g., above a threshold of about 500 nM), and a cortisol measurement may be considered to be "substantially above" the target range if it is a predetermined amount (e.g., percentage) above the first predetermined threshold, for example, at least 33% above the first predetermined threshold (e.g., 665 nM), or at least about 25% above the first predetermined threshold, at least about 30% above the first predetermined threshold, at least 35% above the first predetermined threshold, or at least 40% above the first predetermined threshold, or other suitable second predetermined threshold.

[0283] Additionally, the thresholds for considering a cortisol measurement (or other characterization of a cortisol measurement) within the target range or below the target range, or "above" or "significantly above" the target range may be static or dynamic, and / or may change based on user information, such as past measurements and / or trends or other historical data (e.g., compared to the user's average or expected cortisol measurement at a particular time, or average or expected rate of change). Additionally, while the user interface 3220 includes three consecutive indicator lights, it should be understood that in other variations, the user interface on the housing of the cortisol monitoring device may include fewer (e.g., two) or more (e.g., four, five, six, or more) that may also be individually lit to indicate a cortisol measurement (e.g., each corresponding to a general relative level of a cortisol measurement).

[0284] In some variations, different illumination colors and / or timing of one or more of the indicator lights 3224a, 3224b, 3224c may additionally or alternatively allow a user to easily distinguish between each cortisol measurement level. For example, when the cortisol measurement is within the target range, the appropriate indicator light may be illuminated in a first color (e.g., blue), and when the cortisol measurement is outside the target range, the appropriate indicator light may be illuminated in another color (e.g., white if below the target range and orange if above the target range). As another example, when the cortisol measurement is within the target range, the appropriate indicator light may be illuminated in a first time pattern (e.g., gentle pulses with long illumination "on" times), and when the cortisol measurement is outside the target range, the appropriate indicator light may be illuminated in another time pattern (e.g., flash-like illumination pulses with short "on" times). Shortening the "on" time lighting pulses may help to better capture the user's attention and / or more intuitively convey a warning, for example, when cortisol measurements are below, above, or significantly above a target range. Higher frequency lighting may, in some variations, correlate with a higher warning level (e.g., significantly below or significantly above a target range).

[0285] 27A-27D and Table 1 illustrate different lighting modes used in an exemplary method of operating a user interface 3220 of a cortisol monitoring device. The exact parameter values ​​of these lighting modes are non-limiting and are included in the exemplary variations for illustrative purposes only. For example, in the "below target range" lighting mode, the lighting color may be any suitable color, and / or the lighting "on" time may be about 0.1 seconds to 1 second, about 0.2 seconds to 0.5 seconds, or about 0.3 seconds, and / or the lighting "off" time may be about 0.5 seconds to about 5 seconds, or about 1 second to about 4 seconds, or about 2 seconds to about 4 seconds, or about 3 seconds, and / or the ratio of lighting "on" time to lighting "off" time may be about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, and / or other suitable lighting parameters. As another example, in the "within target range" lighting mode and / or the "above target range lighting mode", the lighting color may be any suitable color, and / or the lighting "on" time may be from about 1 second to about 3 seconds, 0.5 seconds to about 2 seconds, or about 1 second, and / or the lighting "off" mode may be from about 0.5 seconds to about 5 seconds, or from about 1 second to about 4 seconds, or from about 2 seconds to about 4 seconds, or about 3 seconds, and / or the ratio of lighting "on" time to lighting "off" time may be about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, and / or other suitable lighting parameters. As another example, for "significantly above the target range," the lighting color may be any suitable color, and / or the lighting "on" time may be about 0.2 seconds to about 2 seconds, about 0.5 seconds to about 1.5 seconds, or about 0.8 seconds, and / or the lighting "off" time may be about 0.5 seconds to about 5 seconds, or about 1 second to about 4 seconds, or about 2 seconds to about 4 seconds, or about 3 seconds, and / or other suitable lighting parameters. Additionally, other variations may allow for fewer or more lighting modes to indicate the measured cortisol level. [Table 1]

[0286] Additionally or alternatively, in some variations, the indicator lights 3224a, 3224b, 3224c may be illuminated in a progressive sequence to indicate trend information of the cortisol measurement over time. For example, as shown in FIG. 28A, a progressive sequence of illumination in a first direction from the lower indicator light to the upper indicator light of the indicator lights 3224a, 3224b, 3224c (e.g., indicator light 3224a, followed by indicator light 3224b, followed by indicator light 3224c) may intuitively indicate a trend of increasing cortisol measurement. In some variations, the progressive sequence of illumination may have any suitable illumination color. In some variations, such ascending sequential illumination of the indicator lights may be of a suitable color to indicate either that the current cortisol measurement is within the target range and rising, or that the current cortisol measurement is above the target range and rising. For example, Figure 28A shows increasing progressive lighting in a first color (e.g., blue) to indicate that the current cortisol measurement is within the target range and rising, while Figure 28B shows increasing progressive lighting in a second color (e.g., orange) to indicate that the current cortisol measurement is above (or significantly above) the target range. As yet another example, increasing progressive lighting in a third color (e.g., white) may indicate that the current cortisol measurement is below (or significantly below) the target range and rising.

[0287] As another example, as shown in FIG. 28C, a progressive sequence of illumination from higher to lower indicator lights (e.g., indicator light 3224c followed by indicator light 3244b followed by indicator light 3224a) in a second direction of indicator lights 3224a, 3224b, 3224c (e.g., the opposite direction to the first direction) may intuitively indicate a trend toward decreasing cortisol measurements. Similar to that described above with respect to Figures 28A and 28B, such a progressive sequence of descending illumination of the indicator light may be of a color suitable to indicate the state of the current cortisol measurement, which is descending (e.g., descending progressive illumination of a first color (e.g., blue) to indicate that the current cortisol measurement is within the target range and descending, descending progressive illumination of a second color (e.g., orange) to indicate that the current cortisol measurement is above (or significantly above) the target range and descending, or descending progressive illumination of a third color (e.g., white) to indicate that the current cortisol measurement is below (or significantly below) the target range and descending).

[0288] It should be understood that other variations of the progressive sequence of lights may be used to indicate cortisol measurement trends as well. For example, a one-dimensional array of indicator lights (e.g., arranged in a row, column, arc, etc.) may be illuminated in a progressive sequence from a first end of the array to a second end of the array to indicate an ascending cortisol measurement trend, or from the second end of the array to the first end of the array to indicate a descending cortisol measurement trend. For example, the progressive sequence of lights may be characterized as left to right, right to left, top to bottom, bottom to top, clockwise, counterclockwise, etc. Further, although the user interface 3220 includes three sequential indicator lights, it should be understood that in other variations, the user interface on the housing of the cortisol monitoring device may include fewer (e.g., two) or more (e.g., four, five, six, or more) indicator lights that may also be illuminated in a progressive sequence to indicate rising and / or falling cortisol measurement trends.

[0289] In some variations, within each rising or falling sequence of illumination across the indicator lights, illumination of adjacent indicator lights may be interspersed with illumination "off" periods. Additionally, in some variations, the pace at which illumination transitions between indicator lights may indicate the rate of change of the cortisol measurement. For example, the faster the illumination transitions from a lower indicator light to a higher indicator light, the faster the rate of change (and potentially the greater the urgency or need for user attention to the trend). Additionally or alternatively, each rising or falling sequence of illumination across the indicator lights may be separated by an end-of-sequence illumination "off" time to make it easier to distinguish between rising and falling sequences. The end-of-sequence illumination "off" time may be longer than the illumination "off" periods within each sequence. In some variations, the beginning or end of each rising or falling sequence of illumination may additionally or alternatively be segmented in any suitable manner (e.g., all lights are on simultaneously at the beginning or end of a rising or falling sequence).

[0290] Table 2 illustrates different lighting modes used in an exemplary method of operating a user interface 3220 of a cortisol monitoring device to indicate cortisol measurement trends. The exact parameter values ​​of these lighting modes are non-limiting and are included in the exemplary variations for illustrative purposes only. For example, in a progressive sequence of lighting (e.g., for any one of the more suitable lighting modes), the lighting color may be any suitable color, and / or the lighting "on" time may be about 0.1 seconds to 1 second, about 0.2 seconds to 0.5 seconds, or about 0.3 seconds, and / or the lighting "off" time between illumination of adjacent indicator lights may be about 0.05 seconds to about 1 second, about 0.1 seconds to about 0.5 seconds, or about 0.18 seconds, and / or the ratio between lighting "on" time and lighting "off" time may be about 1, about 1.5, or about 2, and / or the end of the sequence may be designated by lighting "off" for about 2 seconds to about 5 seconds, or about 3 seconds. Additionally, other variations may allow for fewer or more lighting modes to indicate cortisol measurement trends. [Table 2]

[0291] Additionally or alternatively, the indicator lights 3222 may be selectively illuminated to communicate device status. Similar to that described above, the color and / or timing of illumination may be varied in a predetermined manner to indicate different device status. The status may include, for example, a warm-up period notification, an end of life notification, a sensor failure state notification, a sensor failure mode (e.g., improper insertion) notification, a low battery notification, and / or a device error notification. Additionally, any suitable number of indicator lights may be illuminated individually and / or collectively (e.g., sequentially or simultaneously) to indicate different device status. For example, as shown in FIG. 29A, a user interface including the indicator lights 3222 may be illuminated in a first illumination mode (e.g., a first illumination color, such as white and / or a first time illumination pattern) to indicate a device "standby" mode. The standby mode may correspond, for example, to a device warm-up period (as described elsewhere herein), detection of a temporary error (e.g., detection of pressure-induced sensor decay). As another example, as shown in FIG. 29B , a user interface including indicator light 3222 may be illuminated in a second lighting mode (e.g., a second lighting color, such as red and / or a second time lighting pattern) to indicate an “end of life” mode of the device (e.g., determining the end of a predetermined wear period, detecting a permanent error, etc., as described below).

[0292] Table 3 illustrates different lighting modes that may be used in an exemplary method of operating a user interface of a cortisol monitoring device to indicate the status of the device. The exact parameter values ​​of these lighting modes are non-limiting and are included in the exemplary variations for illustrative purposes only. For example, in a "standby" lighting mode, the lighting color may be any suitable color, and / or the lighting "on" time may be about 0.1 seconds to about 3 seconds, about 0.5 seconds to about 2 seconds, or about 1 second, and / or the lighting "off" time may be about 0.5 seconds to about 5 seconds, or about 1 second to about 4 seconds, or about 2 seconds to about 4 seconds, or about 3 seconds, and / or the ratio of lighting "on" time to lighting "off" time may be about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, and / or other suitable lighting parameters. As another example, in an “end of life” lighting mode, the lighting color may be any suitable color, and / or the lighting “on” time may be about 0.01 seconds to about 1 second, about 0.01 seconds to about 0.5 seconds, about 0.01 seconds to about 0.3 seconds, about 0.01 seconds to about 0.1 seconds, or about 0.04 seconds, and / or the lighting “off” time may be about 1 second to about 10 seconds, about 3 seconds to about 8 seconds, or about 6 seconds, and / or the ratio of lighting “on” time to lighting “off” time may be about 0.3, about 0.2, about 0.1, about 0.05, about 0.01, or less than about 0.01, and / or other suitable lighting parameters. Although only two lighting modes are shown, in some variations, the cortisol monitoring device may have fewer or more lighting modes, such as for each of the above conditions (e.g., a first lighting mode for the device's warm-up period, a second lighting mode for detecting temporary errors, a third lighting mode for determining the end of the device's life, a fourth lighting mode for detecting permanent errors, etc.). [Table 3]

[0293] In some variations, a photodiode, phototransistor, photodetector, or other suitable ambient light sensor may be used to measure the illumination level in the device's immediate environment. Ambient light measurements may be used to trigger brightness adjustments (e.g., dimming) of the user interface (e.g., display, indicator lights, etc.) to conserve battery charge in a power-saving mode, to improve contrast under various lighting scenarios, and / or to reduce the visibility of the device to other individuals. For example, a cortisol monitoring device may enter a power-saving mode in response to measurements from an ambient light sensor indicating a general absence of ambient light (e.g., sufficient darkness for at least a predetermined period of time), such as when the device is placed under the wearer's clothing or when the wearer is sleeping in a dark environment. In these scenarios, a power-saving mode may be practical because indicator lights may be of limited usefulness or may otherwise be perceived as a nuisance (e.g., during sleep) when hidden and out of the wearer's view (e.g., under clothing). In response to measurements from the ambient light sensor indicating exposure to ambient light (e.g., sufficient brightness for at least a predetermined period of time), the cortisol monitoring device may then exit a power saving mode and increase the brightness of the user interface accordingly. Additional System Features

[0294] In some variations, the mobile application can help the user manage the life and replacement of the cortisol monitoring device. For example, the mobile application can terminate data display when the wearing period of the cortisol monitoring device has elapsed. In some variations, the cortisol monitoring device can have an improved life span compared to conventional continuous monitoring devices. For example, the cortisol monitoring devices described herein can have a wearing period (e.g., intended life span) without material degradation of at least 3 days, at least 5 days, at least 6 days, at least 7 days, at least 10 days, or at least 12 days, between 5 days and 10 days, between 10 days and 14 days, etc.

[0295] Additionally or alternatively, the mobile application can provide a configurable warning to the user that the wearing period is about to expire, allowing the user to apply a new cortisol monitoring device when the expiration date is near, while the current cortisol monitoring device is still active. Furthermore, the new cortisol monitoring device can be allowed to warm up (typically for about 30 minutes to about 2 hours) while the old unit is still delivering cortisol measurements. The old cortisol monitoring device can then be removed at the end of use. The new cortisol monitoring device can then become the primary sensor delivering cortisol measurements to the mobile application. This can provide uninterrupted coverage for cortisol measurements. Furthermore, readings from the old cortisol monitoring device can be used to calibrate or algorithmically improve the accuracy of the new cortisol monitoring device.

[0296] In some variations, the cortisol monitoring device may have a unique serial number contained within a microcontroller (e.g., located within the electronics system). This serial number may allow for tracking of the sensor from manufacture through use of the product. For example, a sensor device history record including manufacture and customer use may be transmitted and stored in a cloud database. This allows for tracking and inference of various parameters such as individual user sensor performance metrics and improvements for individual users and sensor lots, quickly tracing defective sensor lots from field data to manufacturing or supplier issues, personalized health monitoring capabilities for individual users, etc.

[0297] In some variations, the system can track inventory of cortisol monitoring devices from warehousing to product use to purchase transactions, which may enable the system to assist users in fulfilling orders in a timely manner (e.g., to ensure that users do not run out of cortisol monitoring devices). Additionally or alternatively, fulfillment can be performed automatically as usage of the monitoring devices is tracked, helping to ensure timely delivery to the user's residence to ensure sensor supplies do not run out (e.g., "just-in-time" delivery). This can interface with virtual or e-pharmacies, distribution centers, and / or web-based sales portals such as Amazon™.

[0298] Via a web portal, the cloud infrastructure may also allow users to view real-time and historical cortisol data / trends and share the data with caregivers, healthcare providers, support networks, and / or other appropriate individuals.

[0299] In the foregoing description, for purposes of explanation, specific nomenclature was used to provide a thorough understanding of the invention. However, it will be apparent to one skilled in the art that specific details are not required to practice the present invention. Thus, the foregoing descriptions of specific embodiments of the present invention have been presented for purposes of illustration and description. They are not intended to be exhaustive or to limit the invention to the precise forms disclosed. Obviously, many modifications and variations are possible in light of the above teachings. The embodiments were chosen and described in order to explain the principles of the invention and its practical application, thereby enabling those skilled in the art to utilize the present invention and its various embodiments with various modifications as suited to the particular use contemplated. It is intended that the following claims and their equivalents define the scope of the present invention.

Claims

1. 1. A microneedle array for use in sensing cortisol, comprising: A plurality of solid microneedles, at least one microneedle of the plurality of solid microneedles comprising: a tapered distal portion having an insulated distal apex; a working electrode disposed on a surface of the tapered distal portion proximal to the insulated distal tip; The microneedle array, wherein the working electrode is configured to generate a sensor signal indicative of a concentration of cortisol in the skin interstitial fluid when in contact with the skin interstitial fluid.

2. 2. The microneedle array of claim 1, wherein the working electrode comprises an electrode material and a biorecognition layer disposed at least partially on the electrode material, the biorecognition layer comprising an aptamer that selectively and reversibly binds to cortisol.

3. The microneedle array of claim 2 , wherein the aptamer is directly or indirectly bound to the electrode material via a linker.

4. The microneedle array of claim 1 , wherein the electrode material comprises a metal.

5. 5. The microneedle array of claim 4, wherein the metal is gold, platinum, palladium, iridium, rhodium, ruthenium, titanium, nickel, cobalt, chromium, molybdenum, steel, or an alloy of two or more selected of the metals.

6. The microneedle array of claim 1 , wherein the electrode material comprises iridium oxide, titanium nitride, carbon, doped diamond, silicon, or doped silicon.

7. the electrode material comprises gold; The microneedle array of claim 4 , wherein the aptamer is tethered to the electrode material via a thiol bond.

8. The microneedle array of claim 7 , wherein the biorecognition layer further comprises a small molecule thiol attached to the gold via a thiol linker.

9. The microneedle array of claim 8 , wherein the small molecule thiol comprises a hydrophilic moiety.

10. The microneedle array of claim 9, wherein the small molecule thiol is selected from the group consisting of zwitterions, 6-mercapto-1-hexanols or homologs thereof having different carbon chain lengths, 1-hexanethiols or homologs thereof having different carbon chain lengths, 6-mercaptohexanoic acids or homologs thereof having different carbon chain lengths, 6-mercapto-1-hexanamines or homologs thereof having different carbon chain lengths, and 6-mercapto-1-phosphatidylcholine hexanes or homologs thereof having different carbon chain lengths.

11. the biorecognition layer comprises a conductive polymer layer at least partially disposed over the electrode material; The microneedle array of claim 2 , wherein the aptamer is bound to the conductive polymer layer.

12. The microneedle array of claim 11 , wherein the aptamer is attached to the conductive polymer layer via an amide linker.

13. the electrode material comprises silicon; The microneedle array of claim 2 , wherein the aptamer is attached to the electrode material via a silane linker.

14. the electrode material comprises carbon; The microneedle array of claim 2 , wherein the aptamer is attached to the electrode material via an amide linker.

15. The microneedle array of claims 2 to 14, wherein the aptamer is covalently attached to a redox active molecule at the 3' or 5' end of the aptamer such that selective binding of the cortisol to the aptamer and the resulting conformational change of the aptamer alters the proximity between the redox active molecule and the surface of the electrode material to modulate electron transfer between the redox active molecule and the electrode material, thereby generating the sensor signal.

16. The microneedle array of claim 15, wherein selective binding of the cortisol to the aptamer and the resulting conformational change of the aptamer brings the redox active molecule closer to the surface of the electrode material and facilitates electron transfer between the redox active molecule and the electrode material, thereby generating the sensor signal.

17. The microneedle array of claim 15, wherein selective binding of the cortisol to the aptamer and the resulting conformational change of the aptamer moves the redox active molecule away from the surface of the electrode material, attenuating electron transfer between the redox active molecule and the electrode material, thereby generating the sensor signal.

18. The microneedle array of claims 15 to 17, wherein the redox active molecule is methylene blue, ferrocene, pentamethylferrocene, C5-ferrocene, Nile blue, thionine, anthraquinone, C5-anthraquinone, gallocyanine, indophenol, neutral red, dabsyl, or carboxy-X-rhodamine.

19. The microneedle array of any one of claims 2 to 18, wherein the working electrode further comprises a biocompatible layer at least partially disposed on the electrode material and the biorecognition layer.

20. The microneedle array of claim 19 , wherein the biocompatible layer is disposed completely over the electrode material and the biorecognition layer.

21. The microneedle array of claim 16 or 20, wherein the biocompatible layer comprises a hydrophilic polymer.

22. The microneedle array of claim 21, wherein the hydrophilic polymer is at least one of poly(urethane), poly(N-vinylpyrrolidone), poly(acrylamide), poly(acrylic acid), poly(methacrylic acid), poly(2-hydroxyethyl methacrylate), poly(acrylic acid-co-acrylamide), poly(N-isopropylacrylamide), poly(2-acrylamido-2-methylpropanesulfonic acid), poly(ethylene glycol), poly(vinyl alcohol), poly(lactic acid), poly(glycolic acid), poly(glycolic acid-co-lactic acid), collagen, alginate, hyaluronic acid, heparin, glycosaminoglycan, chitosan, Nafion, carboxymethylcellulose, and cellulose acetate.

23. 23. The microneedle array of any one of claims 1 to 22, further comprising a semiconductor substrate, the plurality of solid microneedles extending from the semiconductor substrate.

24. The microneedle array of any one of claims 1 to 23, wherein the at least one microneedle is configured to sense cortisol in skin interstitial fluid of a user.

25. The microneedle array of any one of claims 1 to 24, wherein at least one of the microneedles comprises a cylindrical body portion.

26. The microneedle array of any one of claims 1 to 25, wherein the working electrode is a ring-shaped electrode comprising a proximal edge and a distal edge.

27. 27. The microneedle array of claim 26, wherein the distal edge of the annular working electrode is adjacent to the proximal edge of the insulated distal tip.

28. 28. The microneedle array of claim 1, wherein the annular working electrode is on only a segment of the surface of the tapered distal portion of the microneedle.

29. A cortisol monitoring device comprising the microneedle array according to any one of claims 1 to 28.

30. the cortisol monitoring device is a wearable device comprising a wearable housing; 30. The cortisol monitoring device of claim 29, wherein the microneedle array extends outwardly from the wearable housing and is configured such that a working electrode reaches a user's skin interstitial fluid when the device is worn by a user.

31. 31. The cortisol monitoring device of claim 30, wherein the wearable housing includes a communications module operably connected to the microneedle array and configured to transmit a wireless signal in response to the sensor signal generated by the at least one microneedle.

32. 1. A method for monitoring cortisol in a user, comprising: A cortisol monitoring device is provided that includes a plurality of solid microneedles, at least one microneedle of the plurality of solid microneedles comprising: a tapered distal portion having an insulated distal apex; a working electrode disposed on a surface of the tapered distal portion proximal to the insulated distal tip and configured to generate a sensor signal indicative of a concentration of the cortisol in skin interstitial fluid; accessing interstitial fluid of the user's skin with at least one microneedle; and generating the sensor signal responsive to the working electrode in contact with the skin interstitial fluid with the at least one solid-state microneedle.

33. 33. The method of claim 32, wherein the working electrode comprises an electrode material and a biorecognition layer disposed at least partially on the electrode material, the biorecognition layer comprising an aptamer that selectively and reversibly binds to cortisol.

34. The method of claim 33, wherein the aptamer is directly or indirectly bound to the electrode material via a linker.

35. The method of claim 32 , wherein the electrode material comprises a metal.

36. 36. The method of claim 35, wherein the metal is gold, platinum, palladium, iridium, rhodium, ruthenium, titanium, nickel, cobalt, chromium, molybdenum, steel, or an alloy of a selection of two or more of the metals.

37. 33. The method of claim 32, wherein the electrode material comprises iridium oxide, titanium nitride, carbon, doped diamond, silicon, or doped silicon.

38. the electrode material comprises gold; The method of claim 35 , wherein the aptamer is attached to the electrode material via a thiol bond.

39. 40. The method of claim 38, wherein the biorecognition layer further comprises a small molecule thiol attached to the gold via a thiol linker.

40. 40. The method of claim 39, wherein the small molecule thiol comprises a hydrophilic moiety.

41. 41. The method of claim 40, wherein the small molecule thiol is selected from the group consisting of zwitterions, 6-mercapto-1-hexanols or homologs thereof having different carbon chain lengths, 1-hexanethiols or homologs thereof having different carbon chain lengths, 6-mercaptohexanoic acids or homologs thereof having different carbon chain lengths, 6-mercapto-1-hexanamines or homologs thereof having different carbon chain lengths, and 6-mercapto-1-phosphatidylcholine hexanes or homologs thereof having different carbon chain lengths.

42. the biorecognition layer comprises a conductive polymer layer at least partially disposed over the electrode material; The method of claim 33 , wherein the aptamer is bound to the conductive polymer layer.

43. 43. The method of claim 42, wherein the aptamer is attached to the conductive polymer layer via an amide linker.

44. the electrode material comprises silicon; The method of claim 33, wherein the aptamer is attached to the electrode material via a silane linker.

45. the electrode material comprises carbon; The method of claim 33, wherein the aptamer is attached to the electrode material via an amide linker.

46. 46. ​​The method of claims 33-45, wherein the aptamer is covalently attached to a redox active molecule at the 3' or 5' end of the aptamer such that selective binding of the cortisol to the aptamer and the resulting conformational change of the aptamer alters the proximity between the redox active molecule and the surface of the electrode material to modulate electron transfer between the redox active molecule and the electrode material, thereby generating the sensor signal.

47. 47. The method of claim 46, wherein selective binding of the cortisol to the aptamer and the resulting conformational change of the aptamer brings the redox active molecule closer to the surface of the electrode material, facilitating electron transfer between the redox active molecule and the electrode material, thereby generating the sensor signal.

48. 47. The method of claim 46, wherein selective binding of the cortisol to the aptamer and the resulting conformational change of the aptamer displaces the redox active molecule away from the surface of the electrode material, attenuating electron transfer between the redox active molecule and the electrode material, thereby generating the sensor signal.

49. 49. The method of claims 46-48, wherein the redox active molecule is methylene blue, ferrocene, pentamethylferrocene, C5-ferrocene, Nile blue, thionine, anthraquinone, C5-anthraquinone, gallocyanine, indophenol, neutral red, dabsyl, or carboxy-X-rhodamine.

50. The microneedle array of any one of claims 33 to 49, wherein the working electrode further comprises a biocompatible layer at least partially disposed on the electrode material and the biorecognition layer.

51. 51. The method of claim 50, wherein the biocompatible layer is disposed entirely over the electrode material and the biorecognition layer.

52. 52. The method of claim 50 or 51, wherein the biocompatible layer comprises a hydrophilic polymer.

53. 53. The method of claim 52, wherein the hydrophilic polymer is at least one of poly(urethane), poly(N-vinylpyrrolidone), poly(acrylamide), poly(acrylic acid), poly(methacrylic acid), poly(2-hydroxyethyl methacrylate), poly(acrylic acid-co-acrylamide), poly(N-isopropylacrylamide), poly(2-acrylamido-2-methylpropanesulfonic acid), poly(ethylene glycol), poly(vinyl alcohol), poly(lactic acid), poly(glycolic acid), poly(glycolic acid-co-lactic acid), collagen, alginate, hyaluronic acid, heparin, glycosaminoglycan, chitosan, Nafion, carboxymethylcellulose, and cellulose acetate.

54. 54. The method of any one of claims 32 to 53, further comprising transmitting a wireless signal in response to the sensor signal generated by the at least one microneedle.

55. 55. The method of any one of claims 32 to 54, further comprising a semiconductor substrate, the plurality of solid microneedles extending from the semiconductor substrate.

56. 56. The method of any one of claims 32 to 55, wherein the at least one microneedle comprises a cylindrical body portion.

57. The method of any one of claims 32 to 56, wherein the working electrode is a ring-shaped electrode comprising a proximal edge and a distal edge.

58. 58. The method of claim 57, wherein the distal edge of the annular working electrode is proximate to a proximal edge of the insulated distal tip.

59. The method of claims 32-58, wherein the annular electrode is on only a surface segment of the tapered distal portion of the microneedle.

60. 1. A cortisol monitoring device, comprising: a wearable housing having a user interface; at least one microneedle extending outwardly from the wearable housing and configured to reach skin interstitial fluid of the user when the device is worn by the user; a working electrode disposed on a surface of the at least one microneedle and configured to generate a sensor signal indicative of a concentration of cortisol in the skin interstitial fluid; A cortisol monitoring device, wherein the user interface comprises one or more indicator lights, each of the one or more indicator lights configured to be selectively illuminated in response to the sensor signal.

61. the working electrode comprises an electrode material and a biorecognition layer at least partially disposed on the electrode material; the biorecognition layer comprises an aptamer that selectively and reversibly binds to the cortisol; 61. The cortisol monitoring device of claim 60, wherein the working electrode is configured to generate the sensor signal in response to the cortisol binding to the aptamer.

62. one or more processors; when executed by the one or more processors; determining a user state based on the sensor signal; and at least one memory storing instructions that result in operation including controlling illumination of the one or more indicator lights based on the user state.

63. 63. The cortisol monitoring device of claim 62, wherein the controlling the lighting comprises selectively illuminating the one or more indicator lights in a spatial and / or temporal pattern based on the user state.

64. 64. A cortisol monitoring device as described in claim 62 or 63, wherein the user state is the user's current cortisol level.

65. 65. The cortisol monitoring device of claim 64, wherein the current cortisol level is the current cortisol concentration in the skin interstitial fluid.

66. 66. The cortisol monitoring device of claim 65, wherein the current cortisol level indicates a current concentration of cortisol in the user's bloodstream.

67. 67. A cortisol monitoring device as described in claim 65 or 66, wherein the user state is the user's psychological state.

68. 68. The cortisol monitoring device of claim 67, wherein the psychological state is the user's degree of stress.

69. the one or more indicator lights include a plurality of indicator lights; 69. A cortisol monitoring device as claimed in any one of claims 60 to 68, wherein the controlling of the lighting comprises lighting the plurality of indicator lights in a progressive manner in response to an upward or downward trend in the sensor signal.

70. said controlling said lighting further comprises: illuminating the plurality of indicator lights in a first direction to communicate the upward trend; and and illuminating the plurality of indicator lights in a second direction to communicate the downward trend.

71. 71. The cortisol monitoring device of any one of claims 60 to 70, wherein the cortisol monitoring device is an adhesive skin patch.

72. 72. A cortisol monitoring device according to any one of claims 60 to 71, further comprising a plurality of solid microneedles, said plurality of solid microneedles comprising said at least one microneedle.

73. 73. The cortisol monitoring device of claim 72, wherein the plurality of solid microneedles extend outwardly from the wearable housing in a direction away from the user interface.

74. 74. A cortisol monitoring device as described in any one of claims 60 to 73, wherein the wearable housing comprises a communications module operably connected to the at least one microneedle and configured to transmit a wireless signal in response to the sensor signal generated by the working electrode.

75. 1. A method for monitoring cortisol in a user, comprising: accessing interstitial fluid of the user's skin with at least one solid microneedle; generating a sensor signal indicative of a concentration of cortisol in skin interstitial fluid in contact with the at least one microneedle; determining a user state based on the sensor signal; and selectively illuminating one or more indicator lights based on the user state.

76. At least one solid microneedle includes a working electrode including a biorecognition layer at least partially disposed on an electrode material; the biorecognition layer comprises an aptamer that selectively binds to the cortisol; 76. The method of claim 75, wherein the working electrode is configured to generate the sensor signal in response to the cortisol binding to the aptamer.

77. 77. The method of claim 75 or claim 76, wherein the at least one solid microneedle is at least one of a plurality of solid microneedles extending outwardly from the wearable housing.

78. A method according to any one of claims 75 to 77, wherein the one or more indicator lights are illuminated in a spatial and / or temporal pattern based on the user state.

79. A method according to any one of claims 75 to 78, wherein the user state is the user's current cortisol level.

80. 80. The method of claim 79, wherein the current cortisol level is the current cortisol concentration in the skin interstitial fluid.

81. 80. The method of claim 79, wherein the current cortisol level indicates a current concentration of cortisol in the user's bloodstream.

82. A method according to any one of claims 75 to 81, wherein the user state is a psychological state of the user.

83. 83. The method of claim 82, wherein the psychological state is the user's degree of stress.

84. the one or more indicator lights include a plurality of indicator lights; A method as claimed in any one of claims 75 to 83, further comprising illuminating the one or more indicator lights in a progressive sequence in response to an upward or downward trend in the user condition.

85. illuminating the plurality of indicator lights in a first direction to communicate the upward trend; 85. The method of claim 84, including illuminating the plurality of indicator lights in a second direction to communicate the downward trend.

86. The method of any one of claims 75 to 85, further comprising transmitting a wireless signal based on the sensor signal or the user condition.